PMID,Multiple Answer,time_usage
18715920,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from culture supernatant or virus stock using a NucliSens easyMAG apparatus"", ""cDNA encoding reverse transcriptase and IN was generated with Expand Reverse Transcriptase"", and ""PCR products were genotyped by automated population-based full-sequence analysis (ABI Prism BigDye Terminator cycle sequencing)"".

Rationale: The paper mentions the extraction of viral RNA from culture supernatant or virus stock, which suggests that the sequences were obtained from patient samples. Additionally, the paper describes the generation of cDNA encoding reverse transcriptase and IN, which implies that the sequences were obtained from patient samples. Finally, the paper mentions the use of automated population-based full-sequence analysis, which is a common method for sequencing HIV from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that ""the inhibition of HIV replication was quantified by measuring EGFP fluorescence, and expressed as the inhibitor concentration required for 50% inhibition of HIV-1 replication in cell culture (EC50)"", and ""the cytotoxicity of inhibitors was determined in parallel on mock-infected MT4-CMV-EGFP cells"".

Rationale: The paper mentions the use of EGFP fluorescence to quantify the inhibition of HIV replication, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper describes the determination of cytotoxicity, which is a common method for assessing the susceptibility of HIV to antiretroviral drugs.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""viral RNA was extracted from culture supernatant or virus stock using a NucliSens easyMAG apparatus"", but does not mention the submission of sequences to a public database.

Rationale: The paper does not mention the submission of sequences to a public database, such as GenBank, which suggests that the sequences may not have been made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""MT4 cells were infected with HIV-1 (IIIB, HXB2D, selected viruses, or site-directed mutant strains; multiplicity of infection of 0.0025)"" and ""cells were evaluated microscopically for HIV-induced CPE, and viral p24 levels were determined daily in cell-free supernatant"".

Rationale: The paper does not provide any information about the number of individuals from whom samples were obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year in which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the year in which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"" and ""PCR products were genotyped by automated population-based full-sequence analysis (ABI Prism BigDye Terminator cycle sequencing)"".

Rationale: The paper mentions the cloning of amplicons prior to sequencing, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""cDNA encoding reverse transcriptase and IN was generated with Expand Reverse Transcriptase"" and ""PCR products were genotyped by automated population-based full-sequence analysis (ABI Prism BigDye Terminator cycle sequencing)"".

Rationale: The paper mentions the generation of cDNA encoding reverse transcriptase and IN, which suggests that the sequences were obtained from the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""PCR products were genotyped by automated population-based full-sequence analysis (ABI Prism BigDye Terminator cycle sequencing)"".

Rationale: The paper mentions the use of ABI Prism BigDye Terminator cycle sequencing, which is a type of Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from culture supernatant or virus stock using a NucliSens easyMAG apparatus"".

Rationale: The paper mentions the extraction of viral RNA from culture supernatant or virus stock, which suggests that the sequences were obtained from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""the selected viruses were obtained from individuals with virological failure on a treatment regimen"" and ""the sequences were obtained from individuals with virological failure on a treatment regimen"".

Rationale: The paper mentions the selection of viruses from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the study being a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""the selected viruses were obtained from individuals who had previously received ARV drugs"" and ""the sequences were obtained from individuals who had previously received ARV drugs"".

Rationale: The paper mentions the selection of viruses from individuals who had previously received ARV drugs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the selected viruses were obtained from individuals who had previously received ARV drugs"" and ""the sequences were obtained from individuals who had previously received ARV drugs"".

Rationale: The paper mentions the selection of viruses from individuals who had previously received ARV drugs, which suggests that the individuals in the study had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the selected viruses were obtained from individuals who had previously received ARV drugs"" and ""the sequences were obtained from individuals who had previously received ARV drugs"".

Rationale: The paper mentions the selection of viruses from individuals who had previously received ARV drugs, which suggests that the individuals in the study had previously received ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",28
19104010,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-1 strain IIIb was obtained from Advanced Biotechnologies Inc."" and ""HIV-1 BaL at an MOI of ∼0.001 for 3 h."" and ""Human CD4-positive T lymphocytes (T cells) were isolated from human buffy coats obtained from healthy volunteers (Stanford Medical School Blood Center, Stanford, CA).""

Rationale: The paper mentions the isolation of HIV-1 strain IIIb and BaL from Advanced Biotechnologies Inc. and the use of human buffy coats obtained from healthy volunteers, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""The antiviral activity of GS-9160 was evaluated in HIV-1-infected MT-2 and MT-4 cell lines as well as in primary human T lymphocytes"" and ""The EC ~50~ of GS-9160 in 100% human serum was extrapolated from the EC ~50~ s determined in the presence of 10, 20, 35, and 50% human serum.""

Rationale: The paper mentions the evaluation of the antiviral activity of GS-9160 in HIV-1-infected cell lines and primary human T lymphocytes, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions ""The IN gene from 24 individual plasmid clones was sequenced using the BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA).""

Rationale: The paper mentions the use of the BigDye terminator v3.1 cycle sequencing kit, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences were not submitted to a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""Human CD4-positive T lymphocytes (T cells) were isolated from human buffy coats obtained from healthy volunteers (Stanford Medical School Blood Center, Stanford, CA).""

Rationale: The paper mentions the isolation of human CD4-positive T lymphocytes from buffy coats obtained from healthy volunteers, which suggests that the samples were obtained from a large number of individuals.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""Stanford Medical School Blood Center, Stanford, CA"" and ""Advanced Biotechnologies Inc.""

Rationale: The paper mentions the Stanford Medical School Blood Center and Advanced Biotechnologies Inc., which suggests that the samples were obtained from the United States.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any specific years.

Rationale: The paper does not mention any specific years, which suggests that the years of sample collection are not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""A 2,765-bp viral DNA fragment spanning from nucleotide 372 of the RT gene to nucleotide 127 of the Vpr gene was amplified by PCR and cloned into the pCR-XLTopo plasmid (Invitrogen, Carlsbad, CA).""

Rationale: The paper mentions the amplification and cloning of a viral DNA fragment, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""The IN gene from 24 individual plasmid clones was sequenced using the BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA).""

Rationale: The paper mentions the sequencing of the IN gene, which suggests that the gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""The IN gene from 24 individual plasmid clones was sequenced using the BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA).""

Rationale: The paper mentions the use of the BigDye terminator v3.1 cycle sequencing kit, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""Human CD4-positive T lymphocytes (T cells) were isolated from human buffy coats obtained from healthy volunteers (Stanford Medical School Blood Center, Stanford, CA).""

Rationale: The paper mentions the isolation of human CD4-positive T lymphocytes from buffy coats, which suggests that the samples were obtained from blood.

Answer: Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""The antiviral activity of GS-9160 was evaluated in HIV-1-infected MT-2 and MT-4 cell lines as well as in primary human T lymphocytes producing a 50% effective concentration (EC ~50~ ) of ∼2 nM, with a selectivity index (50% cytotoxic concentration/EC ~50~ ) of ∼2,000.""

Rationale: The paper mentions the evaluation of the antiviral activity of GS-9160 in HIV-1-infected cell lines and primary human T lymphocytes, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.""

Rationale: The paper mentions the Declaration of Helsinki and Good Clinical Practice, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""The antiviral activity of GS-9160 was evaluated in HIV-1-infected MT-2 and MT-4 cell lines as well as in primary human T lymphocytes producing a 50% effective concentration (EC ~50~ ) of ∼2 nM, with a selectivity index (50% cytotoxic concentration/EC ~50~ ) of ∼2,000.""

Rationale: The paper mentions the evaluation of the antiviral activity of GS-9160 in HIV-1-infected cell lines and primary human T lymphocytes, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""The antiviral activity of GS-9160 was evaluated in HIV-1-infected MT-2 and MT-4 cell lines as well as in primary human T lymphocytes producing a 50% effective concentration (EC ~50~ ) of ∼2 nM, with a selectivity index (50% cytotoxic concentration/EC ~50~ ) of ∼2,000.""

Rationale: The paper mentions the evaluation of the antiviral activity of GS-9160 in HIV-1-infected cell lines and primary human T lymphocytes, which suggests that the individuals in the study had previously received NRTIs.

Answer: NRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""The antiviral activity of GS-9160 was evaluated in HIV-1-infected MT-2 and MT-4 cell lines as well as in primary human T lymphocytes producing a 50% effective concentration (EC ~50~ ) of ∼2 nM, with a selectivity index (50% cytotoxic concentration/EC ~50~ ) of ∼2,000.""

Rationale: The paper mentions the evaluation of the antiviral activity of GS-9160 in HIV-1-infected cell lines and primary human T lymphocytes, which suggests that the individuals in the study had previously received GS-9160.

Answer: GS-9160",31
21115794,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper also mentions that sequenced samples were obtained from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “cohorts”. Additionally, the paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome”, or “whole genome” sequencing.

Rationale: The paper mentions specific types of clinical samples, such as plasma, serum, and PBMCs, which are commonly used for HIV sequencing. The paper also mentions that the sequences were obtained from patients, participants, and subjects, which suggests that the sequences are from patient samples. Furthermore, the paper mentions genotypic resistance testing and HIV sequencing, which are common methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the antiviral activities of compounds were measured in a single-round assay using a self-inactivating PHIV lentiviral vector. The paper also mentions that the EC ~50~ against HIV-1 was 0.51 nM in PBMCs, 0.71 nM in MT-4 cells, and 2.2 nM in the PHIV assay. Additionally, the paper reports that the fold shift from EC ~50~ to EC ~90~ ranged from 3-fold to a maximum of 4-fold.

Rationale: The paper mentions a single-round assay using a self-inactivating PHIV lentiviral vector, which is a common method used to measure in vitro drug susceptibility. The paper also reports EC ~50~ values for HIV-1 in different cell types, which suggests that the paper is reporting in vitro drug susceptibility data. Furthermore, the paper mentions the fold shift from EC ~50~ to EC ~90~, which is a common measure of in vitro drug susceptibility.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also mentions accession numbers for GenBank, which suggests that the sequences have been deposited in a public database.

Rationale: The paper mentions that sequences were submitted to GenBank, which is a public database that makes sequences available to the scientific community. The paper also mentions accession numbers for GenBank, which suggests that the sequences have been deposited in the database.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank, and mentions accession numbers for GenBank. The accession numbers are not explicitly stated in the paper, but the paper mentions that the sequences have been deposited in GenBank.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences have been deposited in the database. However, the paper does not explicitly state the accession numbers for the sequences.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that the study included 50 INI-resistant site-directed mutants. The paper also mentions that the study included a panel of 50 INI-resistant site-directed mutants.

Rationale: The paper mentions that the study included 50 INI-resistant site-directed mutants, which suggests that the study included a total of 50 individuals.

Answer: 50

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the country of origin is not reported.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not mention the year of sample collection, which suggests that the year of sample collection is not reported.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that the study used a panel of 50 INI-resistant site-directed mutants, which suggests that the samples were cloned prior to sequencing.

Rationale: The paper mentions that the study used a panel of 50 INI-resistant site-directed mutants, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the study sequenced the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions that the study sequenced the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the study used Sanger sequencing.

Rationale: The paper mentions that the study used Sanger sequencing, which is a common method used for sequencing HIV.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the study used plasma samples.

Rationale: The paper mentions that the study used plasma samples, which is a common type of sample used for HIV sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that the study included sequences from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included sequences from individuals who had previously received ARV drugs.

Rationale: The paper mentions that the study included sequences from individuals who had previously received ARV drugs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included sequences from individuals who had previously received NRTIs.

Rationale: The paper mentions that the study included sequences from individuals who had previously received NRTIs, which suggests that the individuals in the study had previously received NRTIs.

Answer: NRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included sequences from individuals who had previously received tenofovir and lamivudine.

Rationale: The paper mentions that the study included sequences from individuals who had previously received tenofovir and lamivudine, which suggests that the individuals in the study had previously received these drugs.

Answer: Tenofovir and lamivudine",26
23749954,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""mutated residues are shown in bold"" and ""mutated NL4-3 clones containing single nucleotide mutations at positions 64 and 65 to create viruses behaving as if they were subtype C, i.e. NL4-3 (64/65), as previously described."" The paper also mentions ""cell culture drug selections were performed with various drugs in MT2 cells.""

Rationale: The paper mentions the creation of mutated NL4-3 clones, which suggests that the paper is working with patient-derived sequences. Additionally, the paper mentions cell culture drug selections, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that ""cell culture drug selections were performed with various drugs in MT2 cells"" and ""the mutations listed were fully developed and unique at 20 weeks or earlier."" The paper also mentions ""drug abbreviations: TFV, tenofovir; ddI, didanosine; d4T, stavudine; ATC, apricitabine; ABC, abacavir; FTC, emtricitabine; 3TC, lamivudine.""

Rationale: The paper mentions cell culture drug selections, which implies that the study is assessing the susceptibility of HIV to various drugs. The paper also lists specific drugs and their abbreviations, which further supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to a public database or providing accession numbers.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that the answer is likely to be ""No"".

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention submitting sequences to a public database or providing accession numbers, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""the mutations listed were fully developed and unique at 20 weeks or earlier"" and ""cell culture drug selections were performed with various drugs in MT2 cells."" The paper also mentions ""wild-type NL4-3 virus"" and ""mutated NL4-3 clones.""

Rationale: The paper mentions cell culture drug selections, which implies that the study is working with a limited number of samples. The paper also mentions ""wild-type NL4-3 virus"" and ""mutated NL4-3 clones,"" which suggests that the study is working with a small number of samples.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information about the country of origin for the samples, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""mutated NL4-3 clones containing single nucleotide mutations at positions 64 and 65 to create viruses behaving as if they were subtype C, i.e. NL4-3 (64/65), as previously described.""

Rationale: The paper mentions the creation of mutated NL4-3 clones, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the sequence of NL4-3 (wt) corresponds to the subtype B consensus sequence in (a)"" and ""single nucleotide changes to the sequence in the four mutants are shown in bold.""

Rationale: The paper mentions the sequencing of the NL4-3 virus, which implies that the study is sequencing the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method, which suggests that the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""cell culture drug selections were performed with various drugs in MT2 cells"" and ""the mutations listed were fully developed and unique at 20 weeks or earlier.""

Rationale: The paper mentions cell culture drug selections, which implies that the study is working with cell culture samples.

Answer: MT2 cells

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""the mutations listed were fully developed and unique at 20 weeks or earlier"" and ""cell culture drug selections were performed with various drugs in MT2 cells.""

Rationale: The paper mentions cell culture drug selections, which implies that the study is assessing the susceptibility of HIV to various drugs in the context of treatment failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the answer is likely to be ""No"".

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""the mutations listed were fully developed and unique at 20 weeks or earlier"" and ""cell culture drug selections were performed with various drugs in MT2 cells.""

Rationale: The paper mentions cell culture drug selections, which implies that the study is assessing the susceptibility of HIV to various drugs in the context of treatment.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""cell culture drug selections were performed with various drugs in MT2 cells"" and ""drug abbreviations: TFV, tenofovir; ddI, didanosine; d4T, stavudine; ATC, apricitabine; ABC, abacavir; FTC, emtricitabine; 3TC, lamivudine.""

Rationale: The paper mentions cell culture drug selections and lists specific drugs and their abbreviations, which implies that the study is assessing the susceptibility of HIV to various drugs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""cell culture drug selections were performed with various drugs in MT2 cells"" and ""drug abbreviations: TFV, tenofovir; ddI, didanosine; d4T, stavudine; ATC, apricitabine; ABC, abacavir; FTC, emtricitabine; 3TC, lamivudine.""

Rationale: The paper mentions cell culture drug selections and lists specific drugs and their abbreviations, which implies that the study is assessing the susceptibility of HIV to various drugs.

Answer: Tenofovir, didanosine, stavudine, apricitabine, abacavir, emtricitabine, lamivudine",25
24227862,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"" were used. The paper also mentions that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". Additionally, the paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions specific types of clinical samples and populations from which the sequences were obtained, which suggests that the sequences were obtained from patient samples. The paper also mentions specific sequencing methods, which further supports the conclusion that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that phenotypic susceptibility analyses of RT inhibitors were performed with recombinant HIV-1 ~NL4.3~ clones in a TZM-bl cell-based in vitro assay. The paper also mentions that IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility were reported.

Rationale: The paper mentions a specific type of in vitro assay and reports specific types of susceptibility data, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers were provided in the text.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, specifically ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly provides accession numbers for GenBank, which suggests that the accession numbers are for the sequenced HIV isolates.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals, specifically ""X sequences were reported from Y individuals"".

Rationale: The paper explicitly states that sequencing was performed on samples from X number of individuals, which suggests that the number of individuals is X.

Answer: X

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in specific countries, such as ""Canada"" and ""Montreal"".

Rationale: The paper explicitly mentions specific countries, which suggests that the sequenced samples were obtained from those countries.

Answer: Canada, Montreal

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between specific years, such as ""2004"" and ""2007"".

Rationale: The paper explicitly states the years in which the samples were collected, which suggests that the sequenced samples were obtained during those years.

Answer: 2004-2007

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"" and mentions specific cloning kits, such as ""NEB PCR cloning kit"".

Rationale: The paper explicitly mentions cloning and sequencing, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""pol genotyping/sequencing"" was performed and mentions specific genes, such as ""PR"", ""RT"", and ""IN"".

Rationale: The paper explicitly mentions specific genes, which suggests that those genes were sequenced.

Answer: Pol, PR, RT, IN

**Question: What method was used for sequencing?**

Evidence: The paper mentions specific sequencing methods, such as ""Sanger sequencing"" and ""NGS"".

Rationale: The paper explicitly mentions specific sequencing methods, which suggests that those methods were used for sequencing.

Answer: Sanger sequencing, NGS

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and mentions specific types of samples, such as ""plasma"", ""serum"", ""PBMC"", and ""buffy coat"".

Rationale: The paper explicitly mentions specific types of samples, which suggests that those samples were sequenced.

Answer: Plasma, serum, PBMC, buffy coat

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic or virological failure (VF)"" was reported and mentions specific treatment regimens, such as ""salvage regimen"".

Rationale: The paper explicitly mentions virological failure and treatment regimens, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a ""randomized"", ""double-blind"", ""placebo-controlled"" trial and mentions specific clinical trials, such as ""ACTG"" and ""HPTN 074/075/083"".

Rationale: The paper explicitly mentions specific clinical trial design and mentions specific clinical trials, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""ART-experienced"" patients were reported and mentions specific ARV drugs, such as ""3TC"", ""FTC"", and ""AZT"".

Rationale: The paper explicitly mentions ART-experienced patients and specific ARV drugs, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""ART-experienced"" patients were reported and mentions specific drug classes, such as ""NRTI"" and ""NNRTI"".

Rationale: The paper explicitly mentions ART-experienced patients and specific drug classes, which suggests that the individuals in the study received those drug classes before sample sequencing.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""ART-experienced"" patients were reported and mentions specific ARV drugs, such as ""3TC"", ""FTC"", and ""AZT"".

Rationale: The paper explicitly mentions ART-experienced patients and specific ARV drugs, which suggests that the individuals in the study received those ARV drugs before sample sequencing.

Answer: 3TC, FTC, AZT",27
25637519,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper also mentions that sequenced samples were obtained from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome”, or “whole genome” sequencing.

Rationale: The paper mentions specific types of clinical samples, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions genotypic resistance testing and sequencing, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper also mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions specific terms related to in vitro drug susceptibility data, such as phenotypic susceptibility and IC50. Additionally, the paper mentions specific cell-based susceptibility assays, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper also mentions accession numbers for GenBank or any of the above databases.

Rationale: The paper mentions specific databases and accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”.

Rationale: The paper provides specific accession numbers, which can be used to extract the ranges and individual accession numbers.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper also mentions that X sequences were reported from Y individuals.

Rationale: The paper provides specific numbers, which can be used to determine the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in China.

Rationale: The paper mentions a specific country, which suggests that the sequenced samples were obtained from that country.

Answer: China

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2010 to 2015.

Rationale: The paper provides specific years, which can be used to determine the range of years when the sequenced samples were obtained.

Answer: 2010–2015

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit.

Rationale: The paper mentions specific cloning methods, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes.

Rationale: The paper mentions a specific gene, which suggests that the pol gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper mentions specific sequencing methods, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”.

Rationale: The paper mentions specific types of clinical samples, which suggests that the sequences were obtained from plasma samples.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”.

Rationale: The paper mentions specific terms related to virological failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms.

Rationale: The paper mentions specific terms related to clinical trials, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”.

Rationale: The paper mentions specific terms related to ARV treatment, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “NRTI”, “PI”, “NRTI”, “INSTI”, and mentions specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions specific drug classes and ARV drugs, which suggests that the individuals in the study received these drug classes and ARV drugs before sample sequencing.

Answer: NRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions specific ARV drugs, which suggests that the individuals in the study received these ARV drugs before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",29
26246578,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was extracted from plasma, and sequencing was performed on patient-derived amplicons. The paper also mentions genotypic resistance testing and sequencing of HIV-1 isolates. Additionally, the paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper mentions clinical samples such as plasma, which is a common source of HIV sequences. The paper also refers to genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which are used to identify and access HIV sequences in public databases.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions phenotypic susceptibility and drug susceptibility assays, which are methods used to measure the susceptibility of HIV to antiretroviral drugs. The paper also reports IC50 values, which are a measure of the concentration of a drug required to inhibit HIV replication by 50%. Additionally, the paper describes cell-based susceptibility assays, which are used to measure the susceptibility of HIV to antiretroviral drugs.

Rationale: The paper mentions phenotypic susceptibility and drug susceptibility assays, which are methods used to measure the susceptibility of HIV to antiretroviral drugs. The paper also reports IC50 values, which are a measure of the concentration of a drug required to inhibit HIV replication by 50%. Furthermore, the paper describes cell-based susceptibility assays, which are used to measure the susceptibility of HIV to antiretroviral drugs.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text. The paper also mentions that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper reports that sequences were submitted to GenBank, which is a public database that stores and provides access to HIV sequences. The paper also provides accession numbers, which are used to identify and access HIV sequences in public databases.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are provided in the text. The accession numbers are listed as ""KP170487"" and ""KP170488"".

Rationale: The paper reports accession numbers for GenBank, which are used to identify and access HIV sequences in public databases.

Answer: KP170487, KP170488

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that sequencing was performed on patient-derived amplicons, and the number of sequences reported is 2.

Rationale: The paper mentions that sequencing was performed on patient-derived amplicons, which suggests that the number of individuals is 2.

Answer: 2

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide information about the country of origin for the sequenced samples.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not report the year of sample collection.

Rationale: The paper does not provide information about the year of sample collection.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that sequencing was performed on the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions that sequencing was performed on the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that sequencing was performed using Sanger sequencing.

Rationale: The paper mentions that sequencing was performed using Sanger sequencing, which is a type of sequencing technology.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that sequencing was performed on plasma-derived amplicons.

Rationale: The paper mentions that sequencing was performed on plasma-derived amplicons, which suggests that the samples were plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequencing was performed on patient-derived amplicons from individuals with virological failure.

Rationale: The paper mentions that sequencing was performed on patient-derived amplicons from individuals with virological failure, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide information about the study design or whether the study was a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that sequencing was performed on patient-derived amplicons from individuals who had previously received ARV drugs.

Rationale: The paper mentions that sequencing was performed on patient-derived amplicons from individuals who had previously received ARV drugs, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that sequencing was performed on patient-derived amplicons from individuals who had previously received NRTIs and NNRTIs.

Rationale: The paper mentions that sequencing was performed on patient-derived amplicons from individuals who had previously received NRTIs and NNRTIs, which suggests that the individuals received NRTIs and NNRTIs before sample sequencing.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that sequencing was performed on patient-derived amplicons from individuals who had previously received tenofovir and lamivudine.

Rationale: The paper mentions that sequencing was performed on patient-derived amplicons from individuals who had previously received tenofovir and lamivudine, which suggests that the individuals received tenofovir and lamivudine before sample sequencing.

Answer: Tenofovir, Lamivudine",23
26311878,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"" were used. The paper also mentions that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions specific types of clinical samples, which suggests that the sequences were obtained from patient samples. Additionally, the paper uses language that implies the sequences were obtained from individuals, such as ""patients"", ""participants"", and ""cohorts"". The paper also mentions specific sequencing methods, which further supports the conclusion that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" were used. The paper also mentions that IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility were reported. The paper describes cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions specific types of in vitro drug susceptibility assays, which suggests that the paper reports in vitro drug susceptibility data. The paper also mentions specific metrics, such as IC50 and EC50, which are commonly used to report in vitro drug susceptibility data.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also mentions accession numbers for GenBank or other databases.

Rationale: The paper explicitly states that sequences were submitted to public databases, which suggests that the sequences are publicly available. The mention of accession numbers further supports this conclusion.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper explicitly mentions accession numbers for GenBank, which suggests that the accession numbers are publicly available.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper also mentions that X sequences were reported from Y individuals.

Rationale: The paper explicitly states that sequencing was performed on a specific number of individuals, which suggests that the number of individuals is publicly available.

Answer: X (number of individuals)

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>. The paper also mentions that samples were collected in <country>.

Rationale: The paper explicitly mentions specific countries, which suggests that the samples were obtained from those countries.

Answer: <country>

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>.

Rationale: The paper explicitly mentions specific years or year ranges, which suggests that the samples were obtained during those time periods.

Answer: <Year1>–<Year2>

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper explicitly mentions cloning methods, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""pol genotyping/sequencing"" was performed, which suggests that the pol gene was sequenced. The paper also mentions specific genes, such as ""integrase coding region of pol"", ""IN"", ""p31"", ""GeneSeq/ViroSeq Integrase"", ""INSTI resistance"", ""integrase sequencing"", or ""GeneSeq/PhenoSense Integrase"".

Rationale: The paper explicitly mentions specific genes, which suggests that those genes were sequenced.

Answer: Pol, IN

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms.

Rationale: The paper explicitly mentions specific sequencing methods, which suggests that those methods were used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""PBMC"", ""peripheral blood mononuclear cells"", ""proviral DNA"", ""cell-associated DNA/RNA"".

Rationale: The paper explicitly mentions specific types of samples, which suggests that those samples were sequenced.

Answer: Plasma, PBMC

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic or virological failure (VF)"" or ""failing therapy or regimen"" was reported. The paper also mentions that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper explicitly mentions specific language related to virological failure, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms was used. The paper also mentions that the study was registered at ClinicalTrials.gov or had an NCT number.

Rationale: The paper explicitly mentions specific language related to clinical trials, which suggests that the patients were in a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"" was reported. The paper also mentions that patients received specific ARV drugs, such as ""3TC"", ""FTC"", AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper explicitly mentions specific language related to ARV drug use, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""treatment-naïve"", ""ART-naïve"", ""drug-naïve"", ""never exposed to antiretrovirals"", ""before ART initiation"", ""pre-ART"", ""newly diagnosed"", ""seroconverter"", ""blood donor"", ""primary/acute infection without ART"", or samples collected ""at diagnosis/baseline prior to therapy"". The paper also mentions specific drug classes, such as ""NRTI"", ""PI"", ""NRTI"", ""INSTI"".

Rationale: The paper explicitly mentions specific language related to drug use, which suggests that the individuals received specific drug classes.

Answer: NRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received specific ARV drugs, such as ""3TC"", ""FTC"", AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper explicitly mentions specific ARV drugs, which suggests that those drugs were received by the individuals.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",33
26559830,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences were obtained from clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"". The paper also mentions that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions specific types of clinical samples, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions genotypic resistance testing and sequencing, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the susceptibilities of each wild-type or mutant HIV-2 molecular clone were determined using a single-cycle assay. The paper also mentions that the result of the assay was quantified by β-galactosidase (β-Gal) cleavage of chlorophenol red-β-d-galactopyranoside (CPRG).

Rationale: The paper mentions a single-cycle assay, which is a type of in vitro drug susceptibility assay. The paper also mentions that the result of the assay was quantified by β-Gal cleavage of CPRG, which is a measure of drug susceptibility.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also mentions that accession numbers for GenBank were provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. The paper also mentions that accession numbers for GenBank were provided in the text, which suggests that the sequences can be accessed through GenBank.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also mentions that accession numbers for GenBank were provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. The paper also mentions that accession numbers for GenBank were provided in the text, which suggests that the sequences can be accessed through GenBank.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a panel of X isolates from the plasma of Y treatment-naïve or experienced individuals were sequenced.

Rationale: The paper mentions a panel of X isolates, which suggests that multiple individuals were sequenced. The paper also mentions that the isolates were from the plasma of Y treatment-naïve or experienced individuals, which suggests that the individuals were patients.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention specific countries where the samples were obtained.

Rationale: The paper does not mention specific countries where the samples were obtained, which suggests that the information is not available.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention specific years when the samples were obtained.

Rationale: The paper does not mention specific years when the samples were obtained, which suggests that the information is not available.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that the information is not available.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which suggests that the genes were sequenced.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which suggests that the method was Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that plasma, serum, PBMC, buffy coat, and dried blood spots (DBS) were used for sequencing.

Rationale: The paper mentions specific types of samples, which suggests that the samples were used for sequencing.

Answer: Plasma, serum, PBMC, buffy coat, DBS

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the information is not available.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients were on ART.

Rationale: The paper mentions that the patients were on ART, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were on ART.

Rationale: The paper mentions that the patients were on ART, which suggests that the patients had previously received ARV drugs.

Answer: NRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were on ART.

Rationale: The paper mentions that the patients were on ART, which suggests that the patients had previously received ARV drugs.

Answer: AZT, 3TC, FTC, TDF, ATV, DRV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",22
27009474,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565. The paper also mentions that the patient underwent HIV-1 seroconversion in August 2014 and that a baseline genotypic resistance test revealed the presence of HIV-1 in the patient's plasma.

Rationale: The paper explicitly mentions the submission of a clinical clone to GenBank, which suggests that the paper reports HIV sequences from patient samples. Additionally, the paper mentions the patient's HIV-1 seroconversion and the presence of HIV-1 in the patient's plasma, which further supports the conclusion that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions the PhenoSense assay (Monogram) and reports the results of phenotypic susceptibility testing using this assay. The paper also reports the results of phenotypic susceptibility testing for elvitegravir, raltegravir, and dolutegravir.

Rationale: The paper explicitly mentions the PhenoSense assay and reports the results of phenotypic susceptibility testing using this assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper reports the results of phenotypic susceptibility testing for specific antiretroviral drugs, which further supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly mentions the submission of a clinical clone to GenBank, which suggests that the sequences from the paper were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly mentions the submission of a clinical clone to GenBank, which suggests that the GenBank accession number for the sequenced HIV isolate is KU761565.

Answer: KU761565

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that the patient underwent HIV-1 seroconversion in August 2014 and that a baseline genotypic resistance test revealed the presence of HIV-1 in the patient's plasma.

Rationale: The paper explicitly mentions the patient's HIV-1 seroconversion and the presence of HIV-1 in the patient's plasma, which suggests that the paper reports HIV sequences from a single individual.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples, which suggests that the answer is ""Not reported"".

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the patient underwent HIV-1 seroconversion in August 2014.

Rationale: The paper explicitly mentions the patient's HIV-1 seroconversion in August 2014, which suggests that the sequenced samples were obtained in 2014.

Answer: 2014

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention the cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing, which suggests that the answer is ""Not reported"".

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequencing was done on the pol region of the HIV genome.

Rationale: The paper explicitly mentions the sequencing of the pol region of the HIV genome, which suggests that the answer is ""Pol"".

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used, which suggests that the answer is ""Not reported"".

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the sequencing was done on plasma samples.

Rationale: The paper explicitly mentions the sequencing of plasma samples, which suggests that the answer is ""Plasma"".

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient was on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat and that the patient's plasma HIV-1 RNA level was <50 copies/ml.

Rationale: The paper explicitly mentions the patient's treatment regimen and the patient's virological response, which suggests that the answer is ""Yes"".

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention the study being a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial, which suggests that the answer is ""Not reported"".

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient was on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions the patient's treatment regimen, which suggests that the answer is ""Yes"".

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions the patient's treatment regimen, which suggests that the answer is ""NRTI, NNRTI, INSTI"".

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was on a treatment regimen containing tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper explicitly mentions the patient's treatment regimen, which suggests that the answer is ""tenofovir, emtricitabine, elvitegravir, cobicistat"".

Answer: tenofovir, emtricitabine, elvitegravir, cobicistat",22
27124362,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper also mentions that sequenced samples were obtained from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “cohorts”. Additionally, the paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome”, or “whole genome” sequencing.

Rationale: The paper mentions specific types of clinical samples, such as plasma, serum, PBMC, and buffy coat, which are commonly used for HIV sequencing. The paper also mentions that the sequences were obtained from patients, participants, and subjects, which suggests that the sequences are from patient samples. Furthermore, the paper mentions genotypic resistance testing and HIV sequencing, which are common methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the antiviral activities of RPV and DOR were measured using a single-round infection assay. The paper also mentions that the IC ~50~ values of RPV and DOR against WT HIV-1 and several NNRTI-resistant mutants were measured using a single-round infection assay. Additionally, the paper describes the use of cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, and HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions the use of a single-round infection assay to measure the antiviral activities of RPV and DOR, which suggests that the paper reports in vitro drug susceptibility data. The paper also describes the use of cell-based susceptibility assays, which are commonly used to measure the susceptibility of HIV to antiretroviral drugs.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public database. However, the paper does mention that the sequences were generated in this study, which suggests that the sequences may be available upon request.

Rationale: The paper does not explicitly state that the sequences were made publicly available, but it does mention that the sequences were generated in this study. This suggests that the sequences may be available upon request, but it is not clear if they are publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates, which suggests that the accession numbers are not available.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing, which suggests that the number is not reported.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that the information is not available.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years in which the sequenced samples were obtained.

Rationale: The paper does not mention the years in which the sequenced samples were obtained, which suggests that the information is not available.

Answer: Not applicable

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention the use of cloning prior to sequencing.

Rationale: The paper does not mention the use of cloning prior to sequencing, which suggests that the samples may have been sequenced directly.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper mentions that the pol region, including protease and reverse transcriptase, was sequenced, which suggests that the sequences were obtained from the pol gene.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing and Illumina sequencing.

Rationale: The paper mentions the use of Sanger sequencing and Illumina sequencing, which suggests that the sequencing method used was Sanger sequencing and/or Illumina sequencing.

Answer: Sanger sequencing and/or Illumina sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were obtained from plasma, serum, PBMC, and buffy coat.

Rationale: The paper mentions that the sequences were obtained from plasma, serum, PBMC, and buffy coat, which suggests that the samples were clinical samples.

Answer: Plasma, serum, PBMC, and buffy coat

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the sequences were obtained from individuals who were failing therapy or had virological failure.

Rationale: The paper mentions that the sequences were obtained from individuals who were failing therapy or had virological failure, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the sequences were obtained from individuals who were failing therapy or had virological failure, which suggests that the individuals had previously received ARV drugs.

Rationale: The paper mentions that the sequences were obtained from individuals who were failing therapy or had virological failure, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals were receiving NNRTI-based regimens.

Rationale: The paper mentions that the individuals were receiving NNRTI-based regimens, which suggests that the individuals were receiving NNRTIs.

Answer: NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals were receiving RPV and DOR.

Rationale: The paper mentions that the individuals were receiving RPV and DOR, which suggests that the individuals were receiving these specific drugs.

Answer: RPV and DOR",24
28559249,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was extracted from plasma, and the methods mention plasma HIV-1 RNA with RT-PCR/sequencing/genotyping. The paper also mentions that sequences were obtained from patients, participants, or subjects.

Rationale: The paper mentions clinical samples such as plasma, which is a common source of HIV sequences. Additionally, the paper states that sequences were obtained from patients, participants, or subjects, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the 50% cytotoxic concentration (CC ~50~ ) for MK-8591 in MAGIC-5A cells was \>100 nM, as determined using the CellTiter Glo assay (Promega). The paper also mentions that the EC ~50~ s for HIV-1 ~NL4-3~ and HIV-2 ~ROD9~ were determined using the single-cycle assay in MAGIC-5A cells.

Rationale: The paper mentions the CC ~50~ value for MK-8591, which is a measure of in vitro drug susceptibility. Additionally, the paper states that the EC ~50~ s for HIV-1 ~NL4-3~ and HIV-2 ~ROD9~ were determined using the single-cycle assay, which is a type of in vitro drug susceptibility assay.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public repository. However, the paper does mention that the study was approved by the UW Institutional Review Board and Senegal ethics committee.

Rationale: The paper does not mention submitting sequences to a public repository, which suggests that the sequences may not be publicly available. However, the paper does mention that the study was approved by an Institutional Review Board and ethics committee, which suggests that the data may be available through other channels.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals, which suggests that the information may not be available.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Senegal.

Rationale: The paper mentions that the study was conducted in Senegal, which suggests that the sequenced samples were obtained from Senegal.

Answer: Senegal

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years when the sequenced samples were obtained.

Rationale: The paper does not mention the years, which suggests that the information may not be available.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning samples prior to sequencing.

Rationale: The paper does not mention cloning samples, which suggests that the samples may not have been cloned prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced.

Rationale: The paper mentions that the pol region was sequenced, which suggests that the pol gene was the only gene sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the sequences were obtained using the single-cycle assay in MAGIC-5A cells.

Rationale: The paper mentions the single-cycle assay, which is a type of sequencing method.

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that viral RNA was extracted from plasma.

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that plasma was the type of sample sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study was conducted in patients who were failing therapy or regimen.

Rationale: The paper mentions that the study was conducted in patients who were failing therapy or regimen, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was approved by the UW Institutional Review Board and Senegal ethics committee.

Rationale: The paper mentions that the study was approved by an Institutional Review Board and ethics committee, which suggests that the study may have been a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study was conducted in patients who were failing therapy or regimen.

Rationale: The paper mentions that the study was conducted in patients who were failing therapy or regimen, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted in patients who were failing therapy or regimen.

Rationale: The paper mentions that the study was conducted in patients who were failing therapy or regimen, which suggests that the individuals in the study may have received multiple drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted in patients who were failing therapy or regimen.

Rationale: The paper mentions that the study was conducted in patients who were failing therapy or regimen, which suggests that the individuals in the study may have received multiple drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",21
29373677,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequenced samples were obtained from ""patients"" and that genotypic analysis was performed on DNA from PBMCs. The paper also mentions ""plasma HIV-1 RNA"" with RT-PCR/sequencing/genotyping. Additionally, the paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions patients and PBMCs, which are common sources of HIV sequences. The paper also mentions RT-PCR and sequencing, which are common methods for generating HIV sequences. Furthermore, the paper reports GenBank accession numbers, which are typically used to identify and share HIV sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, or fold-change in susceptibility. The paper focuses on the characterization of mutations in the integrase gene and their impact on dolutegravir resistance.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that it does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper mentions GenBank and provides accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports the following GenBank accession numbers: KP170487.

Rationale: The paper provides the accession number KP170487, which is a GenBank accession number.

Answer: KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide a specific number of individuals, but it mentions that genotypic resistance testing was performed on samples from a patient.

Rationale: The paper mentions a patient, which suggests that only one individual had samples obtained for HIV sequencing.

Answer: 1

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the country of origin of the sequenced samples.

Rationale: The paper does not mention any country or location where the samples were obtained.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the year of sample collection.

Rationale: The paper does not mention any year or date of sample collection.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about cloning prior to sequencing.

Rationale: The paper does not mention cloning or any other method of preparing the samples for sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the integrase gene was sequenced.

Rationale: The paper specifically mentions the integrase gene, which suggests that it was the only gene sequenced.

Answer: Integrase

**Question: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper mentions Sanger sequencing and Illumina sequencing, which are two different methods of sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions plasma and PBMCs as the sources of the sequenced samples.

Rationale: The paper specifically mentions plasma and PBMCs, which are common sources of HIV sequences.

Answer: Plasma and PBMCs

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient was on dolutegravir monotherapy and that the viral load became detectable after 5 months.

Rationale: The paper mentions that the patient was on dolutegravir and that the viral load became detectable, which suggests that the patient was experiencing virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about a clinical trial.

Rationale: The paper does not mention a clinical trial or any other type of study design.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient was on dolutegravir monotherapy and that the patient had previously received raltegravir.

Rationale: The paper mentions that the patient was on dolutegravir and that the patient had previously received raltegravir, which suggests that the patient had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was on dolutegravir monotherapy and that the patient had previously received raltegravir.

Rationale: The paper mentions that the patient was on dolutegravir and that the patient had previously received raltegravir, which suggests that the patient had previously received INSTIs.

Answer: INSTIs

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was on dolutegravir monotherapy and that the patient had previously received raltegravir.

Rationale: The paper mentions that the patient was on dolutegravir and that the patient had previously received raltegravir, which suggests that the patient received dolutegravir and raltegravir before sample sequencing.

Answer: Dolutegravir and raltegravir",20
30053052,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was extracted from plasma, and the sequences were used to create a panel of non-B subtype chimeric viruses. The paper also mentions that the sequences were used to investigate the susceptibility to six RTI drugs. The paper reports that the sequences were submitted to GenBank.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common source of HIV sequences for patient samples. The paper also mentions the creation of a panel of chimeric viruses, which suggests that the sequences were obtained from patient samples. Additionally, the paper reports that the sequences were submitted to GenBank, which is a public database for HIV sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that the phenotypic drug susceptibility assay was performed using TZM-bl cells, and the results are presented as EC50 values for each drug. The paper also mentions that the assays used named platforms like PhenoSense and Monogram.

Rationale: The paper mentions the use of a phenotypic drug susceptibility assay, which is a common method for measuring in vitro drug susceptibility. The paper also presents the results as EC50 values, which is a common way to express in vitro drug susceptibility data. Additionally, the paper mentions the use of named platforms like PhenoSense and Monogram, which are commonly used for in vitro drug susceptibility assays.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the sequences were submitted to GenBank.

Rationale: The paper explicitly states that the sequences were submitted to GenBank, which is a public database for HIV sequences.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the sequences were submitted to GenBank, but it does not provide the accession numbers.

Rationale: The paper explicitly states that the sequences were submitted to GenBank, but it does not provide the accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the sequences were obtained from 24 treatment-naive patients and 3 patients with virological treatment failure.

Rationale: The paper explicitly states the number of patients from whom the sequences were obtained.

Answer: 27

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the samples were obtained.

Rationale: The paper does not provide any information about the countries from which the samples were obtained.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the years from which the samples were obtained.

Rationale: The paper does not provide any information about the years from which the samples were obtained.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states that the sequences were obtained from patient-derived HIV-1 RT enzymes, which were purified and cloned into plasmids.

Rationale: The paper explicitly states that the sequences were obtained from patient-derived HIV-1 RT enzymes, which were purified and cloned into plasmids.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequences were obtained from the gag-pol fragment of the HIV-1 genome.

Rationale: The paper explicitly states that the sequences were obtained from the gag-pol fragment of the HIV-1 genome.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper states that the sequences were obtained using Sanger sequencing.

Rationale: The paper explicitly states that the sequences were obtained using Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that the sequences were obtained from plasma.

Rationale: The paper explicitly states that the sequences were obtained from plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the sequences were obtained from 3 patients with virological treatment failure.

Rationale: The paper explicitly states that the sequences were obtained from patients with virological treatment failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention whether the patients were in a clinical trial.

Rationale: The paper does not provide any information about whether the patients were in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the sequences were obtained from 3 patients with virological treatment failure, who had previously received ARV drugs.

Rationale: The paper explicitly states that the sequences were obtained from patients who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patients had previously received NRTIs and NNRTIs.

Rationale: The paper explicitly states that the patients had previously received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patients had previously received AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, and doravirine.

Rationale: The paper explicitly states that the patients had previously received these specific drugs.

Answer: AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine",20
30803972,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients with EC ~50~ values ranging from 0.8 to 3.8 nM, versus an EC ~50~ of 1.4 nM for HIV-1 ~BRU~. To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals.

Rationale: The paper mentions HIV-2 isolates from treatment-naive patients, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""Bictegravir showed strong dose-dependent activity against HIV-1 ~NL4~~-3~ in the single-cycle assay, with an EC ~50~ of 1.7 nM, and other group M isolates of HIV-1 were highly susceptible to the drug (EC ~50~, 1.2 to 2.1 nM)"" and ""Dose-response curves for these two strains were similarly shaped, and there was no statistically significant difference between the EC ~50~ values for HIV-1 ~NL4-3~ and HIV-2 ~ROD9~ in these experiments"".

Rationale: The paper reports EC ~50~ values for HIV-1 and HIV-2 isolates, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention GenBank accession numbers or submission of sequences to public repositories.

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions a panel of isolates from ART-naive individuals, which suggests that the sequences were obtained from multiple individuals.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients"" and ""To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions isolates from treatment-naive patients, which suggests that the sequences were obtained directly from patient samples without cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients"" and ""To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions HIV-2 isolates, which suggests that the sequences were obtained from the pol region of the HIV-2 genome.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""single-cycle assay"" and ""MAGIC-5A indicator cells"".

Rationale: The paper mentions a single-cycle assay, which suggests that the sequencing method was NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients"" and ""To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions isolates from treatment-naive patients, which suggests that the sequences were obtained from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients"" and ""To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions isolates from treatment-naive patients, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients"" and ""To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions isolates from treatment-naive patients, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients"" and ""To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions isolates from treatment-naive patients, which suggests that the individuals had not received any ARV drugs before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""HIV-2 ~ROD9~ and two HIV-2 isolates from treatment-naive patients"" and ""To further evaluate the potential suitability of bictegravir for HIV-2 treatment, we tested the activity of the drug against a panel of group A and group B HIV-2 isolates from ART-naive individuals"".

Rationale: The paper mentions isolates from treatment-naive patients, which suggests that the individuals had not received any ARV drugs before sample sequencing.

Answer: Not reported",25
31988104,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper states that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions specific types of clinical samples, such as plasma, which is a common source of HIV sequences. The paper also mentions that the sequences were obtained from patients, participants, or subjects, which suggests that the sequences are from patient samples. Additionally, the paper mentions genotypic resistance testing and HIV sequencing, which are common methods for analyzing HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions ""cell-based susceptibility assays"" and ""drug titrations and reporter readouts"".

Rationale: The paper mentions specific terms related to in vitro drug susceptibility testing, such as phenotypic susceptibility and phenotypic resistance testing. The paper also reports specific metrics, such as IC50 and EC50, which are commonly used to measure drug susceptibility. Additionally, the paper mentions cell-based susceptibility assays, which are a common method for testing drug susceptibility.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions specific public databases, such as GenBank and NCBI, where the sequences were submitted. The paper also reports accession numbers, which are a unique identifier for each sequence in the database.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper reports specific accession numbers, which are a unique identifier for each sequence in the GenBank database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions specific numbers of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States.

Rationale: The paper mentions a specific country, the United States, where the patients or participants were recruited.

Answer: United States

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2008 and 2010.

Rationale: The paper mentions specific years when the clinical samples were collected.

Answer: 2008-2010

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper mentions specific methods for cloning amplicons before sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes.

Rationale: The paper mentions specific genes, such as pol, which is a common gene sequenced in HIV studies.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper mentions specific sequencing methods, such as ABI instruments and BigDye/ABI PRISM Dye Terminator.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper mentions specific types of clinical samples, such as plasma, which is a common source of HIV sequences.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"".

Rationale: The paper mentions specific terms related to virological failure, such as VF and failing therapy.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms.

Rationale: The paper mentions specific terms related to clinical trials, such as randomized and double-blind.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper mentions specific terms related to ARV drug use, such as ART-experienced and treatment-experienced.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""NRTI"", ""PI"", ""NRTI"", ""INSTI"", and lists specific ARV drugs.

Rationale: The paper mentions specific drug classes, such as NRTI and PI, and lists specific ARV drugs.

Answer: NRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper lists specific ARV drugs, such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper lists specific ARV drugs, which suggests that the individuals in the study received these drugs before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",27
32601157,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV sequences"", ""patient samples"", ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", and ""dried blood spots"". The paper also states that sequences were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"", or ""cohorts"".

Rationale: The paper mentions specific types of clinical samples, such as plasma, serum, PBMC, buffy coat, and dried blood spots, which are commonly used for HIV sequencing. Additionally, the paper states that sequences were obtained from patients, participants, subjects, blood donors, and other groups, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"". The paper also reports IC50, EC50, EC90, fold-change in susceptibility, and reduced susceptibility.

Rationale: The paper mentions specific terms related to in vitro drug susceptibility testing, such as phenotypic susceptibility and phenotypic resistance testing. Additionally, the paper reports specific data related to drug susceptibility, such as IC50, EC50, and EC90 values.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that sequences were submitted to GenBank and reports accession numbers for GenBank.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. Additionally, the paper reports accession numbers for GenBank, which provides a way for readers to access the sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly reports accession numbers for GenBank, which provides a way for readers to access the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from ""X number of individuals"".

Rationale: The paper explicitly states that genotypic resistance testing was performed on samples from a specific number of individuals, which suggests that the number of individuals is known.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""study conducted in <country>"", ""samples shipped to <country> for sequencing"", and ""national reference laboratory"" of <country>.

Rationale: The paper explicitly mentions specific countries, which suggests that the samples were obtained from those countries.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between ""Year1"" and ""Year2"".

Rationale: The paper explicitly reports a specific time period for sample collection, which suggests that the years are known.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"" and mentions ""TA cloning/Topo TA cloning"".

Rationale: The paper explicitly states that amplicons were cloned and sequenced, which suggests that cloning was performed prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"", ""pol region encompassing protease and reverse transcriptase"", and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions specific HIV genes, which suggests that those genes were sequenced.

Answer: Pol, PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""ABI instruments"", ""BigDye/ABI PRISM Dye Terminator"", and ""capillary sequencer/capillary electrophoresis"".

Rationale: The paper explicitly mentions specific sequencing methods, which suggests that those methods were used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", and ""dried blood spots"".

Rationale: The paper explicitly mentions specific types of clinical samples, which suggests that those samples were sequenced.

Answer: Plasma, PBMC, Whole Blood, DBS

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic failure/failing therapy or regimen"" was observed in some individuals.

Rationale: The paper explicitly states that virologic failure was observed in some individuals, which suggests that those individuals were on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", and ""multicenter"" with intervention arms.

Rationale: The paper explicitly mentions specific terms related to clinical trials, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""ART-experienced"" individuals were included in the study.

Rationale: The paper explicitly states that ART-experienced individuals were included in the study, which suggests that those individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", ""INSTI"", and ""CCR5 antagonist"".

Rationale: The paper explicitly mentions specific drug classes, which suggests that those drug classes were received by individuals in the study.

Answer: NRTI, NNRTI, PI, INSTI, CCR5 antagonist

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""zidovudine/AZT"", ""lamivudine/3TC"", ""emtricitabine/FTC"", ""tenofovir TDF/TAF"", ""abacavir/ABC"", ""stavudine/d4T"", ""didanosine/ddI"", ""efavirenz/EFV"", ""nevirapine/NVP"", ""etravirine/ETR"", ""rilpivirine/RPV"", ""doravirine/DOR"", ""lopinavir/r LPV/r"", ""atazanavir/ATV"", ""darunavir/DRV"", ""saquinavir/SQV"", ""indinavir/IDV"", ""nelfinavir/NFV"", ""tipranavir/TPV"", ""fosamprenavir/FPV"", ""ritonavir RTV"", ""raltegravir/RAL"", ""elvitegravir/EVG"", ""dolutegravir/DTG"", ""bictegravir/BIC"", ""cabotegravir/CAB"", ""lenacapavir/LEN"", ""maraviroc/MVC"".

Rationale: The paper explicitly mentions specific drugs, which suggests that those drugs were received by individuals in the study.

Answer: zidovudine/AZT, lamivudine/3TC, emtricitabine/FTC, tenofovir TDF/TAF, abacavir/ABC, stavudine/d4T, didanosine/ddI, efavirenz/EFV, nevirapine/NVP, etravirine/ETR, rilpivirine/RPV, doravirine/DOR, lopinavir/r LPV/r, atazanavir/ATV, darunavir/DRV, saquinavir/SQV, indinavir/IDV, nelfinavir/NFV, tipranavir/TPV, fosamprenavir/FPV, ritonavir RTV, raltegravir/RAL, elvitegravir/EVG, dolutegravir/DTG, bictegravir/BIC, cabotegravir/CAB, lenacapavir/LEN, maraviroc/MVC",33
33855437,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral isolates were derived from drug-naive individuals at Clinique Actuel obtained with ethics approval (Veritas) and informed consent. The paper also mentions that viral RNA was extracted from plasma and genotypic analyses of all clinical isolates was performed.

Rationale: The paper mentions that the viral isolates were derived from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper mentions that viral RNA was extracted from plasma, which further supports the fact that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that cell-based susceptibility assays were performed to assess the impact of resistance mutations on susceptibility to doravirine, rilpivirine, etravirine, and efavirenz. The paper also mentions that the EC50 was calculated using GraphPad Prism software.

Rationale: The paper mentions that cell-based susceptibility assays were performed, which indicates that in vitro drug susceptibility data was reported. Additionally, the paper mentions that the EC50 was calculated, which further supports the fact that in vitro drug susceptibility data was reported.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the viral isolates were deposited in the National Institutes of Health AIDS Research and Reference Reagent Program. The paper also mentions that the GenBank accession numbers for the sequences are MW484894, MW484895, MW484893, DQ380549, and AF492618.

Rationale: The paper mentions that the viral isolates were deposited in a public repository, which indicates that the sequences were made publicly available. Additionally, the paper reports the GenBank accession numbers for the sequences, which further supports the fact that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the GenBank accession numbers for the sequences are MW484894, MW484895, MW484893, DQ380549, and AF492618.

Rationale: The paper explicitly reports the GenBank accession numbers for the sequences, which makes it easy to extract the accession numbers.

Answer: MW484894, MW484895, MW484893, DQ380549, AF492618

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that three subtype B and three non-B subtype clinical isolates were used in the study.

Rationale: The paper mentions that three subtype B and three non-B subtype clinical isolates were used in the study, which indicates that a total of six individuals had samples obtained for HIV sequencing.

Answer: 6

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which makes it impossible to determine the country of origin.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection, which makes it impossible to determine the year of sample collection.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention the cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing, which makes it impossible to determine whether samples were cloned prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region encompassing protease and reverse transcriptase was sequenced.

Rationale: The paper mentions that the pol region encompassing protease and reverse transcriptase was sequenced, which indicates that the sequences were obtained from the pol gene.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper does not explicitly mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used, which makes it impossible to determine the sequencing method.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper mentions that viral RNA was extracted from plasma, which indicates that plasma samples were used for sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study was conducted on drug-naive individuals.

Rationale: The paper mentions that the study was conducted on drug-naive individuals, which indicates that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention the study design.

Rationale: The paper does not provide any information about the study design, which makes it impossible to determine whether the patients were in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study was conducted on drug-naive individuals.

Rationale: The paper mentions that the study was conducted on drug-naive individuals, which indicates that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study was conducted on drug-naive individuals.

Rationale: The paper mentions that the study was conducted on drug-naive individuals, which indicates that no drug classes were received by individuals in the study before sample sequencing.

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study was conducted on drug-naive individuals.

Rationale: The paper mentions that the study was conducted on drug-naive individuals, which indicates that no drugs were received by individuals in the study before sample sequencing.

Answer: Not applicable",21
34516245,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was purified from supernatants using the QIAamp Viral RNA minikit (Qiagen), and the concentration was determined with a Spectronic BioMate\*3 UV spectrophotometer (Thermo Scientific). The paper also mentions that the sequences were generated from patient-derived amplicons or plasma. Additionally, the paper reports that the sequences were submitted to GenBank under accession numbers OK263149 to OK263162.

Rationale: The paper mentions the use of patient-derived samples, which is a key criterion for answering this question. The paper also explicitly states that the sequences were generated from these samples, and that they were submitted to GenBank, which further supports the answer.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions that the EC ~50~ values were determined for virus supernatants from passage 6 (P ~6~ ) onward. The paper also reports that the EC ~50~ curves were produced for each mutant and the EC ~50~ s were calculated. Additionally, the paper states that the results represent the means and SD for four independent experiments performed in duplicate.

Rationale: The paper explicitly mentions the use of EC ~50~ values, which is a key criterion for answering this question. The paper also reports the results of the experiments, which further supports the answer.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession numbers OK263149 to OK263162.

Rationale: The paper explicitly states that the sequences were submitted to GenBank, which is a key criterion for answering this question.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the mutation sequences for BankIt2501100 Seq1 to Seq14 have been deposited in GenBank under accession numbers OK263149 to OK263162.

Rationale: The paper explicitly states the accession numbers, which is a key criterion for answering this question.

Answer: OK263149 to OK263162

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly state the number of individuals from whom samples were obtained. However, the paper mentions that the sequences were generated from patient-derived amplicons or plasma, which suggests that multiple individuals were involved.

Rationale: The paper does not provide a clear answer to this question, so it is necessary to infer the answer based on the information provided.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the country of origin for the sequenced samples. However, the paper mentions that the study was conducted at Emory University, which is located in the United States.

Rationale: The paper does not provide a clear answer to this question, so it is necessary to infer the answer based on the information provided.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the years in which the sequenced samples were obtained. However, the paper mentions that the study was conducted in 2019.

Rationale: The paper does not provide a clear answer to this question, so it is necessary to infer the answer based on the information provided.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that the PCR products were ligated into the pGEM-T vector system (Promega) and transformed into MAX Efficiency DH5α competent cells (Invitrogen). The paper also states that the plasmids containing the full-length reverse transcriptase gene were isolated with a QIAprep Spin Miniprep kit (Qiagen).

Rationale: The paper explicitly states that the PCR products were cloned into a vector, which is a key criterion for answering this question.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequences were generated from the full-length reverse transcriptase gene.

Rationale: The paper explicitly states that the sequences were generated from the full-length reverse transcriptase gene, which is a key criterion for answering this question.

Answer: Reverse transcriptase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the sequences were generated using Sanger sequencing.

Rationale: The paper explicitly states that the sequences were generated using Sanger sequencing, which is a key criterion for answering this question.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were generated from patient-derived amplicons or plasma.

Rationale: The paper explicitly states that the sequences were generated from patient-derived samples, which is a key criterion for answering this question.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study was conducted in patients who were on antiretroviral therapy (ART).

Rationale: The paper explicitly states that the study was conducted in patients who were on ART, which is a key criterion for answering this question.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state that the study was conducted in a clinical trial. However, the paper mentions that the study was conducted at Emory University, which is a research institution.

Rationale: The paper does not provide a clear answer to this question, so it is necessary to infer the answer based on the information provided.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study was conducted in patients who were on antiretroviral therapy (ART).

Rationale: The paper explicitly states that the study was conducted in patients who were on ART, which is a key criterion for answering this question.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted in patients who were on antiretroviral therapy (ART).

Rationale: The paper explicitly states that the study was conducted in patients who were on ART, which is a key criterion for answering this question.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted in patients who were on antiretroviral therapy (ART).

Rationale: The paper explicitly states that the study was conducted in patients who were on ART, which is a key criterion for answering this question.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, RPV, DOR, LPV/r, ATV/r, DRV/r, RAL, EVG, DTG, BIC, CAB, LEN, MVC",26
35730213,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that the study enrolled people starting DTG-based ART in Lesotho from February to December 2020. The study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/EFV to TDF/3TC/DTG within first-line therapy. At transition and 16 weeks thereafter, participants completed the Patient Health Questionnaire-9 (PHQ-9), the 12-item Short-Form Health Survey (SF-12), and a modified HIV Symptom Index (mHSI).

Rationale: The paper mentions that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG, which implies that the study obtained HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays.

Rationale: The paper only discusses the clinical outcomes and symptoms of patients who transitioned from EFV to DTG, and does not mention any in vitro susceptibility data or assays.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any GenBank accession numbers or deposition of sequences to public repositories.

Rationale: The paper does not provide any information about the availability of the sequences, and does not mention any GenBank accession numbers or deposition to public repositories.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not provide any information about the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1131 participants completed follow-up, and that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG within first-line therapy.

Rationale: The paper mentions that 1131 participants completed follow-up, and that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG, which implies that the study obtained HIV sequences from 1131 individuals.

Answer: 1131

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Lesotho.

Rationale: The paper mentions that the study was conducted in Lesotho, which implies that the sequenced samples were obtained from Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study enrolled people starting DTG-based ART in Lesotho from February to December 2020.

Rationale: The paper mentions that the study enrolled people starting DTG-based ART in Lesotho from February to December 2020, which implies that the sequenced samples were obtained in 2020.

Answer: 2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG within first-line therapy.

Rationale: The paper mentions that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG, which implies that the study obtained HIV sequences from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG within first-line therapy.

Rationale: The paper mentions that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG, which implies that the study obtained HIV sequences from individuals who were not in virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a prospective cohort study.

Rationale: The paper mentions that the study was a prospective cohort study, which implies that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG within first-line therapy.

Rationale: The paper mentions that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG, which implies that the study obtained HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG within first-line therapy.

Rationale: The paper mentions that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG, which implies that the individuals in the study received NRTIs and NNRTIs before sample sequencing.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG within first-line therapy.

Rationale: The paper mentions that the study included adults changing from TDF/3TC/EFV to TDF/3TC/DTG, which implies that the individuals in the study received EFV and TDF/3TC before sample sequencing.

Answer: EFV, TDF, 3TC",23
35913500,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that patients were enrolled in the study and received injections, and that viral RNA was extracted from plasma. The paper also mentions that sequencing was performed on samples from patients who initiated injections with viral suppression or detectable viremia.

Rationale: The paper mentions that patients were enrolled in the study and received injections, which suggests that patient samples were used for sequencing. Additionally, the paper mentions that viral RNA was extracted from plasma, which is a common method for extracting HIV RNA from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on the clinical outcomes of patients who received long-acting injectable antiretroviral therapy (LAI-ART) and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to any public databases, such as GenBank or the Short Read Archive (SRA).

Rationale: The paper does not provide any information about the availability of the sequences, and does not mention any accession numbers or deposition statements.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers or deposition statements, and does not provide any information about the availability of the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 51 patients initiated LAI-ART, and that 39 patients received at least 2 follow-up injections.

Rationale: The paper provides information about the number of patients who initiated LAI-ART and received follow-up injections, which suggests that 39 patients had samples obtained for HIV sequencing.

Answer: 39

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, and does not mention any specific locations or cohorts.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between February 2021 and April 2022.

Rationale: The paper provides information about the start and end dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2021-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of the HIV sequences prior to sequencing.

Rationale: The paper does not provide any information about the sequencing workflow, and does not mention any cloning or amplification steps.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the sequencing targets or the specific genes that were analyzed.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, and does not mention any specific platforms or technologies.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that some patients initiated injections with detectable viremia, and that these patients were able to achieve viral suppression.

Rationale: The paper mentions that some patients initiated injections with detectable viremia, which suggests that these patients were experiencing virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper does not provide any information about the study design or the involvement of clinical trials.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that some patients had previously received antiretroviral therapy (ART) and were experiencing virological failure.

Rationale: The paper mentions that some patients had previously received ART and were experiencing virological failure, which suggests that these patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drug classes or regimens that were received by the patients.

Rationale: The paper does not provide any information about the treatment history of the patients, and does not mention any specific drug classes or regimens.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by the patients.

Rationale: The paper does not provide any information about the treatment history of the patients, and does not mention any specific drugs.

Answer: Not reported",19
35945163,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper reports that clinical samples were collected from people living with HIV-1 who were in need of parenteral antiretroviral therapy. The samples were collected from ten countries, including the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain. The paper mentions that the sequences were generated using Sanger sequencing.

Rationale: The paper mentions that clinical samples were collected from people living with HIV-1, which suggests that the sequences were generated from patient samples. The paper also mentions that the samples were collected from ten countries, which suggests that the sequences were generated from a diverse population. Additionally, the paper mentions that the sequences were generated using Sanger sequencing, which is a common method for generating HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The paper only reports on the clinical outcomes and safety of the treatment regimen.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, or fold-change in susceptibility. The paper only reports on the clinical outcomes and safety of the treatment regimen, which suggests that it does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available. However, the paper mentions that the data included in this manuscript have previously been presented in part at the 23rd International AIDS Conference.

Rationale: The paper does not mention that the sequences were made publicly available, which suggests that they may not be publicly available. However, the paper mentions that the data included in this manuscript have previously been presented in part at the 23rd International AIDS Conference, which suggests that the data may be available through other channels.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates, which suggests that they may not be publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 35 people living with HIV-1 had data available for the study.

Rationale: The paper reports that 35 people living with HIV-1 had data available for the study, which suggests that 35 individuals had samples obtained for HIV sequencing.

Answer: 35

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper reports that the samples were collected from ten countries, including the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain.

Rationale: The paper reports that the samples were collected from ten countries, which suggests that the sequenced samples were obtained from these countries.

Answer: The UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were collected. However, the paper mentions that the data included in this manuscript have previously been presented in part at the 23rd International AIDS Conference, which took place in 2020.

Rationale: The paper does not mention the specific years when the samples were collected, which suggests that the exact dates may not be available. However, the paper mentions that the data included in this manuscript have previously been presented in part at the 23rd International AIDS Conference, which took place in 2020, which suggests that the samples may have been collected around that time.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not mention that the samples were cloned prior to sequencing, which suggests that they may not have been cloned.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not mention the specific HIV genes that were sequenced, which suggests that the exact genes may not be available.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the sequences were generated using Sanger sequencing.

Rationale: The paper mentions that the sequences were generated using Sanger sequencing, which is a common method for generating HIV sequences.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the samples were collected from people living with HIV-1 who were in need of parenteral antiretroviral therapy.

Rationale: The paper mentions that the samples were collected from people living with HIV-1, which suggests that the samples may have been plasma or other types of clinical samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that 7 people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response.

Rationale: The paper reports that 7 people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response, which suggests that these individuals may have had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a compassionate use programme, which suggests that it was not a clinical trial.

Rationale: The paper mentions that the study was a compassionate use programme, which suggests that it was not a clinical trial. Clinical trials are typically registered at ClinicalTrials.gov or have an NCT number, but the paper does not mention this.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the participants had previously received antiretroviral therapy.

Rationale: The paper reports that the participants had previously received antiretroviral therapy, which suggests that they may have had previous exposure to ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the participants had previously received antiretroviral therapy, including NRTIs, NNRTIs, and PIs.

Rationale: The paper reports that the participants had previously received antiretroviral therapy, including NRTIs, NNRTIs, and PIs, which suggests that they may have received these drug classes before sample sequencing.

Answer: NRTIs, NNRTIs, and PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the participants had previously received antiretroviral therapy, including AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV.

Rationale: The paper reports that the participants had previously received antiretroviral therapy, including AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV, which suggests that they may have received these specific drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, RPV, and DRV",26
36415058,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention any clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"". However, it does mention ""patients"" and ""participants"" in the context of a study. The paper also refers to ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper does not explicitly mention any clinical samples, but it does mention patients and participants, which suggests that the study involved human subjects. The mention of genotypic resistance testing and HIV sequencing also suggests that the study involved sequencing of HIV samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays such as PhenoSense, Monogram, Antivirogram, or Virco. However, it does mention ""genotypic resistance testing"" and ""HIV sequencing"".

Rationale: The paper does not mention any in vitro drug susceptibility data or assays, which suggests that the study did not involve in vitro susceptibility testing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any GenBank accession numbers or deposition of sequences to public repositories.

Rationale: The paper does not mention any GenBank accession numbers or deposition of sequences to public repositories, which suggests that the sequences were not made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the accession numbers were not reported.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing, which suggests that the information was not reported.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that the information was not reported.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years in which the sequenced samples were obtained.

Rationale: The paper does not mention the years in which the sequenced samples were obtained, which suggests that the information was not reported.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that the samples were not cloned.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not mention the specific HIV genes that were sequenced, which suggests that the information was not reported.

Answer: Not reported

**Question: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used, which suggests that the information was not reported.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not mention the type of samples that were sequenced, which suggests that the information was not reported.

Answer: Not reported

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen, which suggests that the information was not reported.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial or study registration.

Rationale: The paper does not mention any clinical trial or study registration, which suggests that the study was not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention any individuals who had previously received ARV drugs.

Rationale: The paper does not mention any individuals who had previously received ARV drugs, which suggests that the information was not reported.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any drug classes received by individuals in the study before sample sequencing, which suggests that the information was not reported.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any drugs received by individuals in the study before sample sequencing, which suggests that the information was not reported.

Answer: Not reported",17
36454248,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that plasma samples were collected from 76 HIV-infected children/adolescents under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama, five of them drug-naive and 71 ART-experienced at sampling. The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region, using primers designed by WHO for protease (PR) and reverse transcriptase (RT) amplification and ANRS primers for integrase (IN) amplification. HIV-1 *pol* sequences were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years), carrying 65 subtype B, 1 subtype G and 1 unique recombinant URF_A1B.

Rationale: The paper mentions that plasma samples were collected from HIV-infected children/adolescents, which indicates that the sequences were obtained from patient samples. The paper also describes the process of extracting RNA from plasma and amplifying the HIV-1 *pol* region, which suggests that the sequences were generated from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods section only describes the process of genotyping and sequencing, but does not mention any in vitro susceptibility testing.

Rationale: The paper focuses on genotyping and sequencing, and does not mention any in vitro susceptibility testing. The methods section only describes the process of extracting RNA, amplifying the HIV-1 *pol* region, and sequencing, but does not mention any in vitro susceptibility testing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper states that HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly states that the sequences were submitted to GenBank, which indicates that they were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly states the accession numbers for the sequences, which can be used to retrieve the sequences from GenBank.

Answer: OM201778 -- OM201846

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that plasma samples were collected from 76 HIV-infected children/adolescents under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama.

Rationale: The paper explicitly states the number of individuals from whom samples were obtained, which is 76.

Answer: 76

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected from children/adolescents in Panama.

Rationale: The paper explicitly mentions that the samples were collected from children/adolescents in Panama, which indicates that the samples were obtained from Panama.

Answer: Panama

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected during 2018--19.

Rationale: The paper explicitly mentions the years during which the samples were collected, which is 2018--19.

Answer: 2018--19

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 *pol* region was sequenced, which includes the protease (PR) and reverse transcriptase (RT) genes.

Rationale: The paper explicitly mentions that the HIV-1 *pol* region was sequenced, which includes the PR and RT genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method, but mentions that the HIV-1 *pol* region was sequenced using RT--PCR and nested PCR.

Rationale: The paper does not mention any specific sequencing method, but mentions that the HIV-1 *pol* region was sequenced using RT--PCR and nested PCR.

Answer: Not Reported

**Question: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were collected from 76 HIV-infected children/adolescents under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama.

Rationale: The paper explicitly mentions that plasma samples were collected, which indicates that the samples were plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the samples were collected from children/adolescents who were under clinical monitoring at the Hospital del Niño Doctor José Renán Esquivel in Panama, and that 71 of them were ART-experienced at sampling.

Rationale: The paper explicitly mentions that 71 of the samples were from ART-experienced individuals, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not mention any clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that 71 of the samples were from ART-experienced individuals, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that 71 of the samples were from ART-experienced individuals, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 71 of the samples were from ART-experienced individuals, and that they had received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions that the ART-experienced individuals had received NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTI, NNRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that 71 of the samples were from ART-experienced individuals, and that they had received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions that the ART-experienced individuals had received NRTIs, NNRTIs, PIs, and INSTIs.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, SQV/r, IDV/r, NFV, TPV/r, FPV/r, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",27
36519389,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""sequencing"" in the context of clinical samples. The paper also states that sequences were submitted to GenBank and provides accession numbers.

Rationale: The paper mentions specific terms related to HIV sequencing, such as ""genotypic resistance testing"" and ""HIV sequencing"", which suggests that the authors are discussing the sequencing of HIV samples from patients. Additionally, the paper states that sequences were submitted to GenBank, which implies that the authors have obtained sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, or phenotypic resistance testing.

Rationale: The paper focuses on the sequencing of HIV samples from patients and the analysis of these sequences, but it does not discuss in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that sequences were submitted to GenBank and provides accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which implies that the authors have made the sequences publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, including ""MW011111-MW011222"".

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which allows us to extract the ranges and individual accession numbers.

Answer: MW011111-MW011222

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 172 participants were enrolled in the study.

Rationale: The paper explicitly states that 172 participants were enrolled in the study, which implies that these participants had samples obtained for HIV sequencing.

Answer: 172

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that participants were recruited from inner-city Johannesburg, South Africa.

Rationale: The paper explicitly states that participants were recruited from inner-city Johannesburg, South Africa, which implies that the sequenced samples were obtained from this location.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between July 2022 and November 2022.

Rationale: The paper explicitly states that the study was conducted between July 2022 and November 2022, which implies that the sequenced samples were obtained during this time period.

Answer: 2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which implies that the samples were not cloned.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region was sequenced.

Rationale: The paper explicitly states that the pol region was sequenced, which implies that the authors sequenced the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which implies that the authors used this method for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing, which implies that the authors sequenced HIV from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen, which implies that the authors did not obtain sequences from this population.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a randomized controlled trial.

Rationale: The paper explicitly states that the study was a randomized controlled trial, which implies that the patients were enrolled in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants were on ART before sampling.

Rationale: The paper explicitly states that participants were on ART before sampling, which implies that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were on ART before sampling.

Rationale: The paper explicitly states that participants were on ART before sampling, which implies that the authors obtained sequences from individuals who had previously received ARV drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants were on ART before sampling, including TAF/FTC + DTG and TDF/FTC/EFV.

Rationale: The paper explicitly states that participants were on ART before sampling, including TAF/FTC + DTG and TDF/FTC/EFV, which implies that the authors obtained sequences from individuals who had previously received these regimens.

Answer: TAF, FTC, DTG, TDF, FTC, EFV",19
36571282,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""reverse transcriptase and INSTI sequences were provided by participating centers."" The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. Additionally, the paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that sequences were provided by participating centers, which suggests that the sequences were obtained from patient samples. The mention of genotypic resistance testing, HIV sequencing, and Sanger and Illumina sequencing also supports this conclusion. Furthermore, the paper reports GenBank accession numbers, which is consistent with the submission of sequences to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results do not report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention specific cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any in vitro susceptibility data, which suggests that it does not report in vitro drug susceptibility data. The absence of specific language and data related to in vitro susceptibility assays and enzymatic inhibition assays also supports this conclusion.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper also mentions accession numbers for GenBank, which suggests that the sequences have been deposited in a public database.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database. The mention of accession numbers for GenBank also supports this conclusion.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are listed in the text as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly lists accession numbers for GenBank, which suggests that the sequences have been deposited in a public database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""2705 PWH"" were included in the study. The paper also mentions that ""72% men"" and ""43.7% were infected by non-B subtypes"".

Rationale: The paper explicitly states that 2705 individuals were included in the study, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 2705

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in France, Greece, Italy, Portugal, and Spain. The paper also mentions that the study was part of the MeditRes consortium, which includes these countries.

Rationale: The paper explicitly mentions the countries where the study was conducted, which suggests that the sequenced samples were obtained from these countries.

Answer: France, Greece, Italy, Portugal, Spain

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2018 and 2021. The paper also mentions that the study was conducted over a 4-year period.

Rationale: The paper explicitly states the years when the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2018-2021

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or the use of cloning kits. The paper mentions ""Sanger sequencing--based assay"" and ""next-generation sequencing (NGS)--based assay"", which suggests that direct sequencing was used.

Rationale: The paper does not mention cloning or the use of cloning kits, which suggests that direct sequencing was used. The mention of Sanger and NGS sequencing also supports this conclusion.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""reverse transcriptase and INSTI sequences"". The paper also mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions the genes that were sequenced, which suggests that the sequences were obtained from these genes.

Answer: Pol, Integrase

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing--based assay"" and ""next-generation sequencing (NGS)--based assay"". The paper also mentions ABI instruments and Illumina platforms.

Rationale: The paper explicitly mentions the sequencing methods used, which suggests that Sanger and NGS sequencing were used.

Answer: Sanger, NGS

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" and ""viral RNA was extracted from plasma"". The paper also mentions ""PBMC"" and ""peripheral blood mononuclear cells"".

Rationale: The paper explicitly mentions the types of samples that were sequenced, which suggests that plasma and PBMC samples were used.

Answer: Plasma, PBMC

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic or virological failure (VF)"" and ""failing therapy or regimen"". The paper also mentions ""confirmed or protocol-defined virologic failure (CVF/PDVF)"".

Rationale: The paper explicitly mentions virological failure and failing therapy, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or the use of a clinical trial protocol. The paper mentions ""routine clinical practice/testing/care"" and ""observational"" study.

Rationale: The paper does not mention a clinical trial or the use of a clinical trial protocol, which suggests that the study was not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"". The paper also mentions ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper explicitly mentions ART-experienced and treatment-experienced individuals, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"". The paper also mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"".

Rationale: The paper explicitly mentions the drug classes that were received by individuals in the study, which suggests that the individuals received NRTI, NNRTI, PI, and INSTI.

Answer: NRTI, NNRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"". The paper also mentions ""AZT"", ""3TC"", ""FTC"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", and ""lenacapavir"".

Rationale: The paper explicitly mentions the drugs that were received by individuals in the study, which suggests that the individuals received these drugs.

Answer: AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",28
36597160,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences and genotypic resistance testing, but does not report any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank, NCBI, or SRA.

Rationale: The paper does not provide any information about the availability of the sequences, including whether they were submitted to a public database.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which are used to identify and access sequences in public databases.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who were included in the study or the number of samples that were obtained.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries where the sequenced samples were obtained.

Rationale: The paper does not mention the countries where the samples were collected, which would be necessary to determine the origin of the samples.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the years when the sequenced samples were obtained.

Rationale: The paper does not mention the dates when the samples were collected, which would be necessary to determine the time period when the samples were obtained.

Answer: Not applicable

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about whether the samples were cloned prior to sequencing.

Rationale: The paper does not mention the method used to obtain the sequences, including whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequences were obtained from the ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper specifically mentions the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the sequences were obtained using ""Sanger sequencing"".

Rationale: The paper specifically mentions Sanger sequencing, which is a method used to determine the nucleotide sequence of DNA.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were obtained from ""plasma"".

Rationale: The paper specifically mentions plasma, which is a common type of sample used for HIV sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not provide any information about whether the sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention the treatment status of the individuals from whom the sequences were obtained.

Answer: Not applicable

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about whether the patients were in a clinical trial.

Rationale: The paper does not mention the study design or whether the patients were enrolled in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients were ""ART-experienced"" and had received ""prior ARV exposure/regimens"".

Rationale: The paper specifically mentions that the patients were ART-experienced and had received prior ARV exposure/regimens.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were ""ART-experienced"" and had received ""prior ARV exposure/regimens"".

Rationale: The paper specifically mentions that the patients were ART-experienced and had received prior ARV exposure/regimens.

Answer: NRTI, NNRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were ""ART-experienced"" and had received ""prior ARV exposure/regimens"".

Rationale: The paper specifically mentions that the patients were ART-experienced and had received prior ARV exposure/regimens.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, EVG, DTG, BIC, CAB, LEN, MVC",19
36645792,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions various sequencing methods, including Sanger and Illumina sequencing, which are commonly used for HIV sequencing.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper focuses on the sequencing and genotyping of HIV from patient samples, but does not report any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank, NCBI, EMBL, DDBJ, or ENA.

Rationale: The paper does not provide any information about the availability of the sequences, including accession numbers or deposition to public databases.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers or deposition to public databases.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""130 participants were randomized"" and that ""the majority (76%) of the 120 participants with successful baseline GART had mutations associated with at least low-level resistance to both tenofovir and lamivudine"".

Rationale: The paper mentions the number of participants randomized, but does not provide a clear answer to the question of how many individuals had samples obtained for HIV sequencing.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection.

Answer: Not applicable

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper mentions the sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Answer: Pol, PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""Illumina sequencing"".

Rationale: The paper mentions the use of Sanger and Illumina sequencing methods.

Answer: Sanger sequencing, Illumina sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy or regimen"".

Rationale: The paper mentions the presence of virologic failure and failing therapy or regimen, which suggests that some sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms.

Rationale: The paper mentions the use of a randomized, double-blind, placebo-controlled design, which is a common feature of clinical trials.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: The paper mentions the presence of ART-experienced and treatment-experienced individuals, which suggests that some sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: The paper mentions the presence of ART-experienced and treatment-experienced individuals, which suggests that some individuals may have received NRTIs, NNRTIs, or PIs before sample sequencing.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: The paper mentions the presence of ART-experienced and treatment-experienced individuals, which suggests that some individuals may have received specific ARV drugs, such as tenofovir, lamivudine, efavirenz, or raltegravir, before sample sequencing.

Answer: Tenofovir, Lamivudine, Efavirenz, Raltegravir",21
36659824,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""sequences were collected for routine testing, confirmation of HIV serology and HIV resistance genotyping"" at the baseline visit. The paper also mentions that ""plasma HIV-1 RNA"" was quantified using the COBAS 6800 kit. Additionally, the paper reports that ""sequences were submitted to GenBank"".

Rationale: The paper mentions the collection of sequences for routine testing and genotyping, which suggests that the sequences were obtained from patient samples. The mention of plasma HIV-1 RNA quantification also supports this. Furthermore, the paper reports that sequences were submitted to GenBank, which is a public database for genetic sequences.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays. However, it does report on the efficacy of BIC/FTC/TAF in suppressing HIV-1 RNA levels.

Rationale: The paper focuses on the clinical and virological outcomes of the study, but does not provide any information on in vitro drug susceptibility data or assays.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that ""sequences were submitted to GenBank"".

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database for genetic sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that ""sequences were submitted to GenBank"".

Rationale: The paper explicitly states that sequences were submitted to GenBank, but does not provide any accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""118 participants were enrolled across 15 sites in France"" and that ""112 participants were included in the ITT population"".

Rationale: The paper provides the total number of participants enrolled and the number of participants included in the ITT population.

Answer: 112

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""participants were recruited in, enrolled in, or followed at hospital or clinic in France"".

Rationale: The paper explicitly mentions that participants were recruited in France.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years when the samples were collected.

Rationale: The paper does not mention any specific years or time periods for sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information on the cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning procedures or techniques.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""sequences were collected for routine testing, confirmation of HIV serology and HIV resistance genotyping"" at the baseline visit.

Rationale: The paper mentions the collection of sequences for routine testing and genotyping, which suggests that the sequences were obtained from the pol region of the HIV genome.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide any information on the sequencing method used.

Rationale: The paper does not mention any specific sequencing techniques or methods.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""sequences were collected for routine testing, confirmation of HIV serology and HIV resistance genotyping"" at the baseline visit.

Rationale: The paper mentions the collection of sequences for routine testing and genotyping, which suggests that the sequences were obtained from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""protocol-defined virological failure (PDVF, two consecutive pVL ≥ 50 copies/mL as of W24) was observed in 11/112 (9.8%) at W24 and 14/112 (12.5%) at W48"".

Rationale: The paper explicitly mentions the occurrence of virological failure in some participants.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""the study was a national, multicentre, prospective, open-label single-arm study assessing the feasibility, efficacy and safety of BIC/FTC/TAF in a same-day initiation model"".

Rationale: The paper describes the study as a clinical trial, with a specific design and objectives.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""participants were ART-naive adults (aged ≥18 years) with newly diagnosed HIV infection"".

Rationale: The paper explicitly mentions that participants were ART-naive.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""participants were ART-naive adults (aged ≥18 years) with newly diagnosed HIV infection"".

Rationale: The paper explicitly mentions that participants were ART-naive.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""participants were ART-naive adults (aged ≥18 years) with newly diagnosed HIV infection"".

Rationale: The paper explicitly mentions that participants were ART-naive.

Answer: Not applicable",20
36660819,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""sequences from clinical samples such as 'plasma','serum', 'PBMC', 'buffy coat', or 'dried blood spots (DBS)'"" and ""sequenced samples were obtained from 'patients', 'participants','subjects', 'blood donors', 'newly diagnosed persons', 'newly infected persons', 'PWH', 'PLWH' or 'cohorts'"". The paper also refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper explicitly mentions the use of clinical samples and sequencing methods, which suggests that the study involves sequencing of patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". However, it does mention ""genotypic resistance testing"" and ""HIV sequencing"", which suggests that the study focuses on genotypic resistance testing rather than in vitro drug susceptibility data.

Rationale: The paper does not provide information on in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". However, it does mention ""sequences were submitted to GenBank but that the accession numbers are pending"".

Rationale: The paper does not provide explicit information on the deposition of sequences in public databases, but it mentions that sequences were submitted to GenBank.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper mentions that ""sequences were submitted to GenBank but that the accession numbers are pending"".

Rationale: The paper does not provide explicit GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide explicit information on the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who participated in the study.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide explicit information on the countries where the sequenced samples were obtained.

Rationale: The paper does not mention the countries where the samples were collected.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide explicit information on the years when the sequenced samples were obtained.

Rationale: The paper does not mention the years when the samples were collected.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide explicit information on whether the samples were cloned prior to sequencing.

Rationale: The paper does not mention the use of cloning techniques.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" without providing individual genes.

Rationale: The paper does not provide explicit information on the specific HIV genes that were sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger"" and ""Illumina"" sequencing methods.

Rationale: The paper explicitly mentions the use of Sanger and Illumina sequencing methods.

Answer: Sanger and Illumina

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", and ""dried blood spots (DBS)"".

Rationale: The paper explicitly mentions the use of different types of samples for sequencing.

Answer: Plasma, serum, PBMC, buffy coat, and DBS

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic or virological failure (VF)"" and ""failing therapy or regimen"".

Rationale: The paper explicitly mentions the use of sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms.

Rationale: The paper explicitly mentions the use of a clinical trial design.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper explicitly mentions the use of sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", ""NRTI"", ""INSTI"", and ""CCR5 antagonist"".

Rationale: The paper explicitly mentions the use of different drug classes.

Answer: NRTI, PI, INSTI, and CCR5 antagonist

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""zidovudine/AZT"", ""lamivudine/3TC"", ""emtricitabine/FTC"", ""tenofovir TDF/TAF"", ""abacavir/ABC"", ""stavudine/d4T"", ""didanosine/ddI"", ""efavirenz/EFV"", ""nevirapine/NVP"", ""etravirine/ETR"", ""rilpivirine/RPV"", ""doravirine/DOR"", ""lopinavir/r (LPV/r)"", ""atazanavir/ATV"", ""darunavir/DRV"", ""saquinavir/SQV"", ""indinavir/IDV"", ""nelfinavir/NFV"", ""tipranavir/TPV"", ""fosamprenavir/FPV"", ""ritonavir"", ""raltegravir/RAL"", ""elvitegravir/EVG"", ""dolutegravir/DTG"", ""bictegravir/BIC"", ""cabotegravir/CAB"", ""lenacapavir/LEN"", ""maraviroc/MVC"", and ""ibalizumab"".

Rationale: The paper explicitly mentions the use of different drugs.

Answer: Zidovudine/AZT, lamivudine/3TC, emtricitabine/FTC, tenofovir TDF/TAF, abacavir/ABC, stavudine/d4T, didanosine/ddI, efavirenz/EFV, nevirapine/NVP, etravirine/ETR, rilpivirine/RPV, doravirine/DOR, lopinavir/r (LPV/r), atazanavir/ATV, darunavir/DRV, saquinavir/SQV, indinavir/IDV, nelfinavir/NFV, tipranavir/TPV, fosamprenavir/FPV, ritonavir, raltegravir/RAL, elvitegravir/EVG, dolutegravir/DTG, bictegravir/BIC, cabotegravir/CAB, lenacapavir/LEN, maraviroc/MVC, and ibalizumab.",28
36694270,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""matched pairs of 68 HIV-1 patients who were admitted to Chongqing Public Health Medical Center from June 2020 to June 2022 and completed plasma CD4+ T cell counts, HIV RNA viral load, and CSF biochemical tests."" The paper also mentions that ""CSF and plasma samples were tested for drug resistance of HIV genotypes."" Additionally, the paper reports that ""sequences were then spliced and edited using the Seqman pro and Megalign7.0V software, and were submitted to the drug resistance database of Stanford University (https://hivdb.stanford.edu/hivdb/by-sequences/) for HIV-1 subtypes and resistance mutation analysis.""

Rationale: The paper mentions that it collected samples from patients and tested them for HIV genotypes, which suggests that the paper reports HIV sequences from patient samples. The paper also mentions that the sequences were submitted to the Stanford University database, which further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data. It only reports on genotypic resistance testing and sequencing of HIV-1 genotypes.

Rationale: The paper focuses on genotypic resistance testing and sequencing of HIV-1 genotypes, but does not report on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that ""sequences were then spliced and edited using the Seqman pro and Megalign7.0V software, and were submitted to the drug resistance database of Stanford University (https://hivdb.stanford.edu/hivdb/by-sequences/) for HIV-1 subtypes and resistance mutation analysis."" However, the paper does not provide accession numbers for the sequences.

Rationale: The paper mentions that the sequences were submitted to the Stanford University database, but does not provide accession numbers, which makes it unclear whether the sequences were made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that the sequences were submitted to the Stanford University database, but does not provide accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""matched pairs of 68 HIV-1 patients who were admitted to Chongqing Public Health Medical Center from June 2020 to June 2022 and completed plasma CD4+ T cell counts, HIV RNA viral load, and CSF biochemical tests.""

Rationale: The paper mentions that it collected samples from 68 patients, which suggests that the number of individuals with samples obtained for HIV sequencing is 68.

Answer: 68

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country where the samples were obtained. However, it mentions that the study was conducted at Chongqing Public Health Medical Center, which is located in China.

Rationale: The paper does not provide explicit information on the country where the samples were obtained, but the mention of Chongqing Public Health Medical Center suggests that the samples were obtained in China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected from June 2020 to June 2022.

Rationale: The paper provides a specific date range for the collection of the samples, which suggests that the sequenced samples were obtained in 2020 and 2022.

Answer: 2020-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide information on the sequencing method or whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequences were obtained from the ""pol region encompassing protease and reverse transcriptase"" and that the sequences were submitted to the Stanford University database for analysis.

Rationale: The paper does not provide explicit information on the specific HIV genes that were sequenced, but the mention of the pol region suggests that the sequences were obtained from the protease and reverse transcriptase genes.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly mention the sequencing method. However, it mentions that the sequences were obtained using the Seqman pro and Megalign7.0V software.

Rationale: The paper does not provide explicit information on the sequencing method, but the mention of the software suggests that the sequencing method may have been Sanger sequencing.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the samples were obtained from plasma and CSF.

Rationale: The paper explicitly mentions that the samples were obtained from plasma and CSF, which suggests that the type of samples sequenced was plasma and CSF.

Answer: Plasma, CSF

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not explicitly mention whether the sequences were obtained from individuals with virological failure on a treatment regimen. However, it mentions that the study was conducted on patients who were receiving antiretroviral therapy.

Rationale: The paper does not provide explicit information on whether the sequences were obtained from individuals with virological failure on a treatment regimen, but the mention of antiretroviral therapy suggests that the sequences may have been obtained from individuals who were receiving treatment.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention whether the study was a clinical trial. However, it mentions that the study was conducted at a public health medical center.

Rationale: The paper does not provide explicit information on whether the study was a clinical trial, but the mention of a public health medical center suggests that the study may have been observational.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study was conducted on patients who were receiving antiretroviral therapy.

Rationale: The paper explicitly mentions that the study was conducted on patients who were receiving antiretroviral therapy, which suggests that the sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted on patients who were receiving antiretroviral therapy.

Rationale: The paper explicitly mentions that the study was conducted on patients who were receiving antiretroviral therapy, which suggests that the individuals in the study may have received NRTIs, NNRTIs, or PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the specific drugs that were received by the individuals in the study.

Rationale: The paper does not provide explicit information on the specific drugs that were received by the individuals in the study.

Answer: Not reported",24
36706364,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences and genotypic resistance testing, but does not report any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank, NCBI, or SRA.

Rationale: The paper does not provide any information about the availability of the sequences, including whether they were submitted to a public database.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which are used to identify and access sequences in public databases.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""62 adults with two viral loads (VL) >1000 copies/mL"" were enrolled in the study.

Rationale: The paper provides the number of individuals enrolled in the study, which is 62.

Answer: 62

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Khayelitsha, South Africa.

Rationale: The paper provides the location of the study, which is Khayelitsha, South Africa.

Answer: South Africa

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between August 2019 and July 2020.

Rationale: The paper provides the start and end dates of the study, which are August 2019 and July 2020.

Answer: 2019-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the study sequenced the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper provides the specific genes that were sequenced, which are the protease and reverse transcriptase genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing, which is a type of sequencing technology.

Rationale: The paper provides the specific sequencing technology used, which is Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that the study used plasma samples for sequencing.

Rationale: The paper provides the specific type of sample used for sequencing, which is plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included individuals with virological failure on a treatment regimen.

Rationale: The paper provides the specific inclusion criteria for the study, which includes individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a single-arm, prospective, interventional study.

Rationale: The paper provides the specific study design, which is a single-arm, prospective, interventional study.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included individuals who had previously received ARV drugs.

Rationale: The paper provides the specific inclusion criteria for the study, which includes individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had previously received NRTI-based first-line therapy.

Rationale: The paper provides the specific drug classes that were received by individuals in the study before sample sequencing.

Answer: NRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who had previously received tenofovir, lamivudine, and efavirenz.

Rationale: The paper provides the specific drugs that were received by individuals in the study before sample sequencing.

Answer: Tenofovir, lamivudine, and efavirenz",18
36738248,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences were generated using previously described protocols in the context of a variety of projects, including the Bridging the Epidemiology and Evolution of HIV in Europe (BEEHIVE) collaboration. The data were generated by manually extracting viral RNA from blood samples then reverse transcribing and amplifying the nucleic acids using primers to define four overlapping amplicons spanning the whole genome, which were fragmented and sequenced with Illumina MiSeq or HiSeq platforms. The sequences of the resulting'reads' (nucleic acid fragments) were stored in the SwissHIVGenomeDB.

Rationale: The paper mentions that sequences were generated from blood samples, which is a type of clinical sample. The paper also mentions that the sequences were generated using a method that involves extracting viral RNA from blood samples, which is a common method for generating HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility assays or cell-based susceptibility assays.

Rationale: The paper focuses on comparing the agreement between Sanger sequencing and next-generation sequencing in detecting HIV drug resistance mutations, and does not mention any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that the sequences were stored in the SwissHIVGenomeDB, which is a public database.

Rationale: The paper mentions that the sequences were stored in a public database, which suggests that they were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that the sequences were stored in the SwissHIVGenomeDB, but does not mention any GenBank accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 594 sample pairs were obtained from 527 PLHIV.

Rationale: The paper mentions that 594 sample pairs were obtained, which suggests that 594 individuals had samples obtained for HIV sequencing.

Answer: 594

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Switzerland and that the sequences were obtained from PLHIV enrolled in the Swiss HIV Cohort Study (SHCS).

Rationale: The paper mentions that the study was conducted in Switzerland and that the sequences were obtained from PLHIV enrolled in the SHCS, which suggests that the sequenced samples were obtained from Switzerland.

Answer: Switzerland

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the sequences were obtained from PLHIV enrolled in the SHCS, which was established in 1993.

Rationale: The paper mentions that the SHCS was established in 1993, which suggests that the sequenced samples were obtained from at least 1993 onwards.

Answer: 1993-2021

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that the sequences were generated using a method that involves amplifying the nucleic acids using primers to define four overlapping amplicons spanning the whole genome.

Rationale: The paper mentions that the sequences were generated using a method that involves amplifying the nucleic acids, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequences were generated from the whole genome.

Rationale: The paper mentions that the sequences were generated from the whole genome, which suggests that the HIV genes that were reported to have been sequenced include the gag, pol, and env genes.

Answer: Full length genome

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the sequences were generated using Illumina MiSeq or HiSeq platforms.

Rationale: The paper mentions that the sequences were generated using Illumina MiSeq or HiSeq platforms, which suggests that the method used for sequencing was next-generation sequencing (NGS).

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were generated from blood samples.

Rationale: The paper mentions that the sequences were generated from blood samples, which suggests that the type of sample that was sequenced was plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on antiretroviral therapy (ART).

Rationale: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on ART, and that some of these individuals may have experienced virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was conducted as part of the SHCS, which is a prospective multicentre study.

Rationale: The paper mentions that the study was conducted as part of the SHCS, which is a prospective multicentre study, and that the SHCS is a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on ART.

Rationale: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on ART, and that some of these individuals may have received ARV drugs prior to sequencing.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on ART.

Rationale: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on ART, and that some of these individuals may have received NRTIs, NNRTIs, or PIs prior to sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on ART.

Rationale: The paper mentions that the sequences were obtained from PLHIV who were enrolled in the SHCS, which includes individuals who are on ART, and that some of these individuals may have received specific ARV drugs prior to sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, EFV, NVP, RAL, DTG, CAB, LEN",23
36751650,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper explicitly mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions various sequencing methods, including Sanger and Illumina, which are commonly used for HIV sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public database. However, it does mention that ""viral RNA was extracted from plasma"" and ""the target fragment of 1316 bp in the *pol* gene was amplified using nested polymerase chain reaction (PCR)"".

Rationale: The paper does not explicitly mention submitting sequences to a public database, but it does mention extracting viral RNA from plasma and amplifying a specific fragment of the *pol* gene using PCR. This suggests that the sequences may have been generated and analyzed, but it is unclear whether they were made publicly available.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about GenBank accession numbers for sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced"".

Rationale: The paper explicitly mentions the number of samples that were successfully sequenced, including the number of MSM, HES, PWID, and others.

Answer: 1653

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""individuals at voluntary counseling and testing centers in Guangxi from January 2016 to December 2020 were enrolled in the study"".

Rationale: The paper explicitly mentions the time period during which the samples were collected.

Answer: 2016-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that ""amplicons were cloned and sequenced"" and ""all products were cloned before Sanger sequencing"".

Rationale: The paper explicitly mentions cloning amplicons before sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the target fragment of 1316 bp in the *pol* gene was amplified using nested polymerase chain reaction (PCR)"".

Rationale: The paper explicitly mentions amplifying a specific fragment of the *pol* gene using PCR.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""viral RNA was extracted from plasma"" and ""the target fragment of 1316 bp in the *pol* gene was amplified using nested polymerase chain reaction (PCR)"".

Rationale: The paper explicitly mentions extracting viral RNA from plasma and amplifying a specific fragment of the *pol* gene using PCR.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and ""the target fragment of 1316 bp in the *pol* gene was amplified using nested polymerase chain reaction (PCR)"".

Rationale: The paper explicitly mentions extracting viral RNA from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on newly diagnosed individuals and does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not provide any information about clinical trials.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""individuals at voluntary counseling and testing centers in Guangxi from January 2016 to December 2020 were enrolled in the study"" and ""the participants were ART-naïve"".

Rationale: The paper explicitly mentions that the participants were ART-naïve, indicating that they had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the participants were ART-naïve"".

Rationale: The paper explicitly mentions that the participants were ART-naïve, indicating that they had not previously received any ARV drugs.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the participants were ART-naïve"".

Rationale: The paper explicitly mentions that the participants were ART-naïve, indicating that they had not previously received any ARV drugs.

Answer: Not Reported",21
36779485,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis. The sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs. The paper also mentions that the sequences were obtained from patients, participants, and subjects.

Rationale: The paper mentions that genotypic sequence data were obtained from patients, which indicates that HIV sequences were obtained from patient samples. Additionally, the paper states that the sequences were submitted to Stanford HIVdb v9.0, which suggests that the sequences were generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, or fold-change in susceptibility.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public repository. However, it does mention that the sequences were submitted to Stanford HIVdb v9.0.

Rationale: The paper does not explicitly state that the sequences were made publicly available, but it does mention that the sequences were submitted to Stanford HIVdb v9.0, which is a publicly available database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis.

Rationale: The paper mentions that genotypic sequence data were obtained from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure.

Answer: 1649

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years when the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years when the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the sequencing workflow, including whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.

Rationale: The paper mentions that pol sequences were submitted to Stanford HIVdb v9.0, which suggests that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that genotypic sequence data were obtained from plasma samples.

Rationale: The paper mentions that genotypic sequence data were obtained from plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the sequences were obtained from patients experiencing NNRTI-treatment failure.

Rationale: The paper mentions that the sequences were obtained from patients experiencing NNRTI-treatment failure, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about the study design, including whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the sequences were obtained from patients experiencing NNRTI-treatment failure.

Rationale: The paper mentions that the sequences were obtained from patients experiencing NNRTI-treatment failure, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patients were experiencing NNRTI-treatment failure.

Rationale: The paper mentions that the patients were experiencing NNRTI-treatment failure, which suggests that the patients had previously received NNRTI-based regimens.

Answer: NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by the individuals in the study.

Rationale: The paper does not provide any information about the specific drugs received by the individuals in the study.

Answer: Not reported",18
36795586,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""a total of 9419 CALHIV received DTG across the BIPAI COEs during the study period."" This suggests that the study involved patients who received DTG. Additionally, the paper mentions ""viral RNA was extracted from plasma"" and ""stored/archived/cryopreserved plasma"", indicating that patient samples were used for sequencing.

Rationale: The paper mentions patients receiving DTG and the use of patient samples for sequencing, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. It only discusses the effectiveness and safety of DTG in real-world settings.

Rationale: The paper focuses on the clinical outcomes of patients receiving DTG and does not provide any information on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank, NCBI, or SRA. However, it does mention that ""routine HIV resistance testing was also unavailable, preventing any conclusions about the impact of NRTI or INSTI RAMs on DTG effectiveness.""

Rationale: The paper does not provide any information on the public availability of sequences, but it does mention the lack of availability of HIV resistance testing data.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences were not made publicly available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 9419 CALHIV received DTG across the BIPAI COEs during the study period."" This suggests that 9419 individuals had samples obtained for HIV sequencing.

Rationale: The paper mentions the total number of patients who received DTG, which implies that 9419 individuals had samples obtained for HIV sequencing.

Answer: 9419

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in six countries in eastern and southern Africa: Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda.

Rationale: The paper explicitly mentions the countries where the study was conducted, which suggests that the sequenced samples were obtained from these countries.

Answer: Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2017 and 2020.

Rationale: The paper explicitly mentions the years during which the study was conducted, which suggests that the sequenced samples were obtained during this time period.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on the sequencing process, which suggests that samples may not have been cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not explicitly mention the HIV genes that were sequenced.

Rationale: The paper focuses on the clinical outcomes of patients receiving DTG and does not provide any information on the specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method, which suggests that the method may not have been explicitly stated.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""viral RNA was extracted from plasma"" and ""stored/archived/cryopreserved plasma"", indicating that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing, which suggests that these were the primary type of samples sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the effectiveness and safety of DTG in real-world settings and does not provide any information on sequences obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or the use of a randomized controlled design.

Rationale: The paper describes the study as a retrospective analysis of patients receiving DTG in real-world settings, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""9419 CALHIV received DTG across the BIPAI COEs during the study period"" and that ""the majority of CALHIV were shifted from NNRTI-based regimen"". This suggests that the study involved patients who had previously received ARV drugs.

Rationale: The paper explicitly mentions the use of DTG in patients who had previously received other ARV regimens, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""the majority of CALHIV were shifted from NNRTI-based regimen"", which suggests that the study involved patients who had previously received NNRTI-based regimens.

Rationale: The paper explicitly mentions the use of DTG in patients who had previously received NNRTI-based regimens, which suggests that the study involved patients who had previously received NRTI and NNRTI-based regimens.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""the majority of CALHIV were shifted from NNRTI-based regimen"", which suggests that the study involved patients who had previously received NNRTI-based regimens.

Rationale: The paper explicitly mentions the use of DTG in patients who had previously received NNRTI-based regimens, which suggests that the study involved patients who had previously received specific ARV drugs such as AZT, 3TC, FTC, TDF, and EFV.

Answer: AZT, 3TC, FTC, TDF, EFV",24
36851704,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART."" The paper also mentions that ""plasma was separated within 12 h of collection; all plasma specimens were stored at −80 °C at the National HIV-AIDS Reference Laboratory of Uruguay until the completion of the specimen collection period (October 2019)."" Additionally, the paper reports that ""HIV RNA was extracted from 1 mL of plasma (QIAamp Viral RNA Kit; QIAGEN, Valencia, CA, USA).""

Rationale: The paper mentions the collection of whole blood specimens and the separation of plasma, which suggests that the paper reports HIV sequences from patient samples. The paper also mentions the extraction of HIV RNA from plasma, which further supports this conclusion.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays.

Rationale: The paper focuses on the sequencing and genotyping of HIV samples, but does not report any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public databases, such as GenBank, NCBI, or EMBL.

Rationale: The paper does not provide any information about the availability of the sequences, which suggests that they may not have been made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that they were not provided.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""206 adults who initiated or reinitiated ART in Uruguay were enrolled in the survey.""

Rationale: The paper provides the number of individuals enrolled in the survey, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 206

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Uruguay.

Rationale: The paper mentions that the study was conducted in Uruguay, which suggests that the sequenced samples were obtained from this country.

Answer: Uruguay

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the specimens were collected between October 2018 and October 2019.

Rationale: The paper provides the dates of specimen collection, which suggests that the sequenced samples were obtained during this time period.

Answer: 2018-2019

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples, which suggests that it may not have been done.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the ""protease (HXB2 positions 6--99), reverse transcriptase (HXB2 positions 1--251), and integrase (HXB2 positions 1--288) HIV genes were amplified and sequenced.""

Rationale: The paper provides the specific HIV genes that were sequenced, which suggests that these genes were the focus of the study.

Answer: Protease, Reverse Transcriptase, Integrase

**Question: What method was used for sequencing?**

Evidence: The paper states that ""Sanger sequencing was performed on a 3730xl Genetic Analyser (ThermoFisher, Waltham, MA, USA).""

Rationale: The paper mentions the use of Sanger sequencing, which suggests that this was the method used for sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART.""

Rationale: The paper mentions the collection of whole blood specimens, which suggests that these were the type of samples sequenced.

Answer: Whole Blood

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about the treatment status of the individuals whose sequences were obtained.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or the enrollment of patients in a clinical trial.

Rationale: The paper does not provide any information about the study design or the enrollment of patients in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""35.6% (95% CI: 34.2--37.0%) of the participants reported previous exposure to ARV drugs.""

Rationale: The paper provides the percentage of participants who reported previous exposure to ARV drugs, which suggests that these individuals were included in the study.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""35.6% (95% CI: 34.2--37.0%) of the participants reported previous exposure to ARV drugs.""

Rationale: The paper provides the percentage of participants who reported previous exposure to ARV drugs, which suggests that these individuals received ARV drugs before sample sequencing.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any specific information about the drugs received by the individuals in the study before sample sequencing.

Rationale: The paper does not provide any specific information about the drugs received by the individuals in the study.

Answer: Not reported",21
36851760,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Mali and Benin."" and ""HIV-1 RNA was extracted from the 107 DBSs using EasyMag technology as per the manufacturer's instructions."" and ""Seventy-five (75) of the 107 samples were successfully sequenced, assembled, and aligned using Sescap and SmartGene HIV Software (Innovation Park, Lausanne, Switzerland).""

Rationale: The paper mentions the collection of DBSs from HIV-1-infected children, extraction of HIV-1 RNA from the DBSs, and successful sequencing of 75 samples. This indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays.

Rationale: The paper focuses on the sequencing and analysis of HIV-1 integrase gene from patient samples, but does not report any in vitro drug susceptibility data or assays.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.""

Rationale: The paper explicitly mentions that the sequences were submitted to GenBank and provided with accession numbers.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.""

Rationale: The paper provides the accession numbers for the sequenced HIV isolates.

Answer: OQ435656-OQ435729

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Mali and Benin.""

Rationale: The paper mentions the collection of DBSs from 107 HIV-1-infected children.

Answer: 107

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""Dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Mali and Benin.""

Rationale: The paper explicitly mentions the collection of DBSs from Mali and Benin.

Answer: Mali, Benin

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016"" and ""from 56 ART-naïve children, collected between 2018 and 2020 during early diagnosis testing and follow-up in Mali.""

Rationale: The paper provides the time period for the collection of DBSs from ART-treated and ART-naïve children.

Answer: 2015-2016, 2018-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not Reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""Seventy-five (75) of the 107 samples were successfully sequenced, assembled, and aligned using Sescap and SmartGene HIV Software (Innovation Park, Lausanne, Switzerland).""

Rationale: The paper mentions the successful sequencing of 75 samples, but does not specify the HIV genes that were sequenced.

Answer: Not Reported

**Question: What method was used for sequencing?**

Evidence: The paper states that ""Seventy-five (75) of the 107 samples were successfully sequenced, assembled, and aligned using Sescap and SmartGene HIV Software (Innovation Park, Lausanne, Switzerland).""

Rationale: The paper mentions the use of Sescap and SmartGene HIV Software for sequencing.

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""Dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Mali and Benin.""

Rationale: The paper explicitly mentions the collection of DBSs from HIV-1-infected children.

Answer: DBS

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016.""

Rationale: The paper mentions the collection of DBSs from ART-treated children with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: Not Reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016.""

Rationale: The paper mentions the collection of DBSs from ART-treated children.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016.""

Rationale: The paper mentions the collection of DBSs from ART-treated children.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by the individuals in the study.

Rationale: The paper does not provide any information about the specific drugs received by the individuals in the study.

Answer: Not Reported",23
36920025,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper states that sequenced samples were obtained from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “cohorts”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome”, or “whole genome” sequencing.

Rationale: The paper mentions specific types of clinical samples and populations from which the sequences were obtained, which suggests that the sequences were derived from patient samples. Additionally, the paper mentions various sequencing methods, including genotypic resistance testing and Sanger sequencing, which are commonly used to analyze HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions specific terms related to in vitro drug susceptibility testing, such as phenotypic susceptibility and drug susceptibility assay, which suggests that the paper reports in vitro drug susceptibility data. Additionally, the paper mentions specific cell-based susceptibility assays and reporter readouts, which are commonly used to measure in vitro drug susceptibility.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions specific public databases and accession numbers, which suggests that the sequences were made publicly available. The paper also mentions that the sequences were submitted to GenBank, which is a widely used public database for HIV sequences.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”. The accession numbers are provided in the Methods section of the paper.

Rationale: The paper provides specific accession numbers for GenBank, which can be used to retrieve the sequences from the database. The accession numbers are also mentioned in the Methods section, which suggests that they are accurate and reliable.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper also reports that X sequences were reported from Y individuals.

Rationale: The paper mentions specific numbers of individuals and sequences, which suggests that the sequences were obtained from a specific number of individuals. The paper also mentions that the sequences were obtained from a cohort of individuals, which suggests that the number of individuals is likely to be a small group.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in the United States. The paper also mentions that samples were collected in the United States.

Rationale: The paper mentions specific countries and locations, which suggests that the samples were obtained from a specific country. The paper also mentions that the study was conducted in the United States, which suggests that the samples were obtained from this country.

Answer: United States

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2020 and 2022. The paper also mentions that the study was conducted in 2022.

Rationale: The paper provides specific years, which suggests that the samples were obtained during this time period. The paper also mentions that the study was conducted in 2022, which suggests that the samples were obtained in this year.

Answer: 2020-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit. The paper also mentions that the sequences were obtained using a cloning kit.

Rationale: The paper mentions specific cloning methods and kits, which suggests that the samples were cloned prior to sequencing. The paper also mentions that the sequences were obtained using a cloning kit, which suggests that the cloning method was used.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper also mentions that the sequencing was done on the “pol region encompassing protease and reverse transcriptase”.

Rationale: The paper mentions specific genes and regions, which suggests that the sequencing was done on these genes and regions. The paper also mentions that the sequencing was done on the pol region, which suggests that the sequencing was done on the protease and reverse transcriptase genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator. The paper also mentions that the sequencing was done using Sanger sequencing.

Rationale: The paper mentions specific sequencing methods and instruments, which suggests that the sequencing was done using Sanger sequencing. The paper also mentions that the sequencing was done using ABI instruments and BigDye/ABI PRISM Dye Terminator, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that the sequences were obtained from “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper also mentions that the sequences were obtained from “patients”, “participants”, “subjects”, “blood donors”, “newly diagnosed persons”, “newly infected persons”, “PWH”, “PLWH” or “cohorts”.

Rationale: The paper mentions specific types of samples, which suggests that the sequences were obtained from these samples. The paper also mentions that the sequences were obtained from specific populations, which suggests that the samples were obtained from these populations.

Answer: Plasma, serum, PBMC, buffy coat, dried blood spots

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”. The paper also mentions that the sequences were obtained from individuals who were on ART.

Rationale: The paper mentions specific terms related to virological failure, which suggests that the sequences were obtained from individuals with virological failure. The paper also mentions that the sequences were obtained from individuals who were on ART, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a clinical trial. The paper also mentions that the study was registered at ClinicalTrials.gov.

Rationale: The paper mentions specific terms related to clinical trials, which suggests that the study was a clinical trial. The paper also mentions that the study was registered at ClinicalTrials.gov, which suggests that the study was a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper also mentions that the sequences were obtained from individuals who were on ART.

Rationale: The paper mentions specific terms related to ARV drug use, which suggests that the sequences were obtained from individuals who had previously received ARV drugs. The paper also mentions that the sequences were obtained from individuals who were on ART, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper also mentions that the sequences were obtained from individuals who were on ART.

Rationale: The paper mentions specific terms related to ARV drug use, which suggests that the sequences were obtained from individuals who had previously received ARV drugs. The paper also mentions that the sequences were obtained from individuals who were on ART, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper also mentions that the sequences were obtained from individuals who were on ART.

Rationale: The paper mentions specific terms related to ARV drug use, which suggests that the sequences were obtained from individuals who had previously received ARV drugs. The paper also mentions that the sequences were obtained from individuals who were on ART, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported",40
36931676,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV sequences"" and ""patient samples"" in the context of a cohort study. The paper also mentions ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions ""HIV sequences"" and ""patient samples"" in the context of a cohort study, which suggests that the paper is reporting on HIV sequences obtained from patient samples. Additionally, the mention of ""GenBank accession numbers"" for sequences generated in this study further supports this conclusion.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, or phenotypic susceptibility assays.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the paper is not reporting on in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that sequences were submitted to GenBank, but does not provide any accession numbers.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences were made publicly available. However, the lack of accession numbers makes it difficult to verify this.

Answer: Not reported

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, which makes it impossible to determine the accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on 13,029 people with diagnosed HIV in Sweden.

Rationale: The paper mentions that the InfCareHIV cohort includes data on 13,029 people with diagnosed HIV in Sweden, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 13029

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden.

Rationale: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, which suggests that the sequenced samples were obtained from Sweden.

Answer: Sweden

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the InfCareHIV cohort was established in 2003 and includes data on people diagnosed with HIV in Sweden up to 2022.

Rationale: The paper mentions that the InfCareHIV cohort was established in 2003 and includes data on people diagnosed with HIV in Sweden up to 2022, which suggests that the sequenced samples were obtained between 2003 and 2022.

Answer: 2003-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on HIV sequences, but does not specify which genes were sequenced.

Rationale: The paper mentions that the InfCareHIV cohort includes data on HIV sequences, but does not specify which genes were sequenced. However, the mention of ""pol genotyping/sequencing"" suggests that the pol gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on HIV sequences, but does not specify the sequencing method.

Rationale: The paper mentions that the InfCareHIV cohort includes data on HIV sequences, but does not specify the sequencing method. However, the mention of ""GenBank accession numbers"" suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on HIV sequences from plasma samples.

Rationale: The paper mentions that the InfCareHIV cohort includes data on HIV sequences from plasma samples, which suggests that plasma samples were sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify whether any sequences were obtained from individuals with virological failure on a treatment regimen. However, the mention of ""virologic failure"" suggests that some sequences may have been obtained from individuals with virological failure.

Answer: Not reported

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the InfCareHIV cohort is a prospective registry-based cohort study, but does not specify whether the study was a clinical trial.

Rationale: The paper mentions that the InfCareHIV cohort is a prospective registry-based cohort study, but does not specify whether the study was a clinical trial. However, the mention of ""registry-based cohort study"" suggests that the study was not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify whether any sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify whether any sequences were obtained from individuals who had previously received ARV drugs. However, the mention of ""ART-experienced"" suggests that some sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Not reported

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify which drug classes were received by individuals in the study before sample sequencing. However, the mention of ""ART-experienced"" suggests that some individuals may have received NRTIs.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper mentions that the InfCareHIV cohort includes data on people with diagnosed HIV in Sweden, but does not specify which drugs were received by individuals in the study before sample sequencing. However, the mention of ""ART-experienced"" suggests that some individuals may have received specific ARV drugs.

Answer: Not reported",25
36961945,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""deep sequencing of HIV DNA from peripheral blood mononuclear cells and consensus sequencing from concurrent blood plasma (BP) was performed from antiretroviral (ART)-naïve adults with recent infection."" Additionally, the paper mentions ""bulk genotyping of HIV reverse transcriptase (RT) was performed to identify transmitted drug resistance (GeneSeq HIV; Monogram Biosciences, Inc., South San Francisco, CA or Viroseq v.2.0; Celera Diagnostics, Alameda, CA)"".

Rationale: The paper explicitly mentions the use of deep sequencing and bulk genotyping from patient samples, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility assays or IC50 values.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public databases, such as GenBank or NCBI.

Rationale: The paper does not provide any information about the availability of the sequences, which suggests that they may not have been made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or any other public database, which suggests that the accession numbers are not available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""190 individuals were included"" in the study.

Rationale: The paper explicitly mentions the number of individuals included in the study, which indicates that 190 individuals had samples obtained for HIV sequencing.

Answer: 190

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which suggests that the information is not available.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""samples were collected from January 2005 to February 2020"".

Rationale: The paper explicitly mentions the time period during which the samples were collected, which indicates that the sequenced samples were obtained between 2005 and 2020.

Answer: 2005-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention the use of cloning prior to sequencing.

Rationale: The paper does not provide any information about the sequencing workflow, which suggests that the samples may not have been cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""deep sequencing of HIV partial pol was performed to identify DRMs present in archived proviral DNA"".

Rationale: The paper explicitly mentions the sequencing of the HIV pol gene, which indicates that the pol gene was the target of the sequencing.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""deep sequencing of HIV DNA from peripheral blood mononuclear cells and consensus sequencing from concurrent blood plasma (BP) was performed"".

Rationale: The paper explicitly mentions the use of deep sequencing, which suggests that the sequencing method was next-generation sequencing (NGS).

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""deep sequencing of HIV DNA from peripheral blood mononuclear cells and consensus sequencing from concurrent blood plasma (BP) was performed"".

Rationale: The paper explicitly mentions the use of peripheral blood mononuclear cells (PBMCs) and blood plasma (BP) as the source of the sequenced samples.

Answer: PBMC, Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""all participants began ART a median of 82 days after the EDI"" and that ""there was no evidence of viral rebound from any participants during the entire follow-up period"".

Rationale: The paper explicitly mentions that all participants were ART-naïve and that there was no evidence of viral rebound, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the study being a clinical trial.

Rationale: The paper does not provide any information about the study design, which suggests that it may not have been a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""all participants were ART-naïve"" and that ""there was no evidence of viral rebound from any participants during the entire follow-up period"".

Rationale: The paper explicitly mentions that all participants were ART-naïve, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all participants were ART-naïve"".

Rationale: The paper explicitly mentions that all participants were ART-naïve, which suggests that they had not received any ARV drugs before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all participants were ART-naïve"".

Rationale: The paper explicitly mentions that all participants were ART-naïve, which suggests that they had not received any ARV drugs before sample sequencing.

Answer: Not reported",20
36967989,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper mentions “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome”, or “whole genome” sequencing. The paper reports “GenBank accession numbers” for sequences generated in this study or states sequences were “submitted/deposited”.

Rationale: The paper mentions specific types of clinical samples, sequencing methods, and GenBank accession numbers, which are all indicators that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions “cell-based susceptibility assays” with drug titrations and reporter readouts.

Rationale: The paper mentions specific types of in vitro drug susceptibility data, such as phenotypic susceptibility and IC50 values, which are all indicators that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions specific public sequence databases and accession numbers, which are all indicators that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions specific accession numbers, which are all indicators that the GenBank accession numbers for sequenced HIV isolates were reported.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions specific numbers of individuals and sequences, which are all indicators that the number of individuals with samples obtained for HIV sequencing can be determined.

Answer: Not reported (the paper does not provide specific numbers)

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country\&gt;. The paper mentions nationwide “cohort” or “surveillance” or “registry” in &lt;country\&gt; or “national reference laboratory” of &lt;country\&gt;.

Rationale: The paper mentions specific countries, which are all indicators that the sequenced samples were obtained from those countries.

Answer: Not reported (the paper does not provide specific countries)

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between &lt;Year1\&gt; to &lt;Year2\&gt; or &lt;Month/Year1\&gt; to &lt;Month/Year2\&gt;. The paper lists per-year counts “collected in 2008, 2009, 2010…”.

Rationale: The paper mentions specific years or year ranges, which are all indicators that the sequenced samples were obtained from those years.

Answer: Not reported (the paper does not provide specific years)

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit. The paper describes “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions specific cloning methods or kits, which are all indicators that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper mentions “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)"".

Rationale: The paper mentions specific HIV genes or gene regions, which are all indicators that the HIV genes were reported to have been sequenced.

Answer: Pol, PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments or Beckman CEQ 2000 XL. The paper mentions BigDye/ABI PRISM Dye Terminator or dideoxy sequencing.

Rationale: The paper mentions specific sequencing methods or instruments, which are all indicators that the method used for sequencing was Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper mentions “PBMC”, “peripheral blood mononuclear cells”, “proviral DNA”, “cell-associated DNA/RNA”.

Rationale: The paper mentions specific types of samples, which are all indicators that the type of samples sequenced were plasma and PBMC.

Answer: Plasma, PBMC

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper reports that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper mentions specific terms related to virological failure, which are all indicators that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”.

Rationale: The paper mentions specific terms related to clinical trials, which are all indicators that the patients in the study were in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states “virologic failure/failing therapy while receiving [drug/regimen]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”.

Rationale: The paper mentions specific terms related to ARV drug use, which are all indicators that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper mentions specific ARV drugs or classes, such as NRTI, PI, NNRTI, and INSTI.

Rationale: The paper mentions specific terms related to ARV drug use, which are all indicators that the drug classes received by individuals in the study before sample sequencing can be determined.

Answer: Not reported (the paper does not provide specific drug classes)

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific ARV drugs or classes, such as NRTI, PI, NNRTI, and INSTI. The paper states “virologic failure/failing therapy while receiving [drug/regimen]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”.

Rationale: The paper mentions specific ARV drugs or classes, which are all indicators that the drugs received by individuals in the study before sample sequencing can be determined.

Answer: Not reported (the paper does not provide specific drugs)",32
36982978,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study or states sequences were “submitted/deposited”.

Rationale: The paper mentions specific types of clinical samples, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions ART-naïve and ART-experienced patients, which implies that the sequences were obtained from individuals who have received antiretroviral treatment. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The paper mentions specific IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility values. The paper describes cell-based susceptibility assays using named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper mentions specific terms related to in vitro drug susceptibility testing, which suggests that the paper reports in vitro susceptibility data. The paper also provides specific values for IC50, EC50, EC90, and fold-change in susceptibility, which further supports the conclusion that the paper reports in vitro susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions specific public databases where the sequences were submitted, which suggests that the sequences are publicly available. The paper also reports accession numbers, which further supports the conclusion that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions specific accession numbers, which suggests that the sequences were submitted to a public database. The paper also reports that the sequences have been deposited or made available in a sequence database, which further supports the conclusion that the accession numbers are publicly available.

Answer: Not reported (the paper does not provide specific accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions specific numbers of individuals who had samples obtained for HIV sequencing, which suggests that the paper reports the number of individuals.

Answer: Not reported (the paper does not provide specific numbers)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country\&gt;. The paper mentions nationwide “cohort” or “surveillance” or “registry” in &lt;country\&gt; or “national reference laboratory” of &lt;country\&gt;. The paper names a province or city uniquely tied to a country.

Rationale: The paper mentions specific countries where the samples were obtained, which suggests that the paper reports the country of origin for the samples.

Answer: Not reported (the paper does not provide specific countries)

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between &lt;Year1\&gt; to &lt;Year2\&gt; or &lt;Month/Year1\&gt; to &lt;Month/Year2\&gt;. The paper lists per-year counts “collected in 2008, 2009, 2010…”.

Rationale: The paper mentions specific years or year ranges where the samples were obtained, which suggests that the paper reports the year of sample collection.

Answer: Not reported (the paper does not provide specific years)

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit. The paper describes “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions specific cloning methods or kits, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper states “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)”. The paper states “integrase coding region of pol”, “IN”, “p31”, “GeneSeq/ViroSeq Integrase”, “INSTI resistance”, “integrase sequencing”, or “GeneSeq/PhenoSense Integrase”.

Rationale: The paper mentions specific HIV genes that were sequenced, which suggests that the paper reports the HIV genes that were sequenced.

Answer: Pol, PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments \(ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant\) or Beckman CEQ 2000 XL. The paper mentions BigDye/ABI PRISM Dye Terminator \(v1.0/v3.0/v3.1\), dye-terminator, dye–deoxy chain terminator, or dideoxy sequencing.

Rationale: The paper mentions specific sequencing methods or instruments, which suggests that the paper reports the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper mentions “PBMC”, “peripheral blood mononuclear cells”, “proviral DNA”, “cell-associated DNA/RNA”.

Rationale: The paper mentions specific types of samples that were sequenced, which suggests that the paper reports the type of samples that were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper reports that sequencing or genotyping were done for participants with VL \&gt;50 copies/mL while on ART.

Rationale: The paper mentions specific terms related to virological failure, which suggests that the paper reports sequences from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”. The paper is registered at ClinicalTrials.gov or has an NCT number.

Rationale: The paper mentions specific terms related to clinical trials, which suggests that the paper reports that the patients were in a clinical trial.

Answer: Not reported (the paper does not provide specific information about clinical trials)

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states “virologic failure/failing therapy while receiving \[drug/regimen\]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”.

Rationale: The paper mentions specific terms related to antiretroviral treatment, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper mentions specific drug classes, such as NRTI, PI, and INSTI.

Rationale: The paper mentions specific terms related to antiretroviral treatment, which suggests that the paper reports the drug classes received by individuals in the study.

Answer: Not reported (the paper does not provide specific information about drug classes)

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states “virologic failure/failing therapy while receiving \[drug/regimen\]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”. The paper mentions specific drugs, such as AZT, 3TC, FTC, TDF, and DRV.

Rationale: The paper mentions specific drugs that were received by individuals in the study, which suggests that the paper reports the drugs received by individuals in the study.

Answer: Not reported (the paper does not provide specific information about drugs)",39
37017009,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube. A minimum of 500 μL plasma was ultra-centrifuged and total nucleic acid extracted using the MagNA Pure 2.0 automated extraction system (Roche Applied Science, Penzberg, Germany). PCR amplification was performed using an in-house method resulting in a single amplicon spanning 1.5 kb of *pol* encompassing the protease gene and the first 250 amino acids of the reverse transcriptase gene (HXB2 2358--3882).""

Rationale: The paper mentions the collection of whole blood and plasma, which are common sources of HIV sequences. The paper also describes the use of PCR amplification to generate a single amplicon spanning the protease and reverse transcriptase genes, which is a common approach for sequencing HIV.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences and resistance patterns in pediatric patients, but does not report any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to a public database.

Rationale: The paper does not provide any information about the availability of the sequences, including whether they were submitted to a public database such as GenBank.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention the submission of sequences to a public database, including GenBank.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""1000 children had participated in the study"" and that ""899 participants from 40 facilities from eight provinces were included in the study analysis"".

Rationale: The paper provides information about the number of participants in the study, but does not specify how many individuals had samples obtained for HIV sequencing.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in South Africa and that participants were recruited from 40 facilities across eight provinces.

Rationale: The paper provides information about the location of the study, which is South Africa.

Answer: South Africa

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from March 2017 to March 2019.

Rationale: The paper provides information about the time period during which the samples were collected.

Answer: 2017-2019

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were prepared using the 96-sample Nextera ^®^ XT DNA Library Preparation Kit (Illumina, USA)"" and that ""libraries were prepared using the 96-sample Nextera ^®^ XT DNA Library Preparation Kit (Illumina, USA)"".

Rationale: The paper describes the use of a library preparation kit, which suggests that the amplicons were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""PCR amplification was performed using an in-house method resulting in a single amplicon spanning 1.5 kb of *pol* encompassing the protease gene and the first 250 amino acids of the reverse transcriptase gene (HXB2 2358--3882)"".

Rationale: The paper describes the use of a single amplicon spanning the protease and reverse transcriptase genes, which suggests that these genes were sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper states that ""libraries were prepared using the 96-sample Nextera ^®^ XT DNA Library Preparation Kit (Illumina, USA)"" and that ""MiSeq FastQ files were analysed using DeepChek ^®^ (Advanced Biological Laboratories, Luxembourg, Luxembourg)"".

Rationale: The paper describes the use of a library preparation kit and the Illumina MiSeq platform, which suggests that next-generation sequencing (NGS) was used.

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube"" and that ""a minimum of 500 μL plasma was ultra-centrifuged and total nucleic acid extracted using the MagNA Pure 2.0 automated extraction system (Roche Applied Science, Penzberg, Germany)"".

Rationale: The paper describes the collection of whole blood and plasma, which are common sources of HIV sequences.

Answer: Plasma, Whole Blood

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""participants were selected at the discretion of the site HCW, with the intention to offer a resistance test when clinically warranted"" and that ""the study was conducted in children with virological failure"".

Rationale: The paper provides information about the selection of participants and the study population, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about the study design or whether the patients were enrolled in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""participants were selected at the discretion of the site HCW, with the intention to offer a resistance test when clinically warranted"" and that ""the study was conducted in children with virological failure"".

Rationale: The paper provides information about the selection of participants and the study population, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""participants were selected at the discretion of the site HCW, with the intention to offer a resistance test when clinically warranted"" and that ""the study was conducted in children with virological failure"".

Rationale: The paper provides information about the selection of participants and the study population, which suggests that the individuals in the study had received various drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""participants were selected at the discretion of the site HCW, with the intention to offer a resistance test when clinically warranted"" and that ""the study was conducted in children with virological failure"".

Rationale: The paper provides information about the selection of participants and the study population, which suggests that the individuals in the study had received various drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, ABC, D4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, MVC, RAL, EVG, DTG, BIC, CAB, LEN",26
37029656,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from 1223 ART-naive PLWH, and that the sequences were obtained from ""patients"" and ""newly diagnosed persons"". The paper also mentions ""HIV sequencing"" and ""Sanger sequencing"" using an ABI PRISM 3130xl Genetic Analyzer.

Rationale: The paper explicitly states that genotypic resistance testing was performed on samples from patients, which suggests that HIV sequences were obtained from patient samples. Additionally, the mention of Sanger sequencing and the use of an ABI PRISM 3130xl Genetic Analyzer further supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or IC50 values.

Rationale: The paper focuses on genotypic resistance testing and the analysis of HIV sequences, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public database, but it does mention that the sequences were obtained from ""patients"" and ""newly diagnosed persons"".

Rationale: The paper does not provide any information about the availability of the sequences, but the fact that the sequences were obtained from patient samples suggests that they may have been submitted to a public database.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences may not have been submitted to a public database.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from 1223 ART-naive PLWH.

Rationale: The paper explicitly states that genotypic resistance testing was performed on samples from 1223 individuals, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 1223

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples, but it does mention that the study was conducted in Italy.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, but the fact that the study was conducted in Italy suggests that the samples may have been obtained from Italian patients.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted over the period 2009-2019.

Rationale: The paper explicitly states that the study was conducted over the period 2009-2019, which suggests that the sequenced samples were obtained during this time period.

Answer: 2009-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing, which suggests that the samples may not have been cloned.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the ""pol region"" was sequenced, which includes the protease and reverse transcriptase genes.

Rationale: The paper explicitly states that the ""pol region"" was sequenced, which suggests that the protease and reverse transcriptase genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used, specifically using an ABI PRISM 3130xl Genetic Analyzer.

Rationale: The paper explicitly states that Sanger sequencing was used, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were obtained from ""plasma"" and ""PBMC"" samples.

Rationale: The paper explicitly states that the sequences were obtained from plasma and PBMC samples, which suggests that these types of samples were sequenced.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on ART-naive individuals and does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial, which suggests that it may not have been a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study was conducted on ART-naive individuals, which suggests that they had not previously received ARV drugs.

Rationale: The paper explicitly states that the study was conducted on ART-naive individuals, which suggests that they had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted on ART-naive individuals, which suggests that they had not received any ARV drugs before sample sequencing.

Rationale: The paper explicitly states that the study was conducted on ART-naive individuals, which suggests that they had not received any ARV drugs before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study was conducted on ART-naive individuals, which suggests that they had not received any ARV drugs before sample sequencing.

Rationale: The paper explicitly states that the study was conducted on ART-naive individuals, which suggests that they had not received any ARV drugs before sample sequencing.

Answer: Not Reported",20
37039023,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-positive patients were recruited during their regular visits at Hospital Federal de Ipanema (HI) and Hospital Universitário Clementino Fraga Filho (HUCFF), both located in Rio de Janeiro (RJ; southeastern Brazil), and at Hospital Universitário Doutor Miguel Riet Corrêa Junior (HU-FURG) in Rio Grande do Sul (RS; southern Brazil)."" The paper also mentions that ""all samples from RJ were collected between February 2016 and November 2018, whereas all samples from RS were collected between August and December 2017."" Additionally, the paper states that ""the HIV near full-length genome (NFLG) was PCR-amplified and ultradeep sequenced from archived proviruses of PLWH under successful ART.""

Rationale: The paper mentions the recruitment of HIV-positive patients from two hospitals in Rio de Janeiro and one hospital in Rio Grande do Sul, which suggests that the paper reports HIV sequences from patient samples. The paper also mentions the collection of samples between specific dates, which further supports the idea that the paper reports HIV sequences from patient samples. Furthermore, the paper states that the HIV near full-length genome was PCR-amplified and ultradeep sequenced, which is a common method for analyzing HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related methods, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and the identification of drug resistance mutations, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""the raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.""

Rationale: The paper explicitly mentions the deposition of raw sequencing reads to the Sequence Read Archive, which suggests that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""the raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.""

Rationale: The paper mentions the deposition of raw sequencing reads to the Sequence Read Archive, but it does not provide any GenBank accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study.""

Rationale: The paper explicitly mentions the number of patients included in the study, which suggests that the answer is 86.

Answer: 86

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""patients were recruited during their regular visits at Hospital Federal de Ipanema (HI) and Hospital Universitário Clementino Fraga Filho (HUCFF), both located in Rio de Janeiro (RJ; southeastern Brazil), and at Hospital Universitário Doutor Miguel Riet Corrêa Junior (HU-FURG) in Rio Grande do Sul (RS; southern Brazil).""

Rationale: The paper explicitly mentions the locations of the hospitals where the patients were recruited, which suggests that the sequenced samples were obtained from Brazil.

Answer: Brazil

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""all samples from RJ were collected between February 2016 and November 2018, whereas all samples from RS were collected between August and December 2017.""

Rationale: The paper explicitly mentions the collection dates of the samples, which suggests that the answer is 2016-2018 for RJ and 2017 for RS.

Answer: 2016-2018 (RJ), 2017 (RS)

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""the HIV near full-length genome (NFLG) was PCR-amplified and ultradeep sequenced from archived proviruses of PLWH under successful ART.""

Rationale: The paper mentions the PCR-amplification of the HIV near full-length genome, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""the HIV near full-length genome (NFLG) was PCR-amplified and ultradeep sequenced from archived proviruses of PLWH under successful ART.""

Rationale: The paper explicitly mentions the sequencing of the HIV near full-length genome, which suggests that the answer is ""Full length genome"".

Answer: Full length genome

**Question: What method was used for sequencing?**

Evidence: The paper states that ""the HIV near full-length genome (NFLG) was PCR-amplified and ultradeep sequenced from archived proviruses of PLWH under successful ART.""

Rationale: The paper mentions the use of PCR-amplification and ultradeep sequencing, which suggests that the method used was NGS.

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""all samples from RJ were collected between February 2016 and November 2018, whereas all samples from RS were collected between August and December 2017.""

Rationale: The paper explicitly mentions the collection of samples from peripheral blood, which suggests that the answer is ""Plasma"".

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""all patients were in therapeutic success at the time of their inclusion in our study.""

Rationale: The paper explicitly mentions that all patients were in therapeutic success, which suggests that the answer is ""No"".

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or the enrollment of patients in a clinical trial.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and the identification of drug resistance mutations, but it does not mention any clinical trials.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""all patients were in therapeutic success at the time of their inclusion in our study.""

Rationale: The paper explicitly mentions that all patients were in therapeutic success, which suggests that the answer is ""Yes"".

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF+3TC+EFV), accounting for 55.8% (n=48) of patients included.""

Rationale: The paper explicitly mentions the use of TDF, 3TC, and EFV, which suggests that the answer is ""NRTI, NNRTI"".

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF+3TC+EFV), accounting for 55.8% (n=48) of patients included.""

Rationale: The paper explicitly mentions the use of TDF, 3TC, and EFV, which suggests that the answer is ""TDF, 3TC, EFV"".

Answer: TDF, 3TC, EFV",27
37042390,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only mentions genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public repository. However, the paper does mention sequencing and genotyping results.

Rationale: The paper does not provide any information about submitting sequences to public repositories, which suggests that the sequences may not be publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or providing accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who were sequenced.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries where the sequenced samples were obtained.

Rationale: The paper does not mention the countries where the samples were collected.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the years when the sequenced samples were obtained.

Rationale: The paper does not mention the years when the samples were collected.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""amplicons were cloned and sequenced"", which suggests that samples were cloned prior to sequencing.

Rationale: The paper mentions cloning and sequencing, which suggests that samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""pol region encompassing protease and reverse transcriptase"", which suggests that the pol gene was sequenced.

Rationale: The paper mentions sequencing the pol gene, which includes the protease and reverse transcriptase regions.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"", which suggests that Sanger sequencing was used.

Rationale: The paper mentions Sanger sequencing and ABI instruments, which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", which suggests that plasma samples were sequenced.

Rationale: The paper mentions extracting viral RNA from plasma, which is a common method for sequencing plasma samples.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic or virological failure"" and ""failing therapy or regimen"", which suggests that sequences were obtained from individuals with virological failure.

Rationale: The paper mentions virological failure and failing therapy, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or any trial-related information.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"", which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions ART-experienced and treatment-experienced, which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"", which suggests that individuals received NRTIs.

Rationale: The paper mentions ART-experienced and treatment-experienced, which suggests that individuals received NRTIs.

Answer: NRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the specific drugs received by individuals in the study.

Rationale: The paper does not mention specific drugs.

Answer: Not reported",18
37052343,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. Additionally, the paper reports ""GenBank accession numbers"" for sequences generated in this study or states sequences were ""submitted/deposited"".

Rationale: The paper mentions clinical samples such as plasma, which is a common source of HIV sequences. The paper also refers to genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences. Furthermore, the paper reports GenBank accession numbers, which are used to identify and share HIV sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results do not report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention specific assays such as PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions that sequences were submitted to public databases, which suggests that they are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper provides specific accession numbers for GenBank, which can be used to identify and access the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 4310 individuals.

Rationale: The paper mentions a specific number of individuals who had samples obtained for HIV sequencing.

Answer: 4310

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in various countries, such as Austria, Australia, France, and others.

Rationale: The paper provides specific information about the countries where the samples were obtained.

Answer: Austria, Australia, France, and others

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2014 and 2020.

Rationale: The paper provides specific information about the years when the samples were obtained.

Answer: 2014-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper provides specific information about the HIV genes that were sequenced.

Answer: Pol, PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""Illumina platforms"".

Rationale: The paper provides specific information about the sequencing method used.

Answer: Sanger sequencing, Illumina platforms

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper provides specific information about the type of samples that were sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic or virological failure (VF)"" and ""failing therapy or regimen"".

Rationale: The paper provides specific information about the sequences obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms.

Rationale: The paper provides specific information about the study design.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper provides specific information about the sequences obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", ""NRTI"", ""INSTI"", and specific drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper provides specific information about the drug classes and specific drugs received by individuals in the study.

Answer: NRTI, PI, NRTI, INSTI, 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", or ""lenacapavir"".

Rationale: The paper provides specific information about the drugs received by individuals in the study.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",27
37071019,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that the study aims to identify and compile information from published reports that include HIV sequences obtained from patient samples, including their corresponding GenBank accession numbers. The paper also mentions that the study focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters without reporting in vitro susceptibility data. However, the paper does not mention any laboratory strains or site-directed mutants.

Rationale: The paper explicitly mentions that it aims to compile information from published reports that include HIV sequences obtained from patient samples, which suggests that the paper does report HIV sequences from patient samples. Additionally, the paper does not mention any laboratory strains or site-directed mutants, which further supports the answer.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper also does not report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA). The paper also does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention that sequences were submitted to any public repositories, which suggests that the paper does not report sequences made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the paper does not report any accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals, which suggests that the paper does not report the number of individuals.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention any countries, which suggests that the paper does not report the countries from which the sequenced samples were obtained.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not mention any years, which suggests that the paper does not report the years from which the sequenced samples were obtained.

Answer: Not applicable

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention cloning, which suggests that the paper does not report samples cloned prior to sequencing.

Answer: Not applicable

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were reported to have been sequenced.

Rationale: The paper does not mention any specific HIV genes, which suggests that the paper does not report which HIV genes were sequenced.

Answer: Not applicable

**Question: What method was used for sequencing?**

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not mention any sequencing method, which suggests that the paper does not report the method used for sequencing.

Answer: Not applicable

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not mention any specific sample types, which suggests that the paper does not report the type of samples that were sequenced.

Answer: Not applicable

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention virological failure or treatment regimen, which suggests that the paper does not report sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients in the study were in a clinical trial.

Rationale: The paper does not mention any clinical trials, which suggests that the paper does not report patients in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not mention ARV drugs, which suggests that the paper does not report HIV sequences from individuals who had previously received ARV drugs.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any drug classes, which suggests that the paper does not report which drug classes were received by individuals in the study before sample sequencing.

Answer: Not applicable

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any drugs, which suggests that the paper does not report which drugs were received by individuals in the study before sample sequencing.

Answer: Not applicable",20
37085698,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was extracted from plasma, and the IN region covering the first 263 codons of blood samples was amplified and sequenced using an in-house assay. The sequences were then transferred to separate personal computers, and sequence edition and alignment were made using Geneious prime software. The quality of the sequence data was checked using an online sequence quality control tool found in the Los Alamos HIV sequence database.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common source of HIV sequences. Additionally, the paper describes the amplification and sequencing of the IN region, which is a specific gene region that is often sequenced in HIV studies. The use of Geneious prime software and the Los Alamos HIV sequence database also suggests that the paper is working with HIV sequences.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility or cell-based susceptibility assays.

Rationale: The paper focuses on the sequencing and analysis of HIV sequences, but does not report any data on in vitro drug susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that all nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly states that the sequences have been deposited in Genbank, which is a public repository for genetic sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that all nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper provides the accession numbers for the sequences, which can be used to access the sequences in Genbank.

Answer: MW560010 to MW560058

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 49 study participants were enrolled in this study.

Rationale: The paper explicitly states the number of participants in the study.

Answer: 49

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples, but it does mention that the study was conducted in Addis Ababa.

Rationale: The paper does not provide explicit information on the country of origin for the samples, but it does mention the location of the study.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from June to December 2018.

Rationale: The paper explicitly states the time period during which the study was conducted.

Answer: 2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not describe any cloning of samples prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the IN region covering the first 263 codons of blood samples was amplified and sequenced.

Rationale: The paper explicitly states that the IN region was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the sequences were amplified and sequenced using an in-house assay, and then transferred to separate personal computers for sequence edition and alignment using Geneious prime software.

Rationale: The paper describes the use of an in-house assay for sequencing, which is a type of Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper explicitly states that the RNA was extracted from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not describe any sequences obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial or randomized controlled trial.

Rationale: The paper does not describe any clinical trial or randomized controlled trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study participants were ART-naive.

Rationale: The paper explicitly states that the participants were ART-naive.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study participants were ART-naive.

Rationale: The paper explicitly states that the participants were ART-naive.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study participants were ART-naive.

Rationale: The paper explicitly states that the participants were ART-naive.

Answer: None",18
37104815,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV total DNA was measured using the real-time PCR kit GENERIC HIVDNA Cell ^®^ (Biocentric ^®^, Bandol, France), with a limit of quantification (LOQ) of 10 copies/PCR, as previously described. USpVL was determined at D0 and W48 using the COBAS ^®^ HIV-1 assay, v2.0 (Roche Molecular Systems, Branchburg, NJ, USA). Sequences were performed for the reverse transcriptase (RT), protease (PR) and integrase (INT) regions, according to the Agence Nationale de Recherche sur le SIDA et les Maladies Infectieuses Emergentes (ANRS-MIE) consensus, using Illumina technology (Illumina, San Diego, CA, USA).

Rationale: The paper mentions the use of real-time PCR and COBAS ^®^ HIV-1 assay, which are commonly used for HIV sequencing and genotyping. Additionally, the paper states that sequences were performed for the RT, PR, and INT regions, which are the typical regions sequenced for HIV drug resistance testing.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay.

Rationale: The paper focuses on the analysis of HIV sequences and genotypes, but does not report any in vitro susceptibility data or assays.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the deposition of sequences in any public database, such as GenBank, NCBI, EMBL, DDBJ, or ENA.

Rationale: The paper does not provide any information about the availability of the sequences, including accession numbers or deposition in public databases.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers or deposition in public databases.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study included 121 participants, but it does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper mentions the total number of participants, but does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries where the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries or regions where the samples were collected.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the years when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years or time periods when the samples were collected.

Answer: Not applicable

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about the cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning or amplification of samples prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that sequences were performed for the RT, PR, and INT regions.

Rationale: The paper specifically mentions the sequencing of the RT, PR, and INT regions.

Answer: RT, PR, INT

**Question: What method was used for sequencing?**

Evidence: The paper states that sequences were performed using Illumina technology (Illumina, San Diego, CA, USA).

Rationale: The paper specifically mentions the use of Illumina technology for sequencing.

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper states that HIV total DNA was measured using the real-time PCR kit GENERIC HIVDNA Cell ^®^ (Biocentric ^®^, Bandol, France), with a limit of quantification (LOQ) of 10 copies/PCR, as previously described.

Rationale: The paper mentions the use of real-time PCR, which is commonly used for sequencing DNA from blood samples.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that 10 participants had virological failure, but it does not provide information about the sequencing of these samples.

Rationale: The paper mentions the presence of virological failure, but does not provide information about the sequencing of these samples.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a randomized, multicenter, non-inferiority Phase III trial.

Rationale: The paper specifically mentions the design of the study as a randomized, multicenter, non-inferiority Phase III trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the participants were on standard continuous triple therapy with virological suppression.

Rationale: The paper mentions the use of standard continuous triple therapy, which implies that the participants had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants were on standard continuous triple therapy with virological suppression.

Rationale: The paper mentions the use of standard continuous triple therapy, which implies that the participants had previously received NRTIs, NNRTIs, and PIs.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the specific drugs received by the participants.

Rationale: The paper mentions the use of standard continuous triple therapy, but does not provide information about the specific drugs used.

Answer: Not reported",21
37112971,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"" were used. The paper also mentions that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper explicitly mentions the use of clinical samples and the sequencing of these samples from patients, which indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper only reports genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, but the accession numbers are not provided. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper mentions that sequences were submitted to GenBank, which suggests that the sequences are publicly available. However, the accession numbers are not provided, which makes it difficult to access the sequences.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank, but the accession numbers are not provided.

Rationale: The paper mentions that sequences were submitted to GenBank, but the accession numbers are not provided, which makes it difficult to extract the accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 4481 treatment-naive patients had their samples obtained for HIV sequencing.

Rationale: The paper explicitly mentions the number of patients who had their samples obtained for HIV sequencing.

Answer: 4481

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in Russia and that the samples were collected from patients in different regions of Russia.

Rationale: The paper does not provide explicit information on the countries from which the sequenced samples were obtained, but it can be inferred that the samples were obtained from Russia.

Answer: Russia

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the samples were collected between 2006 and 2022.

Rationale: The paper explicitly mentions the years during which the samples were collected.

Answer: 2006-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning of samples prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol gene region encoding the PR-RT was sequenced.

Rationale: The paper explicitly mentions the sequencing of the pol gene region encoding the PR-RT.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper reports that Sanger sequencing and NGS were used for sequencing.

Rationale: The paper explicitly mentions the use of Sanger sequencing and NGS for sequencing.

Answer: Sanger sequencing, NGS

**Question: What type of samples were sequenced?**

Evidence: The paper reports that plasma, PBMC, and whole blood samples were sequenced.

Rationale: The paper explicitly mentions the sequencing of plasma, PBMC, and whole blood samples.

Answer: Plasma, PBMC, Whole Blood

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not provide any information on clinical trials, which suggests that the patients were not in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the patients were treatment-naive, which suggests that they had not previously received ARV drugs.

Rationale: The paper explicitly mentions that the patients were treatment-naive, which suggests that they had not previously received ARV drugs.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patients were treatment-naive, which suggests that they had not received any drug classes before sample sequencing.

Rationale: The paper explicitly mentions that the patients were treatment-naive, which suggests that they had not received any drug classes before sample sequencing.

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the patients were treatment-naive, which suggests that they had not received any drugs before sample sequencing.

Rationale: The paper explicitly mentions that the patients were treatment-naive, which suggests that they had not received any drugs before sample sequencing.

Answer: Not applicable",21
37147875,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that a 22-year-old man presented to the infectious disease department as seropositive for HIV after a rapid test in a sexually transmitted infection clinic. A fourth-generation serological test revealed a weak index reactivity (9.8; Alinity i HIV Ag/Ab combo assay; Abbott, IL, USA) and the HIV-1 western blot was undetermined, indicating a recent infection. The last negative HIV serology was 3 months prior.

Rationale: The paper mentions that the patient was seropositive for HIV, indicating that the study involves patient samples. The paper also mentions that the patient was recently infected, which suggests that the study involves sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, or EC50.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public repository.

Rationale: The paper does not mention that the sequences were submitted to GenBank or any other public repository, which suggests that the sequences may not be publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that a 22-year-old man was enrolled in the study.

Rationale: The paper mentions that a single individual was enrolled in the study, which suggests that the number of individuals with samples obtained for HIV sequencing is 1.

Answer: 1

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country where the samples were obtained.

Rationale: The paper does not mention the country where the samples were obtained, which suggests that the country may not be reported.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the patient was recently infected, with the last negative HIV serology being 3 months prior.

Rationale: The paper mentions that the patient was recently infected, which suggests that the samples were obtained in the current year.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that the samples may not have been cloned prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequencing was done on the integrase gene.

Rationale: The paper mentions that the sequencing was done on the integrase gene, which suggests that the answer is likely to be ""IN"".

Answer: IN

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the sequencing was done using the MiSeq platform (Illumina, San Diego, CA, USA).

Rationale: The paper mentions that the sequencing was done using the MiSeq platform, which suggests that the answer is likely to be ""NGS"".

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the viral RNA was extracted from plasma.

Rationale: The paper mentions that the viral RNA was extracted from plasma, which suggests that the answer is likely to be ""Plasma"".

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient was experiencing virological failure on a treatment regimen.

Rationale: The paper mentions that the patient was experiencing virological failure on a treatment regimen, which suggests that the answer is likely to be ""Yes"".

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the answer is likely to be ""No"".

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient was experiencing virological failure on a treatment regimen.

Rationale: The paper mentions that the patient was experiencing virological failure on a treatment regimen, which suggests that the answer is likely to be ""Yes"".

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was experiencing virological failure on a treatment regimen.

Rationale: The paper mentions that the patient was experiencing virological failure on a treatment regimen, which suggests that the answer is likely to be ""INSTI"".

Answer: INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was experiencing virological failure on a treatment regimen.

Rationale: The paper mentions that the patient was experiencing virological failure on a treatment regimen, which suggests that the answer is likely to be ""DTG"".

Answer: DTG",17
37272233,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing, genotyping, or sequencing, which are all methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and does not mention any in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any GenBank accession numbers or deposition statements.

Rationale: The paper does not provide any information about the availability of the sequences in public databases.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers or deposition statements.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 248 individuals.

Rationale: The paper mentions the number of individuals from whom samples were obtained for HIV sequencing.

Answer: 248

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any specific countries where the samples were obtained.

Rationale: The paper does not provide any information about the countries where the samples were obtained.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2010 and 2020.

Rationale: The paper mentions the time period during which the samples were collected.

Answer: 2010-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning methods or techniques.

Rationale: The paper does not provide any information about the cloning methods used.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the sequencing of the pol region, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions the specific genes that were sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions the use of ABI instruments and BigDye/ABI PRISM Dye Terminator.

Rationale: The paper mentions the specific sequencing methods used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions the use of plasma samples for sequencing.

Rationale: The paper mentions the specific type of samples used for sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions the sequencing of samples from individuals with virological failure.

Rationale: The paper mentions the specific context in which the sequences were obtained.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or study designs.

Rationale: The paper does not provide any information about the study design or clinical trials.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions the sequencing of samples from individuals who had previously received ART.

Rationale: The paper mentions the specific context in which the sequences were obtained.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of ART and the sequencing of samples from individuals who had previously received ART.

Rationale: The paper mentions the specific drug classes used.

Answer: NRTI, NNRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of specific ART drugs, such as AZT, 3TC, FTC, TDF, and EFV.

Rationale: The paper mentions the specific drugs used.

Answer: AZT, 3TC, FTC, TDF, EFV",16
37279764,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""nucleic acid extraction, PCR amplification work-up and sequencing were performed essentially as described previously."" All available HIV-1 sequences covered a partial pol gene region (HXB2: 2252–3255). The study included 12,320 participants with demographic data and partial pol sequences (GenBank accession no. MW947591–MW957968, OP058117–OP058658).

Rationale: The paper mentions sequencing and PCR amplification work-up, which suggests that the study involved sequencing patient samples. The mention of GenBank accession numbers also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers (MW947591–MW957968, OP058117–OP058658).

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers (MW947591–MW957968, OP058117–OP058658).

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which can be used to retrieve the sequences from GenBank.

Answer: MW947591–MW957968, OP058117–OP058658

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that the study included 12,320 participants with demographic data and partial pol sequences.

Rationale: The paper explicitly states the number of participants included in the study, which can be used to answer this question.

Answer: 12,320

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study included samples collected between 2011 and 2019.

Rationale: The paper explicitly states the time period during which the samples were collected.

Answer: 2011-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or amplification of sequences prior to sequencing.

Rationale: The paper focuses on sequencing and genotypic resistance testing, but does not mention cloning or amplification of sequences.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the study included sequences from a partial pol gene region (HXB2: 2252–3255).

Rationale: The paper explicitly states the region of the HIV genome that was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions PCR amplification work-up and sequencing, but does not specify the sequencing method.

Rationale: The paper focuses on sequencing and genotypic resistance testing, but does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that the study included sequences from blood samples.

Rationale: The paper explicitly states that the study included sequences from blood samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the study included sequences from individuals who were treatment-experienced.

Rationale: The paper explicitly states that the study included sequences from individuals who were treatment-experienced.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper focuses on a observational study and does not mention a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included sequences from individuals who were treatment-experienced.

Rationale: The paper explicitly states that the study included sequences from individuals who were treatment-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included sequences from individuals who were treatment-experienced, but does not specify the drug classes.

Rationale: The paper explicitly states that the study included sequences from individuals who were treatment-experienced, but does not provide any information about the drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included sequences from individuals who were treatment-experienced, but does not specify the drugs.

Rationale: The paper explicitly states that the study included sequences from individuals who were treatment-experienced, but does not provide any information about the drugs.

Answer: Not reported",18
37327289,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. The paper reports ""GenBank accession numbers"" for sequences generated in this study or states sequences were ""submitted/deposited"".

Rationale: The paper mentions clinical samples such as plasma, which is a common source of HIV sequences. The paper also refers to genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper does not report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or named platforms like PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The paper states that the sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions GenBank and provides accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that the sequences have been deposited in GenBank and provides accession numbers for the sequences. The accession numbers are listed as LC723952-LC724015.

Rationale: The paper mentions GenBank and provides accession numbers, which suggests that the sequences were submitted to a public database.

Answer: LC723952-LC724015

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 157 plasma samples were collected from HIV-1 seropositive and treatment-naive FSWs.

Rationale: The paper mentions the number of samples collected, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 157

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, specifically Nairobi City, Donholm, Kawangware, Korogocho, Langata, Majengo, and Thika Road.

Rationale: The paper mentions the location of the clinics, which suggests that the samples were obtained from these locations.

Answer: Kenya

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between November 2020 and April 2021.

Rationale: The paper mentions the time period during which the samples were collected, which suggests that this is the range of years during which the samples were obtained.

Answer: 2020-2021

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or the use of cloning kits. The paper mentions Sanger sequencing and Illumina MiSeq, which suggests that the sequences were generated directly from the samples.

Rationale: The paper does not provide any information about cloning, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the *pol* gene, which includes the protease and reverse transcriptase genes.

Rationale: The paper mentions the *pol* gene, which suggests that this gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina MiSeq.

Rationale: The paper mentions Sanger sequencing and Illumina MiSeq, which suggests that these methods were used for sequencing.

Answer: Sanger sequencing and Illumina MiSeq

**Question: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper mentions plasma, which suggests that this was the type of sample sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: The paper does not provide any information about virological failure or treatment regimens, which suggests that sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial or the use of a clinical trial protocol.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the participants were treatment-naive, which suggests that they had not previously received ARV drugs.

Rationale: The paper mentions that the participants were treatment-naive, which suggests that they had not previously received ARV drugs.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants were treatment-naive, which suggests that they had not received any drug classes before sample sequencing.

Rationale: The paper mentions that the participants were treatment-naive, which suggests that they had not received any drug classes before sample sequencing.

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants were treatment-naive, which suggests that they had not received any drugs before sample sequencing.

Rationale: The paper mentions that the participants were treatment-naive, which suggests that they had not received any drugs before sample sequencing.

Answer: None",22
37340869,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper states that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions specific types of clinical samples, such as plasma, which are commonly used for HIV sequencing. Additionally, the paper states that sequenced samples were obtained from patients, participants, or subjects, which suggests that the sequences were obtained from patient samples. Furthermore, the paper mentions genotypic resistance testing and HIV sequencing, which are common methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, or HEK293.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data. Additionally, the paper does not mention any cell-based susceptibility assays, which are commonly used to measure in vitro drug susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any GenBank accession numbers or any other public sequence databases. The paper does not mention that sequences were submitted to GenBank or any other public sequence databases.

Rationale: The paper does not mention any GenBank accession numbers or any other public sequence databases, which suggests that the sequences were not made publicly available. Additionally, the paper does not mention that sequences were submitted to GenBank or any other public sequence databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the GenBank accession numbers for sequenced HIV isolates are not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing, which suggests that the number of individuals is not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that the countries are not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years in which the sequenced samples were obtained.

Rationale: The paper does not mention the years in which the sequenced samples were obtained, which suggests that the years are not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning methods, such as TA cloning or Topo TA cloning.

Rationale: The paper does not mention any cloning methods, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not mention the specific HIV genes that were sequenced, which suggests that the specific HIV genes are not reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""ABI instruments"" and ""BigDye/ABI PRISM Dye Terminator"", which suggests that Sanger sequencing was used.

Rationale: The paper mentions ""ABI instruments"" and ""BigDye/ABI PRISM Dye Terminator"", which are commonly used for Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", which suggests that plasma samples were used.

Rationale: The paper mentions ""viral RNA was extracted from plasma"", which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms, which suggests that the study was a clinical trial.

Rationale: The paper mentions ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms, which are commonly used in clinical trials.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes that were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any drug classes that were received by individuals in the study before sample sequencing, which suggests that the drug classes are not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any specific drugs that were received by individuals in the study before sample sequencing, which suggests that the specific drugs are not reported.

Answer: Not reported",24
37358226,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that data were derived from the Viral Load Cohort North-East Lesotho (VICONEL), a prospective open cohort including all people receiving HIV viral load (VL) testing in Butha-Buthe or Mokhotlong district in Lesotho. The VICONEL database incorporates routine demographic and clinical data collected at the time of VL testing that are counterchecked by a dedicated data management team. Data closure for analysis was on 1 May 2023.

Rationale: The paper mentions HIV viral load testing, which implies that HIV sequences were obtained from patient samples. The VICONEL cohort includes all people receiving HIV VL testing, suggesting that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Rationale: The paper focuses on the analysis of HIV sequences and their association with viral suppression, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about the availability of the sequences in public databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers or any other accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that among 14 242 eligible participants, the majority were female (9311 [65.4%]) and taking efavirenz-containing ART (13 049 [91.6%]) before and TDF-3TC-DTG (13 505 [94.8%]) after transitioning.

Rationale: The paper mentions the number of participants in the VICONEL cohort, but it does not specify how many of them had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the VICONEL cohort includes all people receiving HIV VL testing in Butha-Buthe or Mokhotlong district in Lesotho.

Rationale: The paper mentions the specific locations where the samples were obtained, which are Butha-Buthe and Mokhotlong district in Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that data closure for analysis was on 1 May 2023.

Rationale: The paper mentions the date of data closure, which implies that the samples were obtained up to that date.

Answer: 2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or the use of molecular clones.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper focuses on the analysis of HIV sequences, but it does not specify which genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the VICONEL cohort includes all people receiving HIV VL testing in Butha-Buthe or Mokhotlong district in Lesotho.

Rationale: The paper mentions HIV VL testing, which implies that the samples were obtained from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that among 14 242 eligible participants, the majority were taking efavirenz-containing ART (13 049 [91.6%]) before and TDF-3TC-DTG (13 505 [94.8%]) after transitioning.

Rationale: The paper mentions that the participants were taking ART before and after transitioning, but it does not specify whether any of them had virological failure.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper describes the VICONEL cohort as a prospective open cohort, which suggests that it is an observational study rather than a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that among 14 242 eligible participants, the majority were taking efavirenz-containing ART (13 049 [91.6%]) before and TDF-3TC-DTG (13 505 [94.8%]) after transitioning.

Rationale: The paper mentions that the participants were taking ART before and after transitioning, which implies that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that among 14 242 eligible participants, the majority were taking efavirenz-containing ART (13 049 [91.6%]) before and TDF-3TC-DTG (13 505 [94.8%]) after transitioning.

Rationale: The paper mentions the specific ART regimens that the participants were taking before and after transitioning, which implies that they received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that among 14 242 eligible participants, the majority were taking efavirenz-containing ART (13 049 [91.6%]) before and TDF-3TC-DTG (13 505 [94.8%]) after transitioning.

Rationale: The paper mentions the specific ART regimens that the participants were taking before and after transitioning, which implies that they received efavirenz, TDF, 3TC, and DTG.

Answer: Efavirenz, TDF, 3TC, DTG",22
37376649,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""retrospective proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot."" The paper also mentions ""GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.""

Rationale: The paper mentions the use of next-generation sequencing (NGS) to analyze HIV-1 polymerase region, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper only discusses the use of proviral DNA genotyping to assess the impact of archived drug resistance on virologic outcomes, and does not mention any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.""

Rationale: The paper mentions that anonymized individual participant data and study documents can be requested for further research, which suggests that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences are not publicly available through GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""retrospective proviral DNA genotypes were performed for 734 participants (post-hoc analysis)"".

Rationale: The paper mentions that 734 participants had samples obtained for HIV sequencing.

Answer: 734

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any specific countries where the samples were obtained.

Rationale: The paper does not mention any specific countries where the samples were obtained, which suggests that the country of origin is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any specific years when the samples were obtained.

Rationale: The paper does not mention any specific years when the samples were obtained, which suggests that the year of sample collection is not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were generated using the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.""

Rationale: The paper mentions the use of the GenoSure Archive assay, which generates amplicons for sequencing, but does not mention any cloning step.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""retrospective proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot.""

Rationale: The paper mentions the use of proviral DNA genotyping to analyze the HIV-1 polymerase region, which suggests that the paper reports sequences from the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.""

Rationale: The paper mentions the use of next-generation sequencing (NGS) to analyze HIV-1 polymerase region, which suggests that the paper reports the use of NGS sequencing.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""retrospective proviral DNA genotypes were performed for 734 participants (post-hoc analysis)"".

Rationale: The paper mentions the use of proviral DNA genotyping, which suggests that the paper reports the sequencing of proviral DNA from whole blood samples.

Answer: Whole blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""the study was conducted in participants without previous virologic failure or documented resistance"".

Rationale: The paper mentions that the study was conducted in participants without previous virologic failure, which suggests that the paper does not report any sequences from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Approval was obtained from ethics committees at each investigational site.""

Rationale: The paper mentions the use of ethics committees and approval from investigational sites, which suggests that the paper reports the use of a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""the study was conducted in participants without previous virologic failure or documented resistance"".

Rationale: The paper mentions that the study was conducted in participants without previous virologic failure, which suggests that the paper does not report any sequences from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the study was conducted in participants without previous virologic failure or documented resistance"".

Rationale: The paper mentions that the study was conducted in participants without previous virologic failure, which suggests that the paper does not report any drug classes received by individuals in the study before sample sequencing.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any specific drugs received by individuals in the study before sample sequencing, which suggests that the paper does not report any drugs received.

Answer: Not reported",22
37381002,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from 200 µl plasma sample following the instructions of the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Switzerland)"". The paper also mentions that ""sequences of *pol* gene fragments were obtained by Sanger sequencing method"" and ""near full-length genomes of recombinant forms of HIV-1 were amplified using the methods described previously"". Additionally, the paper reports that ""sequences were successfully amplified by using an in-house assay"" and ""sequences were obtained by using next-generation sequencing (NGS) method"".

Rationale: The paper mentions the extraction of viral RNA from plasma samples, which is a common source of HIV sequences. The paper also mentions the use of Sanger sequencing and NGS methods, which are commonly used for HIV sequencing. Furthermore, the paper reports the successful amplification of sequences, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. It only reports genotypic resistance testing and sequencing results.

Rationale: The paper focuses on the genetic characterization of HIV-1 viruses and the prevalence of drug resistance mutations, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank. However, it does mention that ""sequences were successfully amplified"" and ""sequences were obtained by using next-generation sequencing (NGS) method"".

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they may not have been made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or any other public database, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 398 viral pol gene sequences were successfully sequenced"" from patients with failed antiviral treatment.

Rationale: The paper provides a specific number of sequences obtained from patient samples, which suggests that the sequencing was performed on a large number of individuals.

Answer: 398

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples. However, it does mention that the study was conducted in Suzhou City, China.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which suggests that the samples may have been obtained from a single country.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2017 and 2020.

Rationale: The paper provides a specific time period for the collection of samples, which suggests that the sequencing was performed on samples obtained over several years.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention the cloning of samples prior to sequencing. However, it does mention that ""sequences were obtained by using next-generation sequencing (NGS) method"" and ""sequences were successfully amplified by using an in-house assay"".

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing, which suggests that the samples may not have been cloned.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""sequences of *pol* gene fragments were obtained by Sanger sequencing method"" and ""near full-length genomes of recombinant forms of HIV-1 were amplified using the methods described previously"".

Rationale: The paper mentions the sequencing of the *pol* gene and near full-length genomes, which suggests that the sequencing was performed on these genes.

Answer: Pol, near full-length genome

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""sequences were obtained by using next-generation sequencing (NGS) method"" and ""sequences were successfully amplified by using an in-house assay"".

Rationale: The paper mentions the use of NGS method for sequencing, which suggests that the sequencing was performed using this method.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from 200 µl plasma sample following the instructions of the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Switzerland)"".

Rationale: The paper mentions the extraction of viral RNA from plasma samples, which is a common source of HIV sequences.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study was conducted on patients with failed antiviral treatment.

Rationale: The paper mentions the study was conducted on patients with failed antiviral treatment, which suggests that the sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the study being a clinical trial. However, it does mention that the study was conducted on patients with failed antiviral treatment.

Rationale: The paper does not provide any information about the study being a clinical trial, which suggests that the study may not have been a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study was conducted on patients with failed antiviral treatment.

Rationale: The paper mentions the study was conducted on patients with failed antiviral treatment, which suggests that the sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drug classes received by the individuals in the study. However, it does mention that the study was conducted on patients with failed antiviral treatment.

Rationale: The paper does not provide any information about the specific drug classes received by the individuals in the study, which suggests that the information may not be available.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by the individuals in the study. However, it does mention that the study was conducted on patients with failed antiviral treatment.

Rationale: The paper does not provide any information about the specific drugs received by the individuals in the study, which suggests that the information may not be available.

Answer: Not reported",24
37439411,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database, a public observational database containing data from more than 100 Italian centres for the study of resistance mutations to antiviral drugs for HIV. Transmitted drug resistance (TDR) was defined as the presence of RAMs transmitted at the moment of the infection, considering genotypes of naïve PLWH. The HIV-1 genotype was considered based on all the tests available (cumulative genotype).

Rationale: The paper mentions the retrieval of HIV-1 RNA protease/reverse transcriptase sequences from the ARCA database, which suggests that the sequences were obtained from patient samples. Additionally, the paper defines TDR as the presence of RAMs transmitted at the moment of the infection, indicating that the sequences were obtained from naïve PLWH.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods and results sections focus on genotypic resistance testing and the analysis of HIV-1 sequences.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank, NCBI, EMBL, DDBJ, or ENA. However, the paper does mention the use of the Antiviral Response Cohort Analysis (ARCA) database, which is a public observational database.

Rationale: The paper does not mention the submission of sequences to any public database, which suggests that the sequences may not be publicly available. However, the use of the ARCA database suggests that the data may be available for researchers who have access to the database.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 5982 naïves were included in the study, and 28,505 genotypes were retrieved from 9,387 treatment-experienced PLWH.

Rationale: The paper mentions the number of naïves and treatment-experienced individuals, which suggests that the number of individuals with samples obtained for HIV sequencing is 9,387.

Answer: 9,387

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Italy, and the samples were retrieved from more than 100 Italian centres.

Rationale: The paper mentions the country where the study was conducted, which suggests that the sequenced samples were obtained from Italy.

Answer: Italy

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study included data from 2000 to 2020.

Rationale: The paper mentions the time period during which the samples were obtained, which suggests that the sequenced samples were obtained between 2000 and 2020.

Answer: 2000-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples, which suggests that the samples may not have been cloned prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved.

Rationale: The paper mentions the retrieval of HIV-1 RNA protease/reverse transcriptase sequences, which suggests that the sequences were obtained from the pol region.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method, such as Sanger sequencing or next-generation sequencing (NGS).

Rationale: The paper does not mention any specific sequencing method, which suggests that the sequencing method may not be reported.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database, which suggests that the sequences were obtained from plasma or other clinical samples.

Rationale: The paper mentions the retrieval of HIV-1 RNA protease/reverse transcriptase sequences from the ARCA database, which suggests that the sequences were obtained from plasma or other clinical samples.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that transmitted drug resistance (TDR) was defined as the presence of RAMs transmitted at the moment of the infection, considering genotypes of naïve PLWH. The paper also mentions the use of the Antiviral Response Cohort Analysis (ARCA) database, which includes data from individuals with virological failure.

Rationale: The paper defines TDR as the presence of RAMs transmitted at the moment of the infection, which suggests that the sequences were obtained from naïve PLWH. The paper also mentions the use of the ARCA database, which includes data from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial or randomized controlled trial.

Rationale: The paper does not mention any clinical trial or randomized controlled trial, which suggests that the study may not have been conducted in a clinical trial setting.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included data from 9,387 treatment-experienced PLWH.

Rationale: The paper mentions the inclusion of treatment-experienced individuals, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included data from 9,387 treatment-experienced PLWH, which suggests that the individuals in the study had received antiretroviral therapy (ART) before sample sequencing.

Rationale: The paper mentions the inclusion of treatment-experienced individuals, which suggests that the individuals in the study had received ART before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any specific drugs, which suggests that the drugs received by individuals in the study before sample sequencing may not be reported.

Answer: Not reported",24
37495103,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual. Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp). DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).

Rationale: The paper mentions the isolation of HIV-1 RNA from plasma, which is a common source of HIV sequences in patient samples. The paper also describes the use of PCR and DNA sequencing to amplify and analyze the HIV-1 PR-RT fragment, which is a common approach for sequencing HIV from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on the analysis of HIV-1 sequences and drug resistance mutations, but does not report any in vitro susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank or the Short Read Archive (SRA).

Rationale: The paper does not provide any information about the availability of the sequences, including accession numbers or deposition statements.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or provide any accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper provides the total number of patients in the study cohort, which is 271.

Answer: 271

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the samples.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study cohort included patients who visited the Novosibirsk, Russia, HIV/AIDS clinic between March 2018 and August 2022.

Rationale: The paper provides the start and end dates for the study period, which is March 2018 to August 2022.

Answer: 2018-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention the use of cloning or TA cloning to prepare the samples for sequencing.

Rationale: The paper describes the use of PCR and DNA sequencing to amplify and analyze the HIV-1 PR-RT fragment, but does not mention cloning.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 PR-RT fragment (1302 bp) was amplified and sequenced.

Rationale: The paper specifically mentions the amplification and sequencing of the HIV-1 PR-RT fragment.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper states that DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).

Rationale: The paper specifically mentions the use of an ABI PRISM 3130xl DNA Analyser for DNA sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual.

Rationale: The paper specifically mentions the isolation of HIV-1 RNA from plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study cohort included patients who were on first-line ART and experienced virological failure.

Rationale: The paper specifically mentions the inclusion of patients who experienced virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the study being a clinical trial or the use of a clinical trial design.

Rationale: The paper describes the study as a cohort study, which is not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study cohort included patients who were on first-line ART and experienced virological failure.

Rationale: The paper specifically mentions the inclusion of patients who were on first-line ART, which implies that they had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study cohort included patients who were on first-line ART, which typically includes NRTIs and NNRTIs.

Rationale: The paper specifically mentions the inclusion of patients who were on first-line ART, which implies that they received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by the patients, but states that they were on first-line ART.

Rationale: The paper does not provide specific information about the drugs received by the patients.

Answer: Not reported",20
37498738,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""sequences from clinical samples such as 'plasma','serum', 'PBMC', 'buffy coat', or 'dried blood spots (DBS)'"" were used. The paper also mentions that ""sequenced samples were obtained from 'patients', 'participants','subjects', 'blood donors', 'newly diagnosed persons', 'newly infected persons', 'PWH', 'PLWH' or 'cohorts'"". Additionally, the paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper explicitly mentions the use of clinical samples and the sequencing of these samples from patients, participants, and subjects. This suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. The paper only reports on genotypic resistance testing and sequencing of HIV sequences from patient samples.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which is a key aspect of this question.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that ""data availability is described in Supplementary Appendix 6"". Additionally, the paper states that ""sequences were submitted to GenBank"" but does not provide any accession numbers.

Rationale: The paper does not explicitly state that sequences were made publicly available, but it does mention that data availability is described in a supplementary appendix.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information on GenBank accession numbers, which is a key aspect of this question.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""sequences were obtained from 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study"".

Rationale: The paper explicitly mentions the number of individuals from whom samples were obtained for HIV sequencing.

Answer: 101

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years in which the sequenced samples were obtained.

Rationale: The paper does not provide any information on the years in which the sequenced samples were obtained.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that ""DNA was isolated from 5 million PBMCs using AllPrep Mini kit (Qiagen) according to the manufacturer's instructions followed by complementary DNA synthesis"". Additionally, the paper states that ""PCR and NGS for bulk sequences was performed for the 3 time points of the 101 individuals participating in the ESS"".

Rationale: The paper does not explicitly mention cloning prior to sequencing, but it does mention the use of PCR and NGS for bulk sequences.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs)"". Additionally, the paper states that ""sequences were obtained for gag, pol, and env"".

Rationale: The paper explicitly mentions the sequencing of gag, pol, and env genes.

Answer: Gag, Pol, Env

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""PCR and NGS for bulk sequences was performed for the 3 time points of the 101 individuals participating in the ESS"". Additionally, the paper states that ""NGS analysis was performed using R version 4.0.4 software"".

Rationale: The paper does not explicitly mention the sequencing method, but it does mention the use of PCR and NGS for bulk sequences.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""sequences were obtained from peripheral blood mononuclear cells (PBMCs)"".

Rationale: The paper explicitly mentions the use of PBMCs for sequencing.

Answer: PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not explicitly mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information on sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not Reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that ""the ESS (NCT00537966) enrolled 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study"". Additionally, the paper states that ""the study was supported by the Swiss National Science Foundation (SNF) (grant number 179571 to H. F. G.) and the University of Zurich's Clinical Research Priority Program Viral Infectious Diseases: Zurich Primary HIV Infection Study (to H. F. G. and D. L. B)"".

Rationale: The paper explicitly mentions the enrollment of patients in a clinical trial and the funding of the study by the Swiss National Science Foundation.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""the ESS enrolled 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study"". Additionally, the paper states that ""the study was conducted in early-treated individuals"".

Rationale: The paper explicitly mentions the enrollment of individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information on the drugs received by individuals in the study before sample sequencing.

Answer: Not Reported",25
37515095,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""mRNA from blood samples was purified using the Ribo-zol-C Kit (InterLabService, Moscow, Russia) and used for RT-PCR, followed by pol gene sequencing using AmpliSens ^®^ HIV-Resist-Seq (Amplisens, Moscow, Russia) and Applied Biosystems ^®^ Genetic Analyzer 3130 (Applied Biosystems Inc., Foster, RI, USA)"". The paper also mentions that ""sequences predominantly represented subtypes A6 (57%) and CRF02_AG (41%), with 32% of sequences exhibiting high-level drug resistance"".

Rationale: The paper mentions the use of RT-PCR and sequencing, which suggests that HIV sequences were obtained from patient samples. Additionally, the paper reports the distribution of HIV subtypes and the prevalence of high-level drug resistance, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences and the prevalence of drug resistance, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""study data are unavailable to protect patient confidentiality"".

Rationale: The paper explicitly states that the data are not publicly available due to confidentiality concerns.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers or any other public sequence database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""968 HIV-1 sequences were collected from PLHIV in Kazakhstan"".

Rationale: The paper explicitly states the number of sequences collected.

Answer: 968

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""samples were collected from all regions of Kazakhstan"".

Rationale: The paper explicitly mentions that the samples were collected from Kazakhstan.

Answer: Kazakhstan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""sequences were collected between 2017 and 2020"".

Rationale: The paper explicitly mentions the time period during which the sequences were collected.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention any cloning steps prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""sequences predominantly represented subtypes A6 (57%) and CRF02_AG (41%), with 32% of sequences exhibiting high-level drug resistance"" and that ""the sequence data consisted of partial HIV-1 pol gene sequences (covering protease and the 5′-end of reverse transcriptase, positions 2253 to 3337 on the HXB2 reference genome)"".

Rationale: The paper explicitly mentions the HIV-1 pol gene and the specific regions that were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""sequences were generated using AmpliSens ^®^ HIV-Resist-Seq (Amplisens, Moscow, Russia) and Applied Biosystems ^®^ Genetic Analyzer 3130 (Applied Biosystems Inc., Foster, RI, USA)"".

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""mRNA from blood samples was purified using the Ribo-zol-C Kit (InterLabService, Moscow, Russia)"".

Rationale: The paper explicitly mentions the use of blood samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""32% of sequences exhibited high-level drug resistance"" and that ""sequences were collected from PLHIV in Kazakhstan who were on antiretroviral therapy"".

Rationale: The paper explicitly mentions the high prevalence of drug resistance and the fact that the sequences were collected from individuals on antiretroviral therapy.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention any clinical trial-related information.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""sequences were collected from PLHIV in Kazakhstan who were on antiretroviral therapy"".

Rationale: The paper explicitly mentions that the sequences were collected from individuals on antiretroviral therapy.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""sequences were collected from PLHIV in Kazakhstan who were on antiretroviral therapy"" and that ""the most common ART regimen administered was FTC + TDF + EFV"".

Rationale: The paper explicitly mentions the antiretroviral therapy regimens used by the individuals.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the most common ART regimen administered was FTC + TDF + EFV"".

Rationale: The paper explicitly mentions the specific antiretroviral drugs used by the individuals.

Answer: FTC, TDF, EFV",21
37515146,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. The paper reports ""GenBank accession numbers"" for sequences generated in this study or states sequences were ""submitted/deposited"".

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The paper states that the sequences have been deposited or made available in a sequence database.

Rationale: The paper provides GenBank accession numbers, which suggests that the sequences were submitted to a public database. The paper also states that the sequences have been deposited or made available in a sequence database, which further supports the idea that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides the following GenBank accession numbers: GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

Rationale: The paper provides the accession numbers for the sequences, which can be used to retrieve the sequences from the GenBank database.

Answer: GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 391 participants were recruited, with sequencing successfully carried out in 379 individual participant samples"".

Rationale: The paper provides the number of participants who were recruited and the number of participants for whom sequencing was successfully carried out.

Answer: 379

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from December 2014 to June 2019.

Rationale: The paper provides the start and end dates for the study, which can be used to determine the years during which the sequenced samples were obtained.

Answer: 2014-2019

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol gene was sequenced.

Rationale: The paper mentions the pol gene, which is a common target for HIV sequencing.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper provides information about the sequencing methods used, which suggests that Sanger sequencing and Illumina sequencing were used.

Answer: Sanger sequencing and Illumina sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that plasma was used for sequencing.

Rationale: The paper mentions plasma, which is a common type of sample used for HIV sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included individuals who were ART-experienced.

Rationale: The paper mentions ART-experienced individuals, which suggests that the study included individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included individuals who were ART-experienced, which suggests that they received NRTIs.

Rationale: The paper mentions ART-experienced individuals, which suggests that they received NRTIs.

Answer: NRTIs

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by individuals in the study.

Rationale: The paper does not provide any information about specific drugs received by individuals in the study.

Answer: Not reported",20
37520425,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. Additionally, the paper reports ""GenBank accession numbers"" for sequences generated in this study or states sequences were ""submitted/deposited"".

Rationale: The paper mentions clinical samples such as plasma, which is a common source of HIV sequences. The paper also refers to genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to obtain HIV sequences from patient samples. Furthermore, the paper reports GenBank accession numbers, which are used to identify and access HIV sequences in public databases.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The paper also does not report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. However, the paper does mention ""HIV-1 genotypic resistance testing (GRT)"" and ""PCR amplification and sequencing for determination of acquired and/or persisting HIV-1 drug resistance-associated mutations"".

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility assays or IC50 values. However, the paper does mention genotypic resistance testing, which is a method used to determine the presence of drug resistance mutations in HIV sequences.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"" and provides GenBank accession numbers. The paper also mentions that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which is a public database of genetic sequences. The paper also provides GenBank accession numbers, which are used to identify and access HIV sequences in public databases.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank and provides GenBank accession numbers. The accession numbers are listed as ""OQ627458-OQ627474"".

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides the accession numbers for the sequences.

Answer: OQ627458-OQ627474

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""195 of 436 (45%) and 211 of 466 (45%) participants in the DTG and NNRTI cohorts, respectively"" had VL results available. The paper also mentions that ""165 of 195 (85%) and 154 of 211 (73%) participants in the DTG and NNRTI cohorts, respectively"" achieved viral suppression.

Rationale: The paper reports the number of participants with VL results available and the number of participants who achieved viral suppression.

Answer: 195

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country where the samples were obtained. However, the paper mentions that the study was conducted in Tanzania and that the participants were recruited from the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO).

Rationale: The paper does not explicitly mention the country where the samples were obtained, but it does mention that the study was conducted in Tanzania and that the participants were recruited from the KIULARCO.

Answer: Tanzania

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2016 and 2020. The paper also mentions that the participants were enrolled in the study between 2016 and 2017 for the NNRTI cohort and between 2019 and 2020 for the DTG cohort.

Rationale: The paper reports the time period during which the study was conducted and the time period during which the participants were enrolled in the study.

Answer: 2016-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention whether the samples were cloned prior to sequencing. However, the paper mentions that ""PCR amplification and sequencing for determination of acquired and/or persisting HIV-1 drug resistance-associated mutations was successful for only 2 of 13 (15%) patients"".

Rationale: The paper does not explicitly mention whether the samples were cloned prior to sequencing, but it does mention that PCR amplification and sequencing were performed on some samples.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequencing was done on the ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper explicitly states that the sequencing was done on the pol region, which includes the protease and reverse transcriptase genes.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions that the sequencing was done using ""Sanger sequencing"" and ""PCR amplification and sequencing for determination of acquired and/or persisting HIV-1 drug resistance-associated mutations"".

Rationale: The paper explicitly states that the sequencing was done using Sanger sequencing, which is a type of sequencing method.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the sequencing was done on ""plasma"" and ""blood plasma"".

Rationale: The paper explicitly states that the sequencing was done on plasma, which is a common source of HIV sequences.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""25 of 30 (83%) and 42 of 57 (74%) had a VL 50--999 copies/mL and 5 of 30 (17%) and 15 of 57 (26%) had VL ≥1000 copies/mL, respectively"".

Rationale: The paper reports the number of participants with VL ≥50 copies/mL, which is a common indicator of virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a ""retrospective, observational study nested within the Kilombero and Ulanga antiretroviral cohort (KIULARCO)"", which is a prospective cohort study.

Rationale: The paper explicitly states that the study was a retrospective, observational study, which is not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the participants were ""treatment-naive"" and ""ART-naive"".

Rationale: The paper explicitly states that the participants were treatment-naive and ART-naive, which means that they had not previously received ARV drugs.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants were ""treatment-naive"" and ""ART-naive"".

Rationale: The paper explicitly states that the participants were treatment-naive and ART-naive, which means that they had not previously received ARV drugs.

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by the participants before sample sequencing.

Rationale: The paper does not mention any specific drugs that were received by the participants before sample sequencing.

Answer: Not applicable",27
37537871,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions various sequencing methods, including Sanger and Illumina sequencing, which are commonly used for HIV sequencing.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper focuses on sequencing and genotyping of HIV, but does not report any in vitro susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank, NCBI, EMBL, DDBJ, or ENA.

Rationale: The paper does not provide any information about the availability of the sequences, including accession numbers or deposition statements.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers or deposition statements for the sequences.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 77 plasma samples, collected from 70 male and 7 female patients ages 18 to 68, were obtained from the Queen Mary Hospital in Hong Kong between 2002 and 2014"".

Rationale: The paper provides the number of samples and patients, which can be used to estimate the number of individuals who had samples obtained for HIV sequencing.

Answer: 77

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from the Queen Mary Hospital in Hong Kong.

Rationale: The paper provides the location of the hospital where the samples were obtained, which can be used to determine the country of origin.

Answer: Hong Kong

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2002 and 2014.

Rationale: The paper provides the date range for the collection of the samples, which can be used to determine the years in which the samples were obtained.

Answer: 2002-2014

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the preparation of the samples for sequencing, including cloning.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the sequencing of the ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper provides specific information about the genes that were sequenced, which can be used to determine the HIV genes that were reported to have been sequenced.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger and Illumina sequencing.

Rationale: The paper provides specific information about the sequencing methods used, which can be used to determine the method that was used for sequencing.

Answer: Sanger and Illumina sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"".

Rationale: The paper provides specific information about the type of samples that were sequenced, which can be used to determine the type of samples that were sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about the treatment status of the individuals from whom the sequences were obtained.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not provide any information about the study design or the involvement of patients in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the samples were obtained from patients who were ""ART-experienced"".

Rationale: The paper provides specific information about the treatment status of the individuals from whom the sequences were obtained.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patients were ""ART-experienced"".

Rationale: The paper provides specific information about the treatment status of the individuals from whom the sequences were obtained.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any specific information about the drugs that were received by the individuals in the study.

Rationale: The paper does not provide any information about the specific drugs that were received by the individuals in the study.

Answer: Not reported",20
37540331,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper states that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper states that sequenced samples were obtained from patients, participants, and blood donors, which suggests that the sequences were obtained from patient samples. Furthermore, the paper refers to genotypic resistance testing, HIV sequencing, and various sequencing methods, which are all relevant to the analysis of HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays, such as PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any GenBank accession numbers or any other public sequence databases. The paper does not mention that sequences were submitted to any public repositories.

Rationale: The paper does not provide any information on the availability of the sequences, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any information on GenBank accession numbers, which suggests that the accession numbers were not reported.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information on the number of individuals, which suggests that the number of individuals was not reported.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the countries where the sequenced samples were obtained.

Rationale: The paper does not provide any information on the countries, which suggests that the countries were not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years when the sequenced samples were obtained.

Rationale: The paper does not provide any information on the years, which suggests that the years were not reported.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information on whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information on the sequencing workflow, which suggests that the cloning status was not reported.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not provide any information on the HIV genes that were sequenced.

Rationale: The paper does not provide any information on the genes, which suggests that the genes were not reported.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide any information on the sequencing method.

Rationale: The paper does not provide any information on the sequencing approach, which suggests that the method was not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper mentions the extraction of viral RNA from plasma, which suggests that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not provide any information on whether the sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information on the treatment status of the individuals, which suggests that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information on whether the patients were in a clinical trial.

Rationale: The paper does not provide any information on the study design, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not provide any information on whether the sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information on the treatment history of the individuals, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the drug classes that were received by the individuals before sample sequencing.

Rationale: The paper does not provide any information on the treatment history of the individuals, which suggests that the drug classes were not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the drugs that were received by the individuals before sample sequencing.

Rationale: The paper does not provide any information on the treatment history of the individuals, which suggests that the drugs were not reported.

Answer: Not reported",21
37541705,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that participants were enrolled from September 9, 2020 through June 28, 2021, and the last Week 24 study visit took place on December 14 2021. Sixty-nine children were screened and 57 were enrolled and initiated study drug, composing the All-Treated population. Most (54 [95%]) were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir (38 [67%]), dolutegravir (8 [14%]), or raltegravir (7 [12%]) as the anchor medication.

Rationale: The paper mentions that participants were enrolled and initiated study drug, which suggests that HIV sequences were obtained from patient samples. The paper also mentions that most participants were treatment-experienced at entry, which implies that they had previously received antiretroviral therapy.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir/dolutegravir/lamivudine tablets in children with HIV, and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the data cannot be made publicly available due to the ethical restrictions in the study’s informed consent documents and in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network’s approved human subjects protection plan.

Rationale: The paper explicitly states that the data cannot be made publicly available, which implies that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 57 children were enrolled and initiated study drug, composing the All-Treated population.

Rationale: The paper explicitly states the number of children enrolled and initiated study drug, which implies that 57 individuals had samples obtained for HIV sequencing.

Answer: 57

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled from study sites in Botswana, South Africa, Thailand, and the U.S.

Rationale: The paper explicitly mentions the countries where participants were enrolled, which implies that the sequenced samples were obtained from these countries.

Answer: Botswana, South Africa, Thailand, and the U.S.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that participants were enrolled from September 9, 2020 through June 28, 2021.

Rationale: The paper explicitly states the enrollment period, which implies that the sequenced samples were obtained in 2020 and 2021.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper focuses on the pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir/dolutegravir/lamivudine tablets in children with HIV, and does not report any specific HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not report any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that participants were enrolled from September 9, 2020 through June 28, 2021, and the last Week 24 study visit took place on December 14 2021. Sixty-nine children were screened and 57 were enrolled and initiated study drug, composing the All-Treated population.

Rationale: The paper mentions that participants were enrolled and initiated study drug, which suggests that HIV sequences were obtained from patient samples.

Answer: Plasma, PBMC, and whole blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that most (54 [95%]) participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir (38 [67%]), dolutegravir (8 [14%]), or raltegravir (7 [12%]) as the anchor medication.

Rationale: The paper mentions that most participants were treatment-experienced at entry, which implies that they had previously received antiretroviral therapy and may have experienced virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was an international phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper explicitly states that the study was a clinical trial, which implies that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that most (54 [95%]) participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir (38 [67%]), dolutegravir (8 [14%]), or raltegravir (7 [12%]) as the anchor medication.

Rationale: The paper mentions that most participants were treatment-experienced at entry, which implies that they had previously received antiretroviral therapy.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that most (54 [95%]) participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir (38 [67%]), dolutegravir (8 [14%]), or raltegravir (7 [12%]) as the anchor medication.

Rationale: The paper mentions that most participants were treatment-experienced at entry, which implies that they had previously received antiretroviral therapy.

Answer: NRTI, PI, and INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that most (54 [95%]) participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir (38 [67%]), dolutegravir (8 [14%]), or raltegravir (7 [12%]) as the anchor medication.

Rationale: The paper mentions that most participants were treatment-experienced at entry, which implies that they had previously received antiretroviral therapy.

Answer: Lopinavir/ritonavir, dolutegravir, and raltegravir",26
37546367,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing."" The paper also mentions that ""partial *pol* sequences were obtained from 2074 out of 3274 samples (63.35%) in this analysis."" Additionally, the paper reports that ""the partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.""

Rationale: The paper mentions the use of plasma samples, which is a type of clinical sample, and the use of Sanger sequencing, which is a method for sequencing HIV. The paper also reports the submission of sequences to GenBank, which is a public database for genetic sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays.

Rationale: The paper focuses on the analysis of HIV sequences and drug resistance mutations, but does not report any in vitro susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that ""the partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.""

Rationale: The paper explicitly states that the sequences were submitted to GenBank, which is a public database for genetic sequences.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that ""the partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.""

Rationale: The paper explicitly states the accession numbers for the sequences submitted to GenBank.

Answer: OQ886077 - OQ888150

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""partial *pol* sequences were obtained from 2074 out of 3274 samples (63.35%) in this analysis.""

Rationale: The paper explicitly states the number of samples that were sequenced.

Answer: 2074

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that ""plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.""

Rationale: The paper explicitly states the time period during which the samples were collected.

Answer: 2011-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention the use of cloning prior to sequencing.

Rationale: The paper does not provide any information about the use of cloning prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that ""partial *pol* sequences were obtained from 2074 out of 3274 samples (63.35%) in this analysis.""

Rationale: The paper explicitly states that the *pol* gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper reports that ""a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing"" was used.

Rationale: The paper explicitly states the sequencing method used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper reports that ""plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.""

Rationale: The paper explicitly states that plasma samples were used.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention the use of sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of HIV sequences and drug resistance mutations, but does not report any sequences from individuals with virological failure on a treatment regimen.

Answer: Not applicable

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the use of a clinical trial.

Rationale: The paper does not provide any information about the study design or the use of a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that ""partial *pol* sequences were obtained from 2074 out of 3274 samples (63.35%) in this analysis"" and that ""the patients were between 5 and 89 years old, with a median age of 43 years."" The paper also reports that ""75.22% (1560/2074) of the subjects were male.""

Rationale: The paper explicitly states that the sequences were obtained from individuals who had received ART.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that ""the patients were between 5 and 89 years old, with a median age of 43 years."" The paper also reports that ""75.22% (1560/2074) of the subjects were male.""

Rationale: The paper does not provide any information about the drug classes received by the individuals in the study.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the use of specific drugs.

Rationale: The paper does not provide any information about the specific drugs received by the individuals in the study.

Answer: Not applicable",21
37554471,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that the patient had been prescribed etravirine 200 mg, dolutegravir 50 mg, darunavir 600 mg and ritonavir 100 mg, all dosed twice daily by mouth. The patient had no known prior history of opportunistic infections. The patient had been prescribed PCP prophylaxis with daily trimethoprim-sulfamethoxazole 800--160 mg and MAI infection prophylaxis with azithromycin 1200 mg every week.

Rationale: The paper mentions that the patient had been prescribed certain medications, which suggests that the patient had been undergoing treatment for HIV. However, it does not explicitly state that the patient's samples were sequenced. Nevertheless, the paper does mention that the patient's HIV viral load became undetectable after initiating cabotegravir/rilpivirine (CAB/RPV) long-acting injections, which suggests that the patient's HIV sequences may have been analyzed.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. It only discusses the patient's treatment history and the results of their HIV viral load tests.

Rationale: The paper does not provide any information about in vitro drug susceptibility testing, which is a laboratory test used to determine the susceptibility of HIV to different antiretroviral drugs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention whether the sequences were made publicly available. However, it does mention that the patient's HIV viral load became undetectable after initiating CAB/RPV long-acting injections.

Rationale: The paper does not provide any information about whether the sequences were deposited in a public database, such as GenBank.

Answer: Not reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that the patient had been prescribed certain medications and had undergone treatment for HIV. However, it does not explicitly state that the patient's samples were sequenced.

Rationale: The paper only mentions one patient, who is the subject of the case report.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country where the patient's samples were obtained.

Rationale: The paper does not provide any information about the country where the patient's samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year when the patient's samples were obtained.

Rationale: The paper does not provide any information about the year when the patient's samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the sequencing process.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about the sequencing process.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing process.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the sequencing process.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient had been prescribed certain medications and had undergone treatment for HIV. However, it does not explicitly state that the patient's samples were sequenced.

Rationale: The paper only mentions one patient, who is the subject of the case report.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention whether the patient was part of a clinical trial.

Rationale: The paper does not provide any information about the study design.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient had been prescribed certain medications and had undergone treatment for HIV.

Rationale: The paper provides information about the patient's treatment history, which suggests that the patient had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had been prescribed etravirine 200 mg, dolutegravir 50 mg, darunavir 600 mg and ritonavir 100 mg, all dosed twice daily by mouth.

Rationale: The paper provides information about the patient's treatment history, which suggests that the patient had received NRTIs, NNRTIs, and PIs.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had been prescribed etravirine 200 mg, dolutegravir 50 mg, darunavir 600 mg and ritonavir 100 mg, all dosed twice daily by mouth.

Rationale: The paper provides information about the patient's treatment history, which suggests that the patient had received etravirine, dolutegravir, darunavir, and ritonavir.

Answer: Etravirine, dolutegravir, darunavir, ritonavir",20
37573167,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient. HIV-1 DNA was extracted from PBMCs by using a commercially available kit (QIAampDNAViral minikit; Qiagen), according to the product specifications. Sanger sequencing was performed as previously described.

Rationale: The paper mentions that HIV-1 DNA was obtained from patient samples, which is a clear indication that the paper reports HIV sequences from patient samples. Additionally, the paper describes the extraction and sequencing methods used to generate these sequences.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay.

Rationale: The paper focuses on genotypic resistance testing and sequencing of HIV-1 DNA, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public sequence database. However, the paper does mention that HIV-1 DNA was extracted from PBMCs using a commercially available kit (QIAampDNAViral minikit; Qiagen).

Rationale: The paper does not provide any information about the public availability of the sequences, but it does mention the use of a commercial kit for DNA extraction.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences were not submitted to GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT were included in the study.

Rationale: The paper provides the total number of individuals included in the study, which is 1126.

Answer: 1126

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the sequenced samples were obtained.

Rationale: The paper does not provide any information about the specific years when the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that HIV-1 DNA was extracted from PBMCs using a commercially available kit (QIAampDNAViral minikit; Qiagen), according to the product specifications. Sanger sequencing was performed as previously described.

Rationale: The paper does not mention any cloning steps prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that HIV-1 DNA was extracted from PBMCs using a commercially available kit (QIAampDNAViral minikit; Qiagen), according to the product specifications. Sanger sequencing was performed as previously described.

Rationale: The paper does not specify which HIV genes were sequenced, but it mentions that Sanger sequencing was performed on HIV-1 DNA.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Sanger sequencing was performed as previously described.

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient.

Rationale: The paper mentions that the samples were obtained from whole-blood or lymphomonocytic cells.

Answer: PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT.

Rationale: The paper mentions that the study included individuals who were virologically suppressed, which suggests that they were not experiencing virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT.

Rationale: The paper mentions that the study included individuals who were drug-experienced, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT.

Rationale: The paper mentions that the study included individuals who were drug-experienced, which suggests that they had previously received ARV drugs.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any specific information about the drugs received by the individuals in the study.

Rationale: The paper does not provide any specific information about the drugs received by the individuals in the study.

Answer: Not reported",21
37574435,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and ""sequences amplified from patient plasma"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"". Additionally, the paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions clinical samples such as ""plasma"" and ""sequences amplified from patient plasma"", which indicates that HIV sequences were obtained from patient samples. The paper also refers to ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"", which are all related to HIV sequencing. Furthermore, the paper reports ""GenBank accession numbers"" for sequences generated in this study, which suggests that the sequences were submitted to GenBank.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only reports genotypic resistance testing and sequencing results.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study only focused on genotypic resistance testing and sequencing. The paper does not mention any cell-based susceptibility assays, phenotypic susceptibility, or drug susceptibility assays, which are all related to in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"" and provides ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions that sequences were submitted to ""GenBank"" and provides ""GenBank accession numbers"" for sequences generated in this study, which suggests that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports ""GenBank accession numbers"" for sequences generated in this study, which are ""MT244321-MT244341"".

Rationale: The paper provides ""GenBank accession numbers"" for sequences generated in this study, which are ""MT244321-MT244341"". These accession numbers can be used to retrieve the sequences from GenBank.

Answer: MT244321-MT244341

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and ""sequences amplified from patient plasma"" from 79 individuals.

Rationale: The paper mentions that ""viral RNA was extracted from plasma"" and ""sequences amplified from patient plasma"" from 79 individuals, which suggests that 79 individuals had samples obtained for HIV sequencing.

Answer: 79

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the country of origin is not reported.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not mention the year of sample collection, which suggests that the year of sample collection is not reported.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""pol genotyping/sequencing"" was performed.

Rationale: The paper mentions ""pol genotyping/sequencing"", which suggests that the pol gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"".

Rationale: The paper mentions ""Sanger sequencing"" and ""ABI instruments"", which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and ""sequences amplified from patient plasma"".

Rationale: The paper mentions ""viral RNA was extracted from plasma"" and ""sequences amplified from patient plasma"", which suggests that plasma samples were sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper mentions ""virologic failure/failing therapy while receiving [drug/regimen]"", which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""patients received drugs belonging to a specific ARV class"" and ""patients were virally suppressed on long-term ART"".

Rationale: The paper mentions that ""patients received drugs belonging to a specific ARV class"" and ""patients were virally suppressed on long-term ART"", which suggests that the study included individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""patients received drugs belonging to a specific ARV class"" and lists specific ARV drugs.

Rationale: The paper mentions that ""patients received drugs belonging to a specific ARV class"" and lists specific ARV drugs, which suggests that the study included individuals who received NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTIs, NNRTIs, PIs, and INSTIs

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper lists specific ARV drugs, including ""3TC"", ""FTC"", ""AZT"", ""TDF"", ""abacavir"", ""efavirenz"", ""rilpivirine"", ""doravirine"", ""atazanavir"", ""lopinavir"", ""darunavir"", ""raltegravir"", ""elvitegravir"", ""dolutegravir"", ""bictegravir"", ""cabotegravir"", and ""lenacapavir"".

Rationale: The paper lists specific ARV drugs, which suggests that the study included individuals who received these drugs before sample sequencing.

Answer: 3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, and lenacapavir",24
37585352,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1 proviral DNA sequences were generated using next-generation sequencing (NGS) as previously described elsewhere. The NGS was performed at the Biopolymers Facility at Harvard Medical School or by the PANGEA HIV consortium at the Wellcome Trust Sanger Institute utilizing Illumina MiSeq and HiSeq platforms. A single consensus sequence represented the population of viral quasispecies per each participant.

Rationale: The paper mentions ""next-generation sequencing (NGS)"" and ""HIV-1 proviral DNA sequences"", which indicates that the study involved sequencing of patient samples. Additionally, the paper describes the use of Illumina MiSeq and HiSeq platforms, which are commonly used for NGS.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the prevalence of resistance-associated mutations, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that HIV-1 sequences are available on request through the PANGEA consortium (www.pangea-hiv.org).

Rationale: The paper explicitly mentions that the sequences are available on request through the PANGEA consortium, which indicates that they have been made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that the sequences are available on request through the PANGEA consortium, but does not provide any accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that a total of 5805 proviral sequences were analyzed from Botswana Combination Prevention Project (BCPP) participants.

Rationale: The paper provides the total number of sequences analyzed, which can be used to estimate the number of individuals who had samples obtained for HIV sequencing.

Answer: 5805

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Botswana.

Rationale: The paper explicitly mentions that the study was conducted in Botswana, which indicates that the sequenced samples were obtained from this country.

Answer: Botswana

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2013 and 2018.

Rationale: The paper provides the date range during which the samples were collected, which can be used to estimate the years during which the sequenced samples were obtained.

Answer: 2013-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that the NGS was performed using Illumina MiSeq and HiSeq platforms, which involves direct sequencing of PCR amplicons.

Rationale: The paper describes the use of Illumina MiSeq and HiSeq platforms, which are commonly used for direct sequencing of PCR amplicons.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that near full-length HIV-1 pol sequences were generated.

Rationale: The paper explicitly mentions that near full-length HIV-1 pol sequences were generated, which indicates that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the NGS was performed using Illumina MiSeq and HiSeq platforms.

Rationale: The paper describes the use of Illumina MiSeq and HiSeq platforms, which are commonly used for NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that HIV-1 proviral DNA sequences were generated from plasma.

Rationale: The paper explicitly mentions that the sequences were generated from plasma, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included a total of 4524 ART-suppressed individuals.

Rationale: The paper provides the total number of ART-suppressed individuals, which can be used to infer that some sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was conducted as part of the Botswana Combination Prevention Project (BCPP), which is a clinical trial.

Rationale: The paper explicitly mentions that the study was conducted as part of the BCPP, which is a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included a total of 1281 ART-naive individuals and 4524 ART-suppressed individuals.

Rationale: The paper provides the total number of ART-naive and ART-suppressed individuals, which can be used to infer that some sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included a total of 1281 ART-naive individuals and 4524 ART-suppressed individuals.

Rationale: The paper provides the total number of ART-naive and ART-suppressed individuals, which can be used to infer that some individuals may have received NRTIs, NNRTIs, or PIs before sample sequencing.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included a total of 1281 ART-naive individuals and 4524 ART-suppressed individuals.

Rationale: The paper provides the total number of ART-naive and ART-suppressed individuals, which can be used to infer that some individuals may have received specific ARV drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, EFV, RPV, ATV, DRV, RAL, EVG, DTG, BIC, CAB, LEN, MVC",22
37593123,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences were obtained from ART-naïve HIV-infected individuals across 31 provincial-level administrative divisions between 2004 and 2022. The sequences were procured from both the National Center for AIDS/STD Control and Prevention, China CDC and the HIV sequence databases of the Los Alamos National Laboratory. The HIV-1 *pol* gene region was extracted from the sequences.

Rationale: The paper explicitly mentions that sequences were obtained from patient samples, specifically ART-naïve HIV-infected individuals. The sequences were obtained from both clinical samples and databases, and the HIV-1 *pol* gene region was extracted from the sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The study focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. The study focuses on sequencing, phylogenetics, recombination, epidemiology, surveillance, prevalence of transmitted drug resistance, or transmission clusters.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The accession numbers for the sequences are provided in the text.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, and the accession numbers for the sequences are provided in the text.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank, and the accession numbers for the sequences are provided in the text. The accession numbers are FJ800379–FJ800386, GQ477441-GQ477451, and KP170487.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, and the accession numbers for the sequences are provided in the text.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a total of 57,902 ART-naïve HIV-infected individuals were included in the study.

Rationale: The paper explicitly mentions that a total of 57,902 ART-naïve HIV-infected individuals were included in the study.

Answer: 57,902

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the study was conducted in China.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the study was conducted in China, and the samples were obtained from ART-naïve HIV-infected individuals across 31 provincial-level administrative divisions in China.

Answer: China

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the sequences were obtained between 2004 and 2022.

Rationale: The paper explicitly mentions that the sequences were obtained between 2004 and 2022.

Answer: 2004-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention whether the samples were cloned prior to sequencing. However, the study used a clinical genotyping platform that does not require cloning.

Rationale: The paper does not explicitly mention whether the samples were cloned prior to sequencing. However, the study used a clinical genotyping platform that does not require cloning, such as ViroSeq or TruGene.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the HIV-1 *pol* gene region was extracted from the sequences.

Rationale: The paper explicitly mentions that the HIV-1 *pol* gene region was extracted from the sequences.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper reports that the study used a clinical genotyping platform that uses Sanger sequencing.

Rationale: The paper explicitly mentions that the study used a clinical genotyping platform that uses Sanger sequencing, such as ViroSeq or TruGene.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper reports that the sequences were obtained from plasma.

Rationale: The paper explicitly mentions that the sequences were obtained from plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not explicitly mention whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not explicitly mention whether any sequences were obtained from individuals with virological failure on a treatment regimen. However, the study focused on ART-naïve HIV-infected individuals.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention whether the patients were in a clinical trial.

Rationale: The paper does not explicitly mention whether the patients were in a clinical trial. However, the study was observational and did not mention any clinical trial design.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included ART-naïve HIV-infected individuals.

Rationale: The paper explicitly mentions that the study included ART-naïve HIV-infected individuals.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included ART-naïve HIV-infected individuals.

Rationale: The paper explicitly mentions that the study included ART-naïve HIV-infected individuals.

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not explicitly mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not applicable",21
37626789,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. The paper reports ""GenBank accession numbers"" for sequences generated in this study or states sequences were ""submitted/deposited"".

Rationale: The paper mentions clinical samples such as plasma, which is a common source of HIV sequences. The paper also refers to genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper only reports genotypic resistance testing and sequencing.

Rationale: The paper focuses on genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences and identify resistance mutations. However, it does not report any in vitro drug susceptibility data, such as phenotypic susceptibility or resistance testing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which is a public database. The accession numbers provided in the text suggest that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, including ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper provides accession numbers for GenBank, which suggests that the sequences are publicly available.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""viral RNA was extracted from plasma"" from 551 HIV-positive children.

Rationale: The paper mentions that 551 HIV-positive children were included in the study, and viral RNA was extracted from their plasma.

Answer: 551

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries where the samples were obtained. However, it mentions that the study was conducted in Ethiopia.

Rationale: The paper mentions that the study was conducted in Ethiopia, but it does not provide information on the countries where the samples were obtained.

Answer: Ethiopia

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between 2007 and 2019.

Rationale: The paper mentions that the study was conducted between 2007 and 2019, which suggests that the samples were obtained during this time period.

Answer: 2007-2019

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on the sequencing method or whether cloning was performed prior to sequencing.

Answer: Not Reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol gene region was sequenced.

Rationale: The paper mentions that the pol gene region was sequenced, which suggests that the sequencing was focused on this region.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper mentions Sanger sequencing and Illumina sequencing, which suggests that these methods were used for sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper reports that viral RNA was extracted from plasma.

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that plasma samples were used for sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the study included children with virological failure.

Rationale: The paper mentions that the study included children with virological failure, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the study was a clinical trial or not.

Answer: Not Reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included children who were on ART.

Rationale: The paper mentions that the study included children who were on ART, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included children who were on ART.

Rationale: The paper mentions that the study included children who were on ART, which suggests that the individuals in the study received ART.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the study included children who were on ART, including regimens such as AZT/3TC/NVP and d4T/3TC/NVP.

Rationale: The paper mentions that the study included children who were on ART, including specific regimens such as AZT/3TC/NVP and d4T/3TC/NVP.

Answer: AZT, 3TC, NVP, d4T, TDF, FTC, ABC, EFV, NVP, RAL, DTG, BIC, CAB, LEN",21
37632026,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. The paper reports ""GenBank accession numbers"" for sequences generated in this study or states sequences were ""submitted/deposited"".

Rationale: The paper mentions clinical samples such as plasma, which is a common source of HIV sequences. The paper also mentions genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The paper does not report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention specific cell-based susceptibility assays or recombinant/pseudotyped/site-directed mutant viruses.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the study focused on genotypic resistance testing and sequencing rather than phenotypic susceptibility testing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank. The paper reports accession numbers for GenBank, which contain two letters followed by a series of numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, which suggests that the sequences are publicly available. The paper also reports accession numbers, which can be used to access the sequences in GenBank.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, which are MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; and OQ985493-OQ985958.

Rationale: The paper explicitly reports accession numbers for GenBank, which can be used to access the sequences in GenBank.

Answer: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; and OQ985493-OQ985958

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 759 participants were included in the study.

Rationale: The paper explicitly states that 759 participants were included in the study, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 759

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted at the Chantal Biya International Reference Centre in Yaoundé, Cameroon.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but the mention of the Chantal Biya International Reference Centre in Yaoundé, Cameroon suggests that the samples were obtained from Cameroon.

Answer: Cameroon

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between November 2011 and August 2019.

Rationale: The paper explicitly states the start and end dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2011-2019

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing. However, the paper mentions that ""viral RNA was extracted from plasma"" and ""PCR product was cloned into a vector and then sequenced"".

Rationale: The paper does not explicitly mention cloning prior to sequencing, but the mention of PCR product being cloned into a vector suggests that cloning may have occurred.

Answer: Not Reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol region, including protease and reverse transcriptase, was sequenced.

Rationale: The paper explicitly states that the pol region, including protease and reverse transcriptase, was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that plasma was used as the source of HIV sequences.

Rationale: The paper explicitly states that plasma was used as the source of HIV sequences.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly states that the study included participants who were experiencing virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention a clinical trial.

Rationale: The paper does not explicitly mention a clinical trial, which suggests that the study may not have been a clinical trial.

Answer: Not Reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on a treatment regimen.

Rationale: The paper explicitly states that the study included participants who were experiencing virological failure on a treatment regimen, which suggests that these individuals had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on a treatment regimen that included NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly states that the study included participants who were experiencing virological failure on a treatment regimen that included NRTIs, NNRTIs, and PIs.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included participants who were experiencing virological failure on a treatment regimen that included AZT, 3TC, FTC, TDF, EFV, NVP, ATV/r, LPV/r, and DRV/r.

Rationale: The paper explicitly states that the study included participants who were experiencing virological failure on a treatment regimen that included AZT, 3TC, FTC, TDF, EFV, NVP, ATV/r, LPV/r, and DRV/r.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, ATV/r, LPV/r, DRV/r",25
37632071,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""sequences from clinical samples such as 'plasma','serum', 'PBMC', 'buffy coat', or 'dried blood spots (DBS)'"" were used. The paper also mentions that ""sequenced samples were obtained from 'patients', 'participants','subjects', 'blood donors', 'newly diagnosed persons', 'newly infected persons', 'PWH', 'PLWH' or 'cohorts'"". Additionally, the paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions specific types of clinical samples, which suggests that the sequences were obtained from patient samples. The paper also mentions that the samples were obtained from patients, participants, or subjects, which further supports the idea that the sequences were obtained from patient samples. Furthermore, the paper mentions specific sequencing methods, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The paper only mentions sequencing and genotyping, but does not mention any susceptibility testing or phenotypic resistance testing.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the answer is no. The paper only mentions sequencing and genotyping, but does not mention any susceptibility testing or phenotypic resistance testing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public database. The paper does not mention any accession numbers for GenBank or any other public database.

Rationale: The paper does not mention that the sequences were submitted to GenBank or any other public database, which suggests that the answer is no. The paper does not mention any accession numbers for GenBank or any other public database, which further supports the idea that the sequences were not made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates, which suggests that the answer is not reported.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 329 PLWH had plasma HIV RNA which was either undetectable or detectable at <50 copies/mL at T0"". The paper also states that ""a total of 197 patients were included in the study"".

Rationale: The paper mentions that 329 individuals had plasma HIV RNA that was either undetectable or detectable at <50 copies/mL at T0, but only 197 patients were included in the study. This suggests that the answer is 197.

Answer: 197

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any specific countries where the sequenced samples were obtained. However, the paper mentions that the study was conducted at 4 Italian Infectious Diseases Units.

Rationale: The paper does not mention any specific countries where the sequenced samples were obtained, but it mentions that the study was conducted at 4 Italian Infectious Diseases Units. This suggests that the answer is Italy.

Answer: Italy

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any specific years when the sequenced samples were obtained. However, the paper mentions that the study was conducted between 2019 and 2022.

Rationale: The paper does not mention any specific years when the sequenced samples were obtained, but it mentions that the study was conducted between 2019 and 2022. This suggests that the answer is 2019-2022.

Answer: 2019-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that the answer is no.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any specific HIV genes that were sequenced. However, the paper mentions that ""pol genotyping/sequencing"" was performed.

Rationale: The paper does not mention any specific HIV genes that were sequenced, but it mentions that ""pol genotyping/sequencing"" was performed. This suggests that the answer is Pol.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method. However, the paper mentions that ""Sanger sequencing"" was used.

Rationale: The paper does not mention any specific sequencing method, but it mentions that ""Sanger sequencing"" was used. This suggests that the answer is Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and that ""plasma HIV-1 RNA"" was used for sequencing.

Rationale: The paper mentions that viral RNA was extracted from plasma, which suggests that the answer is Plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen, which suggests that the answer is no.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not mention any clinical trial, which suggests that the answer is no.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen"".

Rationale: The paper mentions that most of the patients were on a previous INSTI-based regimen, which suggests that the answer is yes.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen"".

Rationale: The paper mentions that most of the patients were on a previous INSTI-based regimen, which suggests that the answer is INSTI.

Answer: INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen"".

Rationale: The paper mentions that most of the patients were on a previous INSTI-based regimen, which suggests that the answer is raltegravir, dolutegravir, elvitegravir, bictegravir, and cabotegravir.

Answer: raltegravir, dolutegravir, elvitegravir, bictegravir, and cabotegravir",25
37649807,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that viral RNA was extracted from plasma, and sequencing was performed on samples from patients who initiated ART during 2015-2021. The paper also mentions that the study used retrospective longitudinal VL data from the National AIDs and STIs Control Programme (NASCOP) VL database of PLHIV on ART.

Rationale: The paper mentions sequencing from clinical samples such as plasma, which is a common source of HIV sequences. Additionally, the paper states that the study used data from patients who initiated ART, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility or IC50 values.

Rationale: The paper focuses on the analysis of viral load data and does not mention any in vitro susceptibility testing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to any public database, such as GenBank or NCBI.

Rationale: The paper does not provide any information about the availability of the sequences, which suggests that they may not have been made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that they may not have been provided.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study included 793,902 records from clients who initiated ART during 2015-2021.

Rationale: The paper provides the total number of records included in the study, which suggests that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 793,902

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the samples, which suggests that it may not have been reported.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study included data from 2015 to 2021.

Rationale: The paper provides the time period during which the samples were obtained, which suggests that this is the answer to the question.

Answer: 2015-2021

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the sequencing process, which suggests that cloning may not have been performed.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the genes that were sequenced, which suggests that it may not have been reported.

Answer: Not reported

**Question: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that it may not have been reported.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper states that viral RNA was extracted from plasma.

Rationale: The paper mentions sequencing from plasma, which is a common source of HIV sequences.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of viral load data and does not mention any sequences obtained from individuals with virological failure.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not provide any information about the study design, which suggests that it may not have been a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included data from patients who initiated ART during 2015-2021.

Rationale: The paper mentions that the study included data from patients who initiated ART, which suggests that some of the patients may have received ARV drugs prior to sequencing.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drug classes received by the individuals in the study.

Rationale: The paper does not provide any information about the drug classes received by the individuals, which suggests that it may not have been reported.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by the individuals in the study.

Rationale: The paper does not provide any information about the drugs received by the individuals, which suggests that it may not have been reported.

Answer: Not reported",18
37662576,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention any clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"". The paper does not mention that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing, but it does not mention any patient samples.

Rationale: The paper does not provide any information about patient samples, which is a requirement for answering this question as ""Yes"". The paper only discusses the HIV-1 protease and its inhibitors, and does not mention any clinical samples or patient data.

Answer: No

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays, such as PhenoSense, Monogram, Antivirogram, or Virco.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which is a requirement for answering this question as ""Yes"". The paper only discusses the HIV-1 protease and its inhibitors, and does not mention any in vitro susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any GenBank accession numbers or any other public sequence databases. The paper does not mention that sequences were submitted to GenBank or any other public repository.

Rationale: The paper does not provide any information about the availability of the sequences, which is a requirement for answering this question as ""Yes"". The paper only discusses the HIV-1 protease and its inhibitors, and does not mention any sequence data.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers or any other public sequence databases.

Rationale: The paper does not provide any information about the GenBank accession numbers, which is a requirement for answering this question.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals, which is a requirement for answering this question.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any information about the countries where the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries, which is a requirement for answering this question.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any information about the years when the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years, which is a requirement for answering this question.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any information about cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning, which is a requirement for answering this question.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the specific genes that were sequenced, which is a requirement for answering this question.

Answer: Not reported

**Question: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method.

Rationale: The paper does not provide any information about the sequencing method, which is a requirement for answering this question.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention any specific type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples, which is a requirement for answering this question.

Answer: Not reported

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any information about individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure, which is a requirement for answering this question as ""Yes"".

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any information about clinical trials.

Rationale: The paper does not provide any information about clinical trials, which is a requirement for answering this question as ""Yes"".

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention any information about individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information about ARV drugs, which is a requirement for answering this question as ""Yes"".

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any information about drug classes.

Rationale: The paper does not provide any information about drug classes, which is a requirement for answering this question.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the specific drugs, which is a requirement for answering this question.

Answer: Not reported",21
37674678,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions various sequencing methods, including Sanger and Illumina, which are commonly used for HIV sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper focuses on genotypic resistance testing and sequencing of HIV sequences from patient samples.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that it does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank, NCBI, or EMBL. However, the paper does mention the use of GenBank accession numbers for some sequences.

Rationale: The paper does not explicitly state that sequences were submitted to a public database, but it does mention the use of GenBank accession numbers, which suggests that some sequences may have been deposited in GenBank.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper mentions the use of GenBank accession numbers for some sequences, but it does not provide a list of accession numbers.

Rationale: The paper mentions the use of GenBank accession numbers, but it does not provide a list of accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 2019 and December 2021 were enrolled in this study"".

Rationale: The paper mentions the total number of participants enrolled in the study, which is 1,393.

Answer: 1393

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""samples were collected between January 2019 and December 2021"".

Rationale: The paper mentions the time period during which samples were collected.

Answer: 2019-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention the use of cloning methods, such as TA cloning or Topo TA cloning, to prepare samples for sequencing.

Rationale: The paper does not mention the use of cloning methods.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the sequencing of the HIV pol gene.

Rationale: The paper mentions the sequencing of the HIV pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing and Illumina sequencing.

Rationale: The paper mentions the use of Sanger sequencing and Illumina sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions the use of plasma samples for sequencing.

Rationale: The paper mentions the use of plasma samples for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention the use of sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention the use of sequences from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the use of a clinical trial.

Rationale: The paper does not mention the use of a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions the use of sequences from individuals who had not received ART.

Rationale: The paper mentions the use of sequences from individuals who had not received ART.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of sequences from individuals who had not received ART.

Rationale: The paper mentions the use of sequences from individuals who had not received ART.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the use of any specific drugs.

Rationale: The paper does not mention the use of any specific drugs.

Answer: Not reported",19
37701387,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it does discuss the use of antiretroviral therapy (ART) in patients with advanced HIV disease. The paper also mentions the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen.

Rationale: The paper does not mention HIV sequences from patient samples, but it does discuss the use of ART in patients with advanced HIV disease. This suggests that the paper may be discussing the use of ART in patients with HIV, but it does not provide information on HIV sequences from patient samples.

Answer: No

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention in vitro drug susceptibility data, which suggests that it does not report this type of data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to a public database such as GenBank. It does mention the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the submission of sequences to a public database, which suggests that the sequences may not be publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing, which suggests that this information may not be available.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained, which suggests that this information may not be available.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years in which the sequenced samples were obtained. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the years in which the sequenced samples were obtained, which suggests that this information may not be available.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention the cloning of samples prior to sequencing. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the cloning of samples prior to sequencing, which suggests that this information may not be available.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the specific HIV genes that were sequenced, which suggests that this information may not be available.

Answer: Not reported

**Question: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the sequencing method used, which suggests that this information may not be available.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the type of samples that were sequenced, which suggests that this information may not be available.

Answer: Not reported

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen, which suggests that this information may not be available.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the patients being in a clinical trial. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the patients being in a clinical trial, which suggests that this information may not be available.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs, which suggests that this information may not be available.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing, which suggests that this information may not be available.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing. It discusses the use of Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as a treatment regimen and its efficacy in patients with advanced HIV disease.

Rationale: The paper does not mention the specific drugs received by individuals in the study before sample sequencing, which suggests that this information may not be available.

Answer: Not reported",27
37716367,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper states that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions clinical samples such as plasma, serum, PBMC, buffy coat, or dried blood spots (DBS), which indicates that the sequences were obtained from patient samples. The paper also mentions that the sequenced samples were obtained from patients, participants, subjects, blood donors, newly diagnosed persons, newly infected persons, PWH, PLWH, or cohorts, which further supports the conclusion that the sequences were obtained from patient samples. Additionally, the paper refers to genotypic resistance testing, HIV sequencing, Sanger, Illumina, MiSeq, single-genome, or whole genome sequencing, which are all methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293 with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay, which indicates that the paper reports in vitro drug susceptibility data. The paper also reports IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are all measures of in vitro drug susceptibility. Additionally, the paper mentions cell-based susceptibility assays such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293 with drug titrations and reporter readouts, which further supports the conclusion that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA), which indicates that the sequences were made publicly available. The paper also reports accession numbers for GenBank or any of the above databases, which further supports the conclusion that the sequences were made publicly available. Additionally, the paper reports that sequences have been deposited or made available in a sequence database, which indicates that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper reports accession numbers for GenBank or any of the above databases, which indicates that the accession numbers are available. The paper also reports that sequences have been deposited or made available in a sequence database, which further supports the conclusion that the accession numbers are available.

Answer: The paper reports accession numbers for GenBank or any of the above databases, which are: KX247148, KX247257.

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions that genotypic resistance testing, genotyping, or sequencing was performed on samples from X number of individuals, which indicates that X individuals had samples obtained for HIV sequencing. The paper also reports that X sequences were reported from Y individuals, which further supports the conclusion that Y individuals had samples obtained for HIV sequencing.

Answer: The paper reports that 1138 HIV-positive adults had samples obtained for HIV sequencing.

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in <country>. The paper states that samples were collected in <country>.

Rationale: The paper mentions that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Taiwan, which indicates that the sequenced samples were obtained from Taiwan. The paper also states that samples were collected in Taiwan, which further supports the conclusion that the sequenced samples were obtained from Taiwan.

Answer: Taiwan

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between <Year1> to <Year2> or <Month/Year1> to <Month/Year2>. The paper lists per-year counts ""collected in 2008, 2009, 2010..."".

Rationale: The paper mentions that clinical samples were collected between June 2012 and March 2016, which indicates that the sequenced samples were obtained between 2012 and 2016. The paper also lists per-year counts ""collected in 2008, 2009, 2010..."", which further supports the conclusion that the sequenced samples were obtained between 2008 and 2010.

Answer: 2008-2016

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states ""amplicons were cloned and sequenced"", ""all products were cloned before Sanger sequencing"", ""TA cloning/Topo TA cloning was performed"", or cites a cloning kit.

Rationale: The paper mentions that amplicons were cloned and sequenced, which indicates that the samples were cloned prior to sequencing. The paper also states that all products were cloned before Sanger sequencing, which further supports the conclusion that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""pol genotyping/sequencing"" without providing individual genes. The paper states ""pol region encompassing protease and reverse transcriptase"", ""PR/RT"", ""ViroSeq"", or ""TruGene (PR/RT)"".

Rationale: The paper mentions that pol genotyping/sequencing was performed, which indicates that the pol gene was sequenced. The paper also states that the pol region encompassing protease and reverse transcriptase was sequenced, which further supports the conclusion that the pol gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms.

Rationale: The paper mentions ABI instruments, BigDye/ABI PRISM Dye Terminator, capillary sequencer/capillary electrophoresis with ABI analyzers, or electropherograms, which indicates that Sanger sequencing was used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper mentions that viral RNA was extracted from plasma, which indicates that plasma samples were used for sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""virologic or virological failure (VF)"" or ""failing therapy or regimen"". The paper reports that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper mentions that virologic or virological failure (VF) or failing therapy or regimen was reported, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen. The paper also reports that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART, which further supports the conclusion that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states ""randomized"", ""double-blind"", ""placebo-controlled"", ""open-label"", ""controlled"", or ""multicenter"" with intervention arms. The paper mentions ""phase I/II/III/IIIb/2/3 trial"" or ""analytical treatment interruption (ATI) within a trial"".

Rationale: The paper mentions that the study was randomized, double-blind, placebo-controlled, open-label, controlled, or multicenter with intervention arms, which indicates that the study was a clinical trial. The paper also mentions that the study was a phase I/II/III/IIIb/2/3 trial or an analytical treatment interruption (ATI) within a trial, which further supports the conclusion that the study was a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"". The paper states ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper mentions that the study included individuals who had previously received ARV drugs, which indicates that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""treatment-naïve"", ""ART-naïve"", ""drug-naïve"", ""never exposed to antiretrovirals"", ""before ART initiation"", ""pre-ART"", ""newly diagnosed"", ""seroconverter"", ""blood donor"", ""primary/acute infection without ART"", or samples collected ""at diagnosis/baseline prior to therapy"". The paper mentions specific drugs or regimens.

Rationale: The paper mentions that the study included individuals who were treatment-naïve, ART-naïve, drug-naïve, never exposed to antiretrovirals, before ART initiation, pre-ART, newly diagnosed, seroconverter, blood donor, primary/acute infection without ART, or samples collected at diagnosis/baseline prior to therapy, which indicates that the individuals had not received any ARV drugs before sample sequencing. The paper also mentions specific drugs or regimens, which further supports the conclusion that the individuals had not received any ARV drugs before sample sequencing.

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs or regimens.

Rationale: The paper mentions specific drugs or regimens, which indicates that the individuals received those drugs before sample sequencing.

Answer: The paper mentions the following drugs: zidovudine/AZT, lamivudine/3TC, emtricitabine/FTC, tenofovir TDF/TAF, abacavir/ABC, stavudine/d4T, didanosine/ddI, efavirenz/EFV, nevirapine/NVP, etravirine/ETR, rilpivirine/RPV, doravirine/DOR, lopinavir/r (LPV/r), atazanavir/ATV, darunavir/DRV, saquinavir/SQV, indinavir/IDV, nelfinavir/NFV, tipranavir/TPV, fosamprenavir/FPV, ritonavir boosting implies PI-based, raltegravir/RAL, elvitegravir/EVG, dolutegravir/DTG, bictegravir/BIC, cabotegravir/CAB, lenacapavir/LEN, maraviroc/MVC.",42
37755428,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that nucleic acids were extracted from remnant dried blood spot specimens collected at the time of HIV diagnosis and sequenced using a Sanger-based method at the WHO-designated laboratory, Service de Virologie, University Hospital of Martinique in Fort de France. Sequences were quality-assured following WHO recommendations. HIVDR was predicted using the Stanford HIVdb algorithm Version 9.09.

Rationale: The paper mentions sequencing of clinical samples, specifically dried blood spots, which is a type of clinical sample. The paper also mentions that the sequences were generated using a Sanger-based method, which is a type of sequencing method. Additionally, the paper reports the use of the Stanford HIVdb algorithm, which is a tool used for predicting HIV drug resistance from sequence data.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences and the prediction of HIV drug resistance, but it does not report any data on in vitro drug susceptibility testing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, but it does not provide any accession numbers.

Rationale: The paper mentions that the sequences were submitted to GenBank, which is a public database of genetic sequences. However, it does not provide any information on the accession numbers, which are the unique identifiers for the sequences in the database.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that the sequences were submitted to GenBank, but it does not provide any information on the accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 276 (5.3%) of the infants tested positive for HIV, and 143 (52%) of these infants had remnant specimens available for HIVDR testing.

Rationale: The paper provides information on the number of infants who tested positive for HIV and the number of infants who had remnant specimens available for HIVDR testing.

Answer: 143

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the country of origin of the sequenced samples.

Rationale: The paper does not mention the country of origin of the sequenced samples.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the survey was conducted between April 2020 and March 2021.

Rationale: The paper provides information on the time period during which the survey was conducted.

Answer: 2020-2021

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information on whether the samples were cloned prior to sequencing.

Rationale: The paper does not mention the cloning of samples prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the sequences were generated for the protease/reverse transcriptase (PR/RT) and integrase regions.

Rationale: The paper provides information on the specific regions of the HIV genome that were sequenced.

Answer: PR/RT, IN

**Question: What method was used for sequencing?**

Evidence: The paper reports that the sequences were generated using a Sanger-based method.

Rationale: The paper mentions the use of a Sanger-based method for sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper reports that the sequences were generated from dried blood spot specimens.

Rationale: The paper provides information on the type of clinical sample that was used for sequencing.

Answer: DBS

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the sequences were generated from infants who were diagnosed with HIV at 14 months of age and had received ZDV-based postnatal prophylaxis.

Rationale: The paper provides information on the treatment history of the infants from whom the sequences were generated.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information on whether the patients were in a clinical trial.

Rationale: The paper does not mention the involvement of a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the infants had received ZDV-based postnatal prophylaxis.

Rationale: The paper provides information on the treatment history of the infants from whom the sequences were generated.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the infants had received ZDV-based postnatal prophylaxis.

Rationale: The paper provides information on the treatment history of the infants from whom the sequences were generated.

Answer: NRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the infants had received ZDV-based postnatal prophylaxis.

Rationale: The paper provides information on the treatment history of the infants from whom the sequences were generated.

Answer: ZDV",18
37775947,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq)"". The paper also mentions ""Methods for sample preparation, amplification of viral RNA and NGS, identification of DRM by means of VirVarSeq, and determination of HIV subtype have been described elsewhere"". Additionally, the paper reports ""Sequence reads (FASTQ files) were analyzed with VirVarSeq version 20140929, which calls variants at the codon level"".

Rationale: The paper mentions the use of NGS on plasma samples, which suggests that HIV sequences were obtained from patient samples. The mention of sample preparation and amplification of viral RNA also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. It only reports on genotypic resistance testing and sequencing.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the deposition of sequences in any public database. However, it does mention that ""Methods for sample preparation, amplification of viral RNA and NGS, identification of DRM by means of VirVarSeq, and determination of HIV subtype have been described elsewhere"".

Rationale: The paper does not explicitly mention the deposition of sequences in any public database, but it does mention that methods have been described elsewhere, which suggests that the sequences may have been deposited in a database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information on GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Overall, of the 1819 participants with NGS data at the ≥200 read depth, 1380 (76%) who started ART with three or more drugs, either in the immediate or the deferred arm, and had virological follow-up of ≥1 month were included in this analysis"".

Rationale: The paper reports that 1380 individuals had samples obtained for HIV sequencing.

Answer: 1380

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""The study was conducted between April 2009 and December 2013"".

Rationale: The paper provides the start and end dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2009-2013

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information on whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information on the sequencing workflow.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""Sequence reads (FASTQ files) were analyzed with VirVarSeq version 20140929, which calls variants at the codon level"" and that ""From the output, we extracted amino acid frequencies in the *pol* gene from amino acid position 1--935"".

Rationale: The paper reports that the *pol* gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Sequence reads (FASTQ files) were analyzed with VirVarSeq version 20140929, which calls variants at the codon level"" and that ""Methods for sample preparation, amplification of viral RNA and NGS, identification of DRM by means of VirVarSeq, and determination of HIV subtype have been described elsewhere"".

Rationale: The paper mentions the use of NGS, which suggests that next-generation sequencing was used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq)"".

Rationale: The paper mentions the use of plasma samples for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""The primary endpoint of this analysis was treatment failure (TF), a composite outcome defined at the time of two possible failure events: (1) the time of experiencing a single plasma HIV RNA \>200 copies/mL after \>6 months of therapy initiation if this event was followed by a change of one or more drugs (including discontinuation) of the regimen received at time of the elevated HIV RNA value or (2) the time of pure confirmed VF, defined at the time of the first of two consecutive HIV-RNA viral loads \>200 copies/mL"".

Rationale: The paper reports on treatment failure, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""The study was conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013"".

Rationale: The paper mentions the International Network for Strategic Initiatives in Global HIV Trials, which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""The study was conducted on ART-naïve participants with HIV"".

Rationale: The paper reports that the study was conducted on ART-naïve participants, which suggests that the individuals had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""The study was conducted on ART-naïve participants with HIV"".

Rationale: The paper reports that the study was conducted on ART-naïve participants, which suggests that the individuals had not previously received any ARV drugs.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""The study was conducted on ART-naïve participants with HIV"".

Rationale: The paper reports that the study was conducted on ART-naïve participants, which suggests that the individuals had not previously received any ARV drugs.

Answer: Not applicable",24
37817087,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences and resistance mutations, but does not report any in vitro susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""all datasets including sequences are available from the corresponding author upon reasonable request"".

Rationale: The paper explicitly states that the sequences are available upon request, which suggests that they have been made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that they were not provided.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""4559 (39.6%) cases, and PR, RT and IN sequences were obtained from 3097 (26.9%) cases"".

Rationale: The paper provides the number of cases with PR/RT and PR/RT/IN sequences, which can be used to estimate the number of individuals with samples obtained for HIV sequencing.

Answer: 4559

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention any countries or nationalities, which suggests that this information was not provided.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between 2017 and 2020.

Rationale: The paper provides the year range for the collection of the samples, which can be used to answer this question.

Answer: 2017-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning methods or techniques, which suggests that cloning was not performed.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequences were obtained from the ""protease (PR) and reverse-transcriptase (RT) genomic regions"".

Rationale: The paper explicitly mentions the PR and RT genomic regions, which suggests that these genes were sequenced.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper states that the sequences were obtained using ""Illumina NGS method (MiSeq)"".

Rationale: The paper explicitly mentions the Illumina NGS method and the MiSeq platform, which suggests that NGS was used for sequencing.

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper states that the sequences were obtained from ""plasma"" and ""stored/archived/cryopreserved plasma"".

Rationale: The paper explicitly mentions plasma as the source of the sequences, which suggests that this type of sample was sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of HIV sequences and resistance mutations, but does not report any sequences from individuals with virological failure.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper does not mention any clinical trials or randomized controlled trials, which suggests that the study was not a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the sequences were obtained from individuals who had previously received ART.

Rationale: The paper explicitly mentions that the sequences were obtained from individuals who had previously received ART, which suggests that these individuals had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the individuals had previously received ART, which includes NRTIs, NNRTIs, and PIs.

Rationale: The paper explicitly mentions that the individuals had previously received ART, which includes NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, PIs

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information about the specific drugs received by the individuals.

Rationale: The paper does not mention any specific drugs, which suggests that this information was not provided.

Answer: Not reported",19
37823653,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral sequences were generated by a long-range HIV genotyping protocol described elsewhere (24, 27) with minor modifications that included a reduced annealing temperature (58°C instead of 62°C) as a backup amplification strategy and using the first-round amplicon as a template for next-generation sequencing (NGS)"". The paper also mentions that ""proviral DNA templates were used for amplification, as the majority of participants were receiving ART"". Additionally, the paper states that ""a single consensus sequence represented the population of viral quasispecies per participant"".

Rationale: The paper mentions the use of long-range HIV genotyping protocol and next-generation sequencing (NGS) to generate viral sequences, which suggests that the sequences were obtained from patient samples. The use of proviral DNA templates for amplification also supports this conclusion.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences and the prevalence of FTR resistance-associated polymorphisms, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database, such as GenBank or NCBI.

Rationale: The paper does not provide any information about the availability of the sequences, and does not mention any accession numbers or deposition statements.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers or deposition statements, and does not provide any information about the availability of the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 6,078 HIV-1 near full-length sequences were generated for the BCPP study"". The paper also mentions that ""48 participants had no ART status and were thus left out from the analysis"", leaving a total of 6,030 participants.

Rationale: The paper provides the total number of sequences generated, and subtracts the number of participants with missing ART status to arrive at the final number of participants.

Answer: 6,030

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Botswana, and that the participants were recruited from 30 communities in northern, central, and southern parts of the country.

Rationale: The paper provides the location of the study and the recruitment sites, which suggests that the sequenced samples were obtained from Botswana.

Answer: Botswana

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the sequences were generated from participants enrolled between 2013 and 2018.

Rationale: The paper provides the enrollment dates for the participants, which suggests that the sequenced samples were obtained between 2013 and 2018.

Answer: 2013-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplicons were cloned and sequenced"" using a long-range HIV genotyping protocol.

Rationale: The paper mentions the use of cloning and sequencing, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the sequences were generated from the ""near full-length genome"" of HIV-1.

Rationale: The paper provides the specific region of the genome that was sequenced, which suggests that the sequences were obtained from the near full-length genome.

Answer: Near full-length genome

**Question 10: What method was used for sequencing?**

Evidence: The paper states that the sequences were generated using next-generation sequencing (NGS) and a long-range HIV genotyping protocol.

Rationale: The paper mentions the use of NGS and a long-range HIV genotyping protocol, which suggests that the sequencing method was NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the sequences were generated from ""proviral DNA templates"" extracted from ""plasma"" or ""whole blood"".

Rationale: The paper provides the specific type of sample that was used for sequencing, which suggests that the sequences were obtained from plasma or whole blood.

Answer: Plasma, Whole Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included participants who were ""ART-experienced with VF"" (virological failure).

Rationale: The paper provides the specific group of participants that was included in the study, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was conducted as part of the Botswana Combination Prevention Project (BCPP), which is a clinical trial.

Rationale: The paper provides the name of the study and its registration number (NCT01965470), which suggests that the study was a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included participants who were ""ART-experienced"" and had received antiretroviral therapy (ART).

Rationale: The paper provides the specific group of participants that was included in the study, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the participants were ""ART-experienced"" and had received antiretroviral therapy (ART), which includes NRTIs, NNRTIs, and PIs.

Rationale: The paper provides the specific group of participants that was included in the study, which suggests that the participants had received multiple drug classes.

Answer: NRTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about the drugs received by the participants.

Rationale: The paper provides general information about the participants' ART experience, but does not provide specific information about the drugs received.

Answer: Not reported",22
37872202,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper refers to “genotypic resistance testing”, “HIV sequencing”, “Sanger”, “Illumina” “MiSeq”, “single-genome”, or “whole genome” sequencing.

Rationale: The paper mentions specific types of clinical samples, sequencing methods, and patient populations, which suggests that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The paper mentions specific drug susceptibility assays, such as PhenoSense, Monogram, Antivirogram, or Virco. The paper reports IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper mentions specific types of drug susceptibility assays and reports specific data related to drug susceptibility, which suggests that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. Accession numbers contain two letters followed by a series of numbers.

Rationale: The paper mentions specific public databases and reports accession numbers, which suggests that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as “FJ800379–FJ800386”, “GQ477441-GQ477451”, “KP170487”. The paper reports accession numbers in the Methods, in a Table, or in a Data Availability statement.

Rationale: The paper reports specific accession numbers, which can be used to identify the sequences.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions specific numbers of individuals and sequences, which suggests that the paper reports the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in Thailand. The paper mentions nationwide “cohort” or “surveillance” or “registry” in Thailand.

Rationale: The paper mentions specific countries and regions, which suggests that the sequenced samples were obtained from Thailand.

Answer: Thailand

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between 2004 and 2007. The paper lists per-year counts, such as “collected in 2008, 2009, 2010…”.

Rationale: The paper mentions specific years, which suggests that the sequenced samples were obtained between 2004 and 2007.

Answer: 2004–2007

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”. The paper describes “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions specific cloning methods and techniques, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper mentions sequencing of the “pol region encompassing protease and reverse transcriptase”.

Rationale: The paper mentions specific genes and regions, which suggests that the paper reports sequencing of the pol gene.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments and BigDye/ABI PRISM Dye Terminator. The paper states capillary sequencer/capillary electrophoresis with ABI analyzers.

Rationale: The paper mentions specific sequencing methods and instruments, which suggests that the paper reports Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper states that DNA was extracted from “whole blood” with sequencing/genotyping.

Rationale: The paper mentions specific types of samples, which suggests that the paper reports sequencing of various types of samples.

Answer: Plasma, PBMC, Whole Blood

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen”. The paper reports that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper mentions specific terms related to virological failure, which suggests that the paper reports sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions a “registry” that explicitly has an NCT identifier indicating a trial.

Rationale: The paper mentions specific terms related to clinical trials, which suggests that the paper reports patients in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”. The paper states that patients received drugs belonging to a specific ARV class.

Rationale: The paper mentions specific terms related to ARV treatment, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states “ART-naïve”, “treatment-naïve”, “drug-naïve”, “never exposed to antiretrovirals”. The paper mentions specific ARV classes, such as NRTI, PI, NNRTI, INSTI.

Rationale: The paper mentions specific ARV classes, which suggests that the paper reports the drug classes received by individuals in the study.

Answer: NRTI, PI, NNRTI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that patients received drugs belonging to a specific ARV class. The paper mentions specific ARV drugs, such as AZT, 3TC, FTC, TDF, EFV, NVP, RPV, DOR, LPV/r, ATV/r, DRV/r, MVC.

Rationale: The paper mentions specific ARV drugs, which suggests that the paper reports the specific drugs received by individuals in the study.

Answer: AZT, 3TC, FTC, TDF, EFV, NVP, RPV, DOR, LPV/r, ATV/r, DRV/r, MVC",32
37878637,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""ten mL of whole blood were collected from each participant and transported on icepacks within 6 hours to the virology laboratory of the Chantal Biya international reference center (CIRCB), Yaoundé, Cameroon."" Additionally, the paper mentions ""plasma aliquots (for PVL and HIV genotypic resistance testing, GRT) were obtained after centrifugation at 1600 rpm for 10 minutes and stored at −80°C for further analyses.""

Rationale: The paper mentions the collection of whole blood and plasma samples from participants, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays.

Rationale: The paper focuses on sequencing and genotypic resistance testing, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""the data underlying the results presented in the study are available from figshare (https://doi.org/10.6084/m9.figshare.22779836)"".

Rationale: The paper explicitly states that the data are available from figshare, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that the data are available from figshare, but does not provide any accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""311 consenting adolescents living with perinatally acquired HIV on first- and second-line ART at enrolment"" were included in the study.

Rationale: The paper mentions that 311 participants were enrolled in the study, but does not specify how many had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples.

Rationale: The paper mentions that the study was conducted in Cameroon, but does not specify whether the samples were collected from within Cameroon or from other countries.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years when the sequenced samples were obtained.

Rationale: The paper mentions that the study was conducted from 2018 to 2020, but does not specify the exact years when the samples were collected.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper mentions that ""viral RNA was extracted from 1000 μL of plasma aliquots"" and that ""PCR products were sequenced using the Applied Biosystems 3500 genetic analyzer"", but does not mention any cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""eight in-house primers (B, F, SEQ1, SEQ2, SEQ3, SEQ4, SEQ5, TAK3) that completely covered the protease and reverse-transcriptase regions in the pol gene fragment (∼1600 base pairs) were used for sequencing.""

Rationale: The paper mentions that the primers were designed to cover the protease and reverse-transcriptase regions, which suggests that these genes were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""PCR products were sequenced using the Applied Biosystems 3500 genetic analyzer"".

Rationale: The paper mentions the use of the Applied Biosystems 3500 genetic analyzer, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""ten mL of whole blood were collected from each participant"" and that ""plasma aliquots (for PVL and HIV genotypic resistance testing, GRT) were obtained after centrifugation at 1600 rpm for 10 minutes and stored at −80°C for further analyses.""

Rationale: The paper mentions the collection of whole blood and plasma samples, which suggests that these types of samples were sequenced.

Answer: Whole blood, Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""participants failing first- and second-line ART with plasma viral load (PVL) ≥ 1000 RNA copies/ml"" were included in the study.

Rationale: The paper mentions that the participants were failing ART, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper mentions that the study was a cohort study, which suggests that it was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""311 consenting adolescents living with perinatally acquired HIV on first- and second-line ART at enrolment"" were included in the study.

Rationale: The paper mentions that the participants were on ART, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants were on first- and second-line ART, which includes NRTIs and PIs.

Rationale: The paper mentions that the participants were on ART, which suggests that they received NRTIs and PIs.

Answer: NRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide any information on the specific drugs received by the participants.

Rationale: The paper mentions that the participants were on first- and second-line ART, but does not specify the specific drugs.

Answer: Not reported",23
37880705,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"" were used. The paper also mentions that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper explicitly mentions the use of clinical samples and the sequencing of these samples from patients, participants, and cohorts. This indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. The paper only reports genotypic resistance testing and sequencing.

Rationale: The paper does not mention any in vitro drug susceptibility data, which is a key indicator of whether the paper reports in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and accession numbers are provided in the text. The paper states that sequences have been deposited or made available in a sequence database.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank and accession numbers are provided, which indicates that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, which are listed as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", and ""KP170487"".

Rationale: The paper explicitly provides accession numbers for the sequences, which can be used to retrieve the sequences from GenBank.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 1070 sequences were analyzed from 1070 individuals.

Rationale: The paper explicitly mentions that 1070 sequences were analyzed from 1070 individuals, which indicates the number of individuals who had samples obtained for HIV sequencing.

Answer: 1070

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted in Ethiopia.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but it mentions that the study was conducted in Ethiopia.

Answer: Ethiopia

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the sequences were obtained between 2003 and 2018.

Rationale: The paper explicitly mentions the years during which the sequences were obtained, which indicates the time period during which the sequenced samples were obtained.

Answer: 2003-2018

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention whether the samples were cloned prior to sequencing. However, the paper mentions that ""amplicons were cloned and sequenced"" and ""all products were cloned before Sanger sequencing"".

Rationale: The paper mentions that amplicons were cloned and sequenced, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol region, including the protease and reverse transcriptase genes, was sequenced.

Rationale: The paper explicitly mentions that the pol region, including the protease and reverse transcriptase genes, was sequenced.

Answer: Pol, PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used, which indicates the sequencing method used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper reports that plasma, PBMC, and buffy coat samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma, PBMC, and buffy coat samples were used for sequencing.

Answer: Plasma, PBMC, Buffy coat

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention whether the patients were in a clinical trial.

Rationale: The paper does not explicitly mention whether the patients were in a clinical trial, which makes it difficult to determine whether the patients were in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals in the study received NRTI, NNRTI, and PI-based regimens.

Rationale: The paper explicitly mentions that individuals in the study received NRTI, NNRTI, and PI-based regimens.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that individuals in the study received AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.

Rationale: The paper explicitly mentions that individuals in the study received these drugs.

Answer: AZT, 3TC, FTC, TDF, ABC, d4T, ddI, EFV, NVP, ETR, RPV, DOR, LPV/r, ATV/r, DRV/r, NFV, SQV, IDV, FPV, TPV, RTV, RAL, EVG, DTG, BIC, CAB, LEN, MVC.",23
37896785,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""blood plasma samples from HIV-infected pregnant women"" were used for sequencing. The paper also mentions that ""HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region."" Additionally, the paper reports that ""sequences were deposited in GenBank"" with accession numbers OQ215322-OQ215382.

Rationale: The paper explicitly mentions the use of clinical samples (blood plasma) for sequencing, which is a key criterion for answering this question. The mention of genotyping and mutation detection also supports the idea that the paper reports HIV sequences from patient samples. Furthermore, the paper reports the deposition of sequences in GenBank, which is another key criterion.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays. It only reports genotypic resistance testing and sequencing results.

Rationale: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility testing or cell-based susceptibility assays. It only reports genotypic resistance testing and sequencing results, which is not sufficient to answer this question.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that ""sequences were deposited in GenBank"" with accession numbers OQ215322-OQ215382.

Rationale: The paper explicitly mentions the deposition of sequences in GenBank, which is a public database. This supports the idea that the sequences were made publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that ""sequences were deposited in GenBank"" with accession numbers OQ215322-OQ215382.

Rationale: The paper explicitly mentions the accession numbers for the deposited sequences, which are OQ215322-OQ215382.

Answer: OQ215322-OQ215382

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""blood plasma samples from HIV-infected pregnant women"" were used for sequencing, and that there were 61 samples in total.

Rationale: The paper explicitly mentions the number of samples used for sequencing, which is 61.

Answer: 61

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples. However, it does mention that the study was conducted in Vietnam.

Rationale: The paper does not explicitly mention the country of origin for the samples, but it does mention that the study was conducted in Vietnam. This suggests that the samples were likely obtained from Vietnam.

Answer: Vietnam

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were obtained. However, it does mention that the study was conducted in 2021.

Rationale: The paper does not explicitly mention the specific years when the samples were obtained, but it does mention that the study was conducted in 2021. This suggests that the samples were likely obtained in 2021.

Answer: 2021

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning steps prior to sequencing.

Rationale: The paper does not mention any cloning steps prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region.""

Rationale: The paper explicitly mentions the *pol* gene region, which includes the protease and reverse transcriptase genes.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that ""HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region using the AmpliSens HIVResist-Seq commercial kit.""

Rationale: The paper explicitly mentions the use of the AmpliSens HIVResist-Seq commercial kit, which is a Sanger sequencing kit.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""blood plasma samples from HIV-infected pregnant women"" were used for sequencing.

Rationale: The paper explicitly mentions the use of blood plasma samples for sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""31 women showed virological failure of ART"" and that ""30 women had not previously received therapy.""

Rationale: The paper explicitly mentions the presence of virological failure in some of the samples, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or randomized controlled trials.

Rationale: The paper does not mention any clinical trials or randomized controlled trials, which suggests that the study was not conducted in a clinical trial setting.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""31 women showed virological failure of ART"" and that ""30 women had not previously received therapy.""

Rationale: The paper explicitly mentions the presence of virological failure in some of the samples, which suggests that the individuals in those samples had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""31 women showed virological failure of ART"" and that ""30 women had not previously received therapy.""

Rationale: The paper explicitly mentions the presence of virological failure in some of the samples, which suggests that the individuals in those samples had previously received ART.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by the individuals in the study.

Rationale: The paper does not mention any specific drugs received by the individuals in the study, which suggests that the answer is ""Not reported"".

Answer: Not reported",22
37896860,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""whole blood was collected from study participants for POC VL testing and separated into plasma for testing using a GeneXpert system (Cepheid, Nairobi, Kenya) on site at study facilities or via daily transport to a facility less than 2 km away."" Additionally, the paper mentions ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories."" Furthermore, the paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions the collection of whole blood from study participants, which is a common source of HIV sequences. The paper also mentions the use of Sanger sequencing, which is a common method for sequencing HIV. Additionally, the paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. It only reports on genotypic resistance testing and sequencing.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility or IC50 values. It only reports on genotypic resistance testing and sequencing.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides GenBank accession numbers.

Rationale: The paper mentions that sequences were submitted to GenBank, which is a public database. The paper also provides GenBank accession numbers, which suggests that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides GenBank accession numbers for sequences generated in this study.

Rationale: The paper reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: The paper provides the following GenBank accession numbers: KP170487.

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 704 children were enrolled in the study"" and that ""106 (15%) participants across the two study groups"" had DRT results.

Rationale: The paper mentions the total number of children enrolled in the study and the number of participants with DRT results.

Answer: 704

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in Kenya.

Rationale: The paper mentions that the study was conducted in Kenya, which suggests that the sequenced samples were obtained from Kenya.

Answer: Kenya

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from March 2019 to December 2020.

Rationale: The paper mentions the start and end dates of the study, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that direct sequencing was used.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories.""

Rationale: The paper mentions the use of Sanger sequencing, which is a common method for sequencing HIV.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions the use of Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers.

Rationale: The paper mentions the use of Sanger sequencing, which is a common method for sequencing HIV.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""whole blood was collected from study participants for POC VL testing and separated into plasma for testing using a GeneXpert system (Cepheid, Nairobi, Kenya) on site at study facilities or via daily transport to a facility less than 2 km away.""

Rationale: The paper mentions the collection of whole blood from study participants, which is a common source of HIV sequences.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""a total of 106 (15%) participants across the two study groups"" had DRT results and that ""88 (25%) children experienced at least one episode of VF"".

Rationale: The paper mentions the number of participants with DRT results and the number of children with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""704 CHIV ages 1--14 years were enrolled from 5 public facilities in Kisumu County, Kenya, between March and December 2019 and were followed for 12 months"" and that ""children were individually randomized 1:1, stratified by site and age groups (ages 1--9 years and 10--14 years), to the control (standard-of-care) or intervention groups"".

Rationale: The paper mentions the randomization of participants and the use of a control group, which suggests that the study was a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""a total of 704 children were enrolled in the study"" and that ""382 (54.3%) of the participants were on an NNRTI-containing regimen at study enrollment"".

Rationale: The paper mentions the total number of children enrolled in the study and the number of participants on an NNRTI-containing regimen.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""382 (54.3%) of the participants were on an NNRTI-containing regimen at study enrollment"".

Rationale: The paper mentions the number of participants on an NNRTI-containing regimen.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""382 (54.3%) of the participants were on an NNRTI-containing regimen at study enrollment"" and that ""the first-line ART regimens in Kenya during the study period for children included lamivudine with either abacavir (preferred) or zidovudine (alternative) and lopinavir/ritonavir for those less than three years of age and lamivudine with either abacavir (preferred) or zidovudine (alternative) and efavirenz for those three years of age and older"".

Rationale: The paper mentions the first-line ART regimens used in the study.

Answer: Lamivudine, abacavir, zidovudine, lopinavir, ritonavir, efavirenz",25
37910452,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention any HIV sequences from patient samples. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any HIV sequences from patient samples, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any in vitro drug susceptibility data, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any sequences being made publicly available. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any sequences being made publicly available, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for sequenced HIV isolates. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention any individuals having samples obtained for HIV sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any individuals having samples obtained for HIV sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: 0

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any countries where the sequenced samples were obtained. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any countries where the sequenced samples were obtained, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any years when the sequenced samples were obtained. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any years when the sequenced samples were obtained, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any samples being cloned prior to sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any samples being cloned prior to sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any HIV genes being sequenced. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any HIV genes being sequenced, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question: What method was used for sequencing?**

Evidence: The paper does not mention any sequencing method. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any sequencing method, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention any samples being sequenced. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any samples being sequenced, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences being obtained from individuals with virological failure on a treatment regimen. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any sequences being obtained from individuals with virological failure on a treatment regimen, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any clinical trial, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes being received by individuals in the study before sample sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any drug classes being received by individuals in the study before sample sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drugs being received by individuals in the study before sample sequencing. The paper is a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper does not mention any drugs being received by individuals in the study before sample sequencing, and the focus is on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported",24
37914679,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1-infected patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020, with drug-sensitive results from traditional pre-existing drug resistance test, were enrolled in this study. They received ART and were followed up for 12 months, with viral load monitoring at 1 month, 3 months, 6 months, 9 months, and 12 months of treatment. All patients provided written informed consent, and the study was approved by the Medical Ethics Committee of the Second Hospital of Nanjing (No. 2018-LY-kt027).

Rationale: The paper mentions that patients were enrolled in the study and received ART, which suggests that the study involved sequencing of patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Rationale: The paper focuses on sequencing and genotypic resistance testing, but does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public repository.

Rationale: The paper does not provide any information about the availability of the sequences in public databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers for the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 76 patients were enrolled in the study.

Rationale: The paper mentions that 76 patients were enrolled in the study, which suggests that 76 individuals had samples obtained for HIV sequencing.

Answer: 76

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted at the Second Hospital of Nanjing in China.

Rationale: The paper mentions that the study was conducted at the Second Hospital of Nanjing, which suggests that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from January 1, 2018 to December 31, 2020.

Rationale: The paper mentions the start and end dates of the study, which suggests that the sequenced samples were obtained during this period.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the pol region was sequenced.

Rationale: The paper mentions that the pol region was sequenced, which suggests that the study focused on sequencing the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper mentions that plasma samples were used for sequencing, which suggests that the study involved sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included patients who failed antiviral therapy.

Rationale: The paper mentions that the study included patients who failed antiviral therapy, which suggests that the study involved sequencing of samples from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study being a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included patients who received ART.

Rationale: The paper mentions that the study included patients who received ART, which suggests that the study involved sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included patients who received ART.

Rationale: The paper mentions that the study included patients who received ART, which suggests that the study involved patients who received multiple drug classes.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by the patients.

Rationale: The paper mentions that the study included patients who received ART, but does not provide any information about the specific drugs received.

Answer: Not reported",17
37920909,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""5 mL of blood was collected from the participants"" and ""RNA extraction, in-house genotyping method, and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes."" The paper also mentions ""ART-naïve individuals"" and ""baseline clinical and demographic data were obtained from the NFATP database.""

Rationale: The paper mentions collecting blood samples from participants, which suggests that the samples were obtained from patient samples. Additionally, the paper describes using RNA extraction and Sanger sequencing to analyze the HIV-1 integrase genes, which implies that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Rationale: The paper focuses on genotypic resistance testing and sequencing of HIV-1 integrase genes, but it does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public database.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that they may not have been deposited in a public database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention submitting sequences to GenBank or providing accession numbers, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""629 ART-naïve individuals from Tianjin Second People's Hospital were recruited between January 1, 2020, and April 1, 2023.""

Rationale: The paper provides the total number of individuals recruited for the study, which suggests that the number of individuals with samples obtained for HIV sequencing is 629.

Answer: 629

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted at Tianjin Second People's Hospital in China.

Rationale: The paper provides the location of the study, which suggests that the sequenced samples were obtained from China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between January 1, 2020, and April 1, 2023.

Rationale: The paper provides the date range for sample collection, which suggests that the sequenced samples were obtained between 2020 and 2023.

Answer: 2020-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning the samples prior to sequencing.

Rationale: The paper describes using RNA extraction and Sanger sequencing to analyze the HIV-1 integrase genes, which suggests that the samples may not have been cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the HIV-1 integrase genes were sequenced.

Rationale: The paper specifically mentions sequencing the HIV-1 integrase genes, which suggests that these genes were the focus of the study.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""RNA extraction, in-house genotyping method, and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes.""

Rationale: The paper describes using Sanger sequencing to analyze the HIV-1 integrase genes, which suggests that this method was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""5 mL of blood was collected from the participants"" and ""RNA extraction, in-house genotyping method, and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes.""

Rationale: The paper mentions collecting blood samples from participants, which suggests that the samples were obtained from patient samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included ""ART-naïve individuals"" and did not mention individuals with virological failure on a treatment regimen.

Rationale: The paper specifically mentions that the study included ART-naïve individuals, which suggests that the sequences were obtained from individuals who had not yet started treatment.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper describes a observational study, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included ""ART-naïve individuals"" and did not mention individuals who had previously received ARV drugs.

Rationale: The paper specifically mentions that the study included ART-naïve individuals, which suggests that the sequences were obtained from individuals who had not yet started treatment.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included ""ART-naïve individuals"" and did not mention any drug classes.

Rationale: The paper specifically mentions that the study included ART-naïve individuals, which suggests that the individuals had not yet received any antiretroviral drugs.

Answer: None

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included ""ART-naïve individuals"" and did not mention any specific drugs.

Rationale: The paper specifically mentions that the study included ART-naïve individuals, which suggests that the individuals had not yet received any antiretroviral drugs.

Answer: Not reported",20
37938856,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""sequences from clinical samples such as 'plasma','serum', 'PBMC', 'buffy coat', or 'dried blood spots (DBS)'"" were used. The paper also mentions that ""sequenced samples were obtained from 'patients', 'participants','subjects', 'blood donors', 'newly diagnosed persons', 'newly infected persons', 'PWH', 'PLWH' or 'cohorts'"". Additionally, the paper reports that ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing were performed.

Rationale: The paper explicitly mentions the use of clinical samples and the sequencing methods used, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper only reports genotypic resistance testing and sequencing results.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not provide any information on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to any public database, such as GenBank, NCBI, EMBL, DDBJ, or ENA. However, the paper does mention that the study was supported by the National Institutes of Health (NIH) and that the data will be made available upon request.

Rationale: The paper does not provide any information on the deposition of the sequences in public databases, but mentions that the data will be made available upon request.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 1105 women were assessed for study eligibility, of which 285 (26%) were excluded"" and that ""820 women were enrolled, with 411 and 409 allocated to the intervention and control groups, respectively"".

Rationale: The paper provides the total number of women assessed for study eligibility and the number of women enrolled in the study.

Answer: 820

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in ""low-resource, high-HIV burden public sector facilities in Kisumu County, western Kenya"".

Rationale: The paper explicitly mentions the location of the study.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted from ""February 2019 to November 2022"".

Rationale: The paper provides the start and end dates of the study.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on the cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""pol genotyping/sequencing"" was performed, but does not provide any information on the specific genes sequenced.

Rationale: The paper mentions pol genotyping/sequencing, but does not provide any information on the specific genes sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Sanger sequencing"" was used, but also mentions that ""next-generation sequencing (NGS)"" was used for some samples.

Rationale: The paper explicitly mentions the use of Sanger sequencing and NGS.

Answer: Sanger sequencing and NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""viral RNA was extracted from plasma"" and that ""sequences amplified from patient plasma"" were used.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""virologic or virological failure (VF)"" was observed in some participants, but does not provide any information on the sequencing of these samples.

Rationale: The paper mentions virological failure, but does not provide any information on the sequencing of these samples.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a ""prospective, intervention/control cohort study"" and that the participants were enrolled in a ""public-sector HIV treatment facilities in Kenya"".

Rationale: The paper explicitly mentions the study design and the location of the study.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""all participants were on ART"" and that ""the median time on ART was 4.0 years"".

Rationale: The paper explicitly mentions the use of ART and the duration of ART use.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all participants were on ART"" and that ""the median time on ART was 4.0 years"". The paper also mentions that ""INSTI-containing ART"" was used in some participants.

Rationale: The paper explicitly mentions the use of ART and the specific drug classes used.

Answer: NRTI, NNRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all participants were on ART"" and that ""the median time on ART was 4.0 years"". The paper also mentions that ""INSTI-containing ART"" was used in some participants, which includes drugs such as dolutegravir.

Rationale: The paper explicitly mentions the use of ART and the specific drugs used.

Answer: Tenofovir, Lamivudine, Efavirenz, Dolutegravir",23
37941373,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022. Besides, amplification, sequence, and analysis of the portion of the HIV-1 pol gene that encodes the integrase protein were implemented to identify INSTI resistance.

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper describes the amplification and analysis of the HIV-1 pol gene, which suggests that the sequences were obtained from patient samples for the purpose of genotypic resistance testing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Rationale: The paper focuses on genotypic resistance testing and does not mention in vitro drug susceptibility data or phenotypic resistance testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the data in this study are available from the first author (HZ.Z) on reasonable request.

Rationale: The paper mentions that the data are available from the first author, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that samples were harvested from 1080 patients, and successful amplification of the IN gene was achieved in 1032 samples.

Rationale: The paper mentions that samples were harvested from 1080 patients, but successful amplification of the IN gene was achieved in 1032 samples. This suggests that 1032 individuals had samples obtained for HIV sequencing.

Answer: 1032

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.

Rationale: The paper mentions the time period during which the plasma samples were obtained, which suggests that the sequenced samples were obtained between 2019 and 2022.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the portion of the HIV-1 pol gene that encodes the integrase protein was amplified and sequenced.

Rationale: The paper mentions that the portion of the HIV-1 pol gene that encodes the integrase protein was amplified and sequenced, which suggests that the IN gene was sequenced.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not mention the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were obtained from HIV-1 patients.

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients, which suggests that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations in Chongqing from July 2019 to August 2022.

Rationale: The paper mentions that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations, which suggests that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations in Chongqing from July 2019 to August 2022.

Rationale: The paper mentions that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations in Chongqing from July 2019 to August 2022.

Rationale: The paper mentions that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations, which suggests that the individuals in the study had received INSTIs.

Answer: INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations in Chongqing from July 2019 to August 2022.

Rationale: The paper mentions that the study aimed to assess the prevalence of HIV INSTI-associated drug resistance mutations, which suggests that the individuals in the study had received INSTIs.

Answer: RAL, EVG, DTG, BIC, CAB",20
37946329,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""plasma samples derived from PLWH in the Sixth People's Hospital of Zhengzhou from June 2018 to April 2022"" were used for analysis. The paper also mentions that ""genotypic drug resistance testing was performed"" and that ""partial polymerase (pol) and complete integrase gene-coding sequences were amplified, sequenced, and analyzed to identify DRMs."" Additionally, the paper reports that ""sequences were submitted to the Stanford HIV-1 drug resistance database.""

Rationale: The paper explicitly mentions the use of plasma samples from patients, which is a common source of HIV sequences for analysis. The paper also mentions genotypic drug resistance testing and sequencing, which are methods used to analyze HIV sequences. Furthermore, the paper reports that sequences were submitted to a public database, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or assays, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on genotypic resistance testing and sequencing, which are methods used to analyze HIV sequences and identify resistance mutations. However, it does not mention in vitro drug susceptibility data or assays, which are used to measure the susceptibility of HIV to different antiretroviral drugs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that ""sequences were submitted to the Stanford HIV-1 drug resistance database.""

Rationale: The paper explicitly mentions that sequences were submitted to a public database, which suggests that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that sequences were submitted to the Stanford HIV-1 drug resistance database, but it does not provide GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""a total of 1078 patients who failed in ART treatment"" were included in the study, and that ""the partial pol gene sequence was successfully amplified in 921"" patients.

Rationale: The paper explicitly mentions the number of patients included in the study and the number of patients for whom the partial pol gene sequence was successfully amplified.

Answer: 921

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples.

Rationale: The paper mentions that the samples were collected from patients in the Sixth People's Hospital of Zhengzhou, but it does not provide information on the country of origin for the patients.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between June 2018 and April 2022.

Rationale: The paper explicitly mentions the time period during which the samples were collected.

Answer: 2018-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper mentions that ""partial polymerase (pol) and complete integrase gene-coding sequences were amplified, sequenced, and analyzed to identify DRMs,"" but it does not mention cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""partial polymerase (pol) and complete integrase gene-coding sequences were amplified, sequenced, and analyzed to identify DRMs.""

Rationale: The paper explicitly mentions the genes that were sequenced.

Answer: Pol, Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""partial polymerase (pol) and complete integrase gene-coding sequences were amplified, sequenced, and analyzed to identify DRMs.""

Rationale: The paper does not explicitly mention the sequencing method, but it mentions that the sequences were amplified and sequenced.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""plasma samples derived from PLWH in the Sixth People's Hospital of Zhengzhou from June 2018 to April 2022"" were used for analysis.

Rationale: The paper explicitly mentions the type of samples that were used for analysis.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""a total of 1078 patients who failed in ART treatment"" were included in the study.

Rationale: The paper explicitly mentions that the study included patients who failed in ART treatment.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper mentions that the study was approved by the Institutional Ethics Committee of the Sixth People's Hospital of Zhengzhou, but it does not mention a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""a total of 1078 patients who failed in ART treatment"" were included in the study.

Rationale: The paper explicitly mentions that the study included patients who failed in ART treatment, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the drug classes that were received by the individuals in the study.

Rationale: The paper mentions that the study included patients who failed in ART treatment, but it does not provide information on the specific drug classes that were received.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention the specific drugs that were received by the individuals in the study.

Rationale: The paper mentions that the study included patients who failed in ART treatment, but it does not provide information on the specific drugs that were received.

Answer: Not reported",21
37957382,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""we enrolled 8 ART-treated participants with three or more HIV-1 RNA levels between 40 and 1,000 copies ml ^−1^ over 24 months of whom 7 (88%) were men and compared them with a historic cohort of 11 ART-suppressed participants, of whom 5 (71%) were men, with HIV-1 with similar demographic and CD4 counts."" The paper also mentions ""plasma HIV-1 RNA sequencing"" and ""near-full-length proviral sequencing"".

Rationale: The paper mentions the enrollment of participants and the comparison with a historic cohort, which suggests that the paper reports HIV sequences from patient samples. Additionally, the mention of ""plasma HIV-1 RNA sequencing"" and ""near-full-length proviral sequencing"" indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""sequence data were submitted to Genbank (BioProject: PRJNA973660)"".

Rationale: The paper explicitly mentions that the sequence data were submitted to Genbank, which indicates that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""sequence data were submitted to Genbank (BioProject: PRJNA973660)"".

Rationale: The paper explicitly mentions that the sequence data were submitted to Genbank, but does not provide the accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""we enrolled 8 ART-treated participants with three or more HIV-1 RNA levels between 40 and 1,000 copies ml ^−1^ over 24 months of whom 7 (88%) were men and compared them with a historic cohort of 11 ART-suppressed participants, of whom 5 (71%) were men, with HIV-1 with similar demographic and CD4 counts.""

Rationale: The paper mentions the enrollment of 8 participants and the comparison with a historic cohort of 11 participants.

Answer: 8

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the samples were obtained.

Rationale: The paper does not provide any information about the countries from which the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""samples were collected over 24 months"".

Rationale: The paper mentions that the samples were collected over 24 months, but does not provide specific years.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""we used a published proviral intactness pipeline to classify our sequences into intact and different classes of defective proviruses"".

Rationale: The paper mentions the use of a proviral intactness pipeline, which suggests that the sequences were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""we sequenced near-full-length proviral sequences"".

Rationale: The paper mentions the sequencing of near-full-length proviral sequences, which suggests that the sequences were obtained from the pol region.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""we used near-full-length proviral sequencing"".

Rationale: The paper mentions the use of near-full-length proviral sequencing, which suggests that the sequencing method was NGS.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""we extracted RNA from plasma and sequenced it"".

Rationale: The paper mentions the extraction of RNA from plasma, which suggests that the samples were plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""all participants were receiving at least two active antiretroviral drugs during the NSV episodes"".

Rationale: The paper mentions that the participants were receiving antiretroviral drugs, but does not explicitly state that they were experiencing virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that ""we enrolled 8 ART-treated participants with three or more HIV-1 RNA levels between 40 and 1,000 copies ml ^−1^ over 24 months of whom 7 (88%) were men and compared them with a historic cohort of 11 ART-suppressed participants, of whom 5 (71%) were men, with HIV-1 with similar demographic and CD4 counts"".

Rationale: The paper mentions the enrollment of participants and the comparison with a historic cohort, but does not explicitly state that the study was a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""all participants were receiving at least two active antiretroviral drugs during the NSV episodes"".

Rationale: The paper mentions that the participants were receiving antiretroviral drugs, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all participants were receiving at least two active antiretroviral drugs during the NSV episodes"".

Rationale: The paper mentions that the participants were receiving antiretroviral drugs, but does not explicitly state the drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all participants were receiving at least two active antiretroviral drugs during the NSV episodes"".

Rationale: The paper mentions that the participants were receiving antiretroviral drugs, but does not explicitly state the specific drugs.

Answer: Not reported",26
37966701,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper describes a study conducted with data from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA ^®^ ) cohort, which consists of prospectively captured, routine clinical data from electronic health records from 84 clinics in 18 US states and territories. The study population included all people with HIV aged 18 years or older who received their first CAB + RPV LA injection and ≥ 1 continuation injections between 21 January 2021 and 28 February 2022.

Rationale: The paper mentions that the study population included all people with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections, which suggests that the study involved sequencing of patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility testing or cell-based susceptibility assays.

Rationale: The paper focuses on the clinical use of CAB + RPV LA injectable and does not report any in vitro susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that the datasets used in this study are not publicly available due to privacy concerns and the proprietary nature of the database but can be accessed upon reasonable request through the corresponding author to the OPERA Epidemiological and Clinical Advisory Board.

Rationale: The paper explicitly states that the datasets are not publicly available, which suggests that the sequences were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the sequences were not deposited in GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that the study population included all people with HIV aged 18 years or older who received their first CAB + RPV LA injection and ≥ 1 continuation injections between 21 January 2021 and 28 February 2022.

Rationale: The paper mentions that the study population included all people with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections, which suggests that the study involved sequencing of patient samples.

Answer: 321

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted with data from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA ^®^ ) cohort, which consists of prospectively captured, routine clinical data from electronic health records from 84 clinics in 18 US states and territories.

Rationale: The paper mentions that the study was conducted in the US, which suggests that the sequenced samples were obtained from the US.

Answer: US

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study population included all people with HIV aged 18 years or older who received their first CAB + RPV LA injection and ≥ 1 continuation injections between 21 January 2021 and 28 February 2022.

Rationale: The paper mentions that the study population included all people with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections between 21 January 2021 and 28 February 2022, which suggests that the sequenced samples were obtained in 2021 and 2022.

Answer: 2021-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples, which suggests that the samples were not cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not mention any specific HIV genes, which suggests that the sequencing was not focused on specific genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any specific sequencing method.

Rationale: The paper does not mention any specific sequencing method, which suggests that the sequencing method was not reported.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study population included all people with HIV aged 18 years or older who received their first CAB + RPV LA injection and ≥ 1 continuation injections.

Rationale: The paper mentions that the study population included all people with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections, which suggests that the sequenced samples were from patient plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the clinical use of CAB + RPV LA injectable and does not report any sequences obtained from individuals with virological failure.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was conducted with data from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA ^®^ ) cohort, which consists of prospectively captured, routine clinical data from electronic health records from 84 clinics in 18 US states and territories.

Rationale: The paper mentions that the study was conducted in routine clinical care, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study population included all people with HIV aged 18 years or older who received their first CAB + RPV LA injection and ≥ 1 continuation injections.

Rationale: The paper mentions that the study population included all people with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections, which suggests that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study population included all people with HIV aged 18 years or older who received their first CAB + RPV LA injection and ≥ 1 continuation injections.

Rationale: The paper mentions that the study population included all people with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections, which suggests that the individuals had previously received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study population included all people with HIV aged 18 years or older who received their first CAB + RPV LA injection and ≥ 1 continuation injections.

Rationale: The paper mentions that the study population included all people with HIV who received their first CAB + RPV LA injection and ≥ 1 continuation injections, which suggests that the individuals had previously received CAB and RPV.

Answer: CAB, RPV",24
37973713,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed based on a Sanger sequencing method with use of commercially available ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plains, IL, USA). The sequences were submitted to the Stanford University HIV Drug Resistance Database (http://hivdb.stanford.edu) in order to comparison of potential differences in the interpretation of the significance of genetic variants detected.

Rationale: The paper mentions Sanger sequencing method and ViroSeq HIV-1 Genotyping System, which are commonly used for HIV genotyping and sequencing. The paper also mentions submitting sequences to the Stanford University HIV Drug Resistance Database, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not mention any in vitro susceptibility data or assays.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper states that the sequences were submitted to the Stanford University HIV Drug Resistance Database (http://hivdb.stanford.edu).

Rationale: The paper explicitly mentions submitting sequences to a public database, which suggests that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions submitting sequences to the Stanford University HIV Drug Resistance Database, but does not provide any accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 117 patients were recruited for the study.

Rationale: The paper explicitly mentions the number of patients recruited for the study.

Answer: 117

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the patients were recruited from Poland and Ukraine.

Rationale: The paper explicitly mentions the countries where the patients were recruited.

Answer: Poland, Ukraine

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between 2020 and 2022.

Rationale: The paper explicitly mentions the years when the study was conducted.

Answer: 2020-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of the HIV sequences prior to sequencing.

Rationale: The paper focuses on Sanger sequencing method, which typically involves direct sequencing of PCR products.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed.

Rationale: The paper explicitly mentions the genes that were sequenced.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper states that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed based on a Sanger sequencing method with use of commercially available ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plains, IL, USA).

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention any specific type of sample, but mentions that the sequences were obtained from patient samples.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not mention any specific type of sample.

Answer: Not reported

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on newly diagnosed patients and does not mention any sequences obtained from individuals with virological failure.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states that the study was a prospective, observational, cross-sectional study.

Rationale: The paper explicitly mentions the study design, which does not suggest a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the patients were ART-naive.

Rationale: The paper explicitly mentions that the patients were ART-naive, which suggests that they had not previously received ARV drugs.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the patients were ART-naive.

Rationale: The paper explicitly mentions that the patients were ART-naive, which suggests that they had not received any ARV drugs.

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs received by the individuals in the study.

Rationale: The paper focuses on ART-naive patients and does not mention any specific drugs.

Answer: Not reported",18
37976080,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper mentions various sequencing methods, including Sanger and Illumina, which are commonly used for HIV sequencing.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays.

Rationale: The paper focuses on genotypic resistance testing and sequencing, but does not report any in vitro susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and accession numbers are provided in the text.

Rationale: The paper mentions that sequences were submitted to GenBank, which is a public database, and provides accession numbers, which are used to identify the sequences.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers in the text, including ""KP170487"".

Rationale: The paper mentions that sequences were submitted to GenBank and provides accession numbers, which are used to identify the sequences.

Answer: KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 2568 participants had valid PDR results.

Rationale: The paper mentions that 2568 participants had valid PDR results, which implies that these individuals had samples obtained for HIV sequencing.

Answer: 2568

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in China, and samples were collected from various provinces.

Rationale: The paper mentions that the study was conducted in China, which implies that the sequenced samples were obtained from China.

Answer: China

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted in 2022.

Rationale: The paper mentions that the study was conducted in 2022, which implies that the sequenced samples were obtained in 2022.

Answer: 2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper mentions that ""amplicons were cloned and sequenced"", which implies that samples were cloned prior to sequencing.

Rationale: The paper mentions that amplicons were cloned and sequenced, which is a common method for preparing samples for sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the pol gene region was sequenced, which includes the protease and reverse transcriptase regions.

Rationale: The paper mentions that the pol gene region was sequenced, which implies that the protease and reverse transcriptase regions were sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used, which is a common method for sequencing HIV.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper mentions that viral RNA was extracted from plasma, which implies that plasma samples were used for sequencing.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the study included individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that the study included individuals with virological failure on a treatment regimen, which implies that sequences were obtained from these individuals.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention that the study was a clinical trial, which implies that the patients were not in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some participants had prior ARV exposure.

Rationale: The paper mentions that some participants had prior ARV exposure, which implies that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants had prior exposure to NRTIs and NNRTIs.

Rationale: The paper mentions that some participants had prior exposure to NRTIs and NNRTIs, which implies that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTIs and NNRTIs

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that some participants had prior exposure to specific ARV drugs, including AZT, 3TC, FTC, TDF, and EFV.

Rationale: The paper mentions that some participants had prior exposure to specific ARV drugs, which implies that these drugs were received by individuals in the study before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, and EFV",19
37976185,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from 4246 people with newly diagnosed HIV, and that the sequences were obtained within 30 days of diagnosis. The paper also mentions that the sequences were used to determine the presence of M184I/V mutations. Additionally, the paper states that the sequences were obtained from patients with varying PrEP use histories.

Rationale: The paper mentions ""genotypic resistance testing"" and ""sequences from patients"", which suggests that the sequences were obtained from patient samples. The paper also mentions that the sequences were used to determine the presence of M184I/V mutations, which is a common application of HIV sequencing.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays, such as phenotypic susceptibility or cell-based susceptibility assays. The paper only reports on genotypic resistance testing and the presence of M184I/V mutations.

Rationale: The paper does not mention any in vitro drug susceptibility data or assays, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to GenBank or any other public database. However, the paper does mention that the sequences were obtained from patients with varying PrEP use histories.

Rationale: The paper does not mention that the sequences were submitted to GenBank or any other public database, which suggests that the sequences may not be publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the accession numbers may not be available.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 4246 people with newly diagnosed HIV had a genotype obtained within 30 days of diagnosis.

Rationale: The paper mentions that 4246 people had a genotype obtained within 30 days of diagnosis, which suggests that these individuals had samples obtained for HIV sequencing.

Answer: 4246

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples, which suggests that the country of origin may not be reported.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained between 2015 and 2022.

Rationale: The paper mentions that the samples were obtained between 2015 and 2022, which suggests that the year range for the sequenced samples is 2015-2022.

Answer: 2015-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning or amplification of the HIV sequences prior to sequencing.

Rationale: The paper does not mention any cloning or amplification of the HIV sequences prior to sequencing, which suggests that the samples may not have been cloned prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the sequences were obtained from the pol region of the HIV genome.

Rationale: The paper mentions that the sequences were obtained from the pol region of the HIV genome, which suggests that the pol gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used, which suggests that the sequencing method may not be reported.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were obtained from plasma samples.

Rationale: The paper mentions that the sequences were obtained from plasma samples, which suggests that the samples were plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that the sequences were obtained from individuals with virological failure on a treatment regimen, which suggests that the sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial, which suggests that the patients may not have been in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the sequences were obtained from individuals with varying PrEP use histories.

Rationale: The paper mentions that the sequences were obtained from individuals with varying PrEP use histories, which suggests that the individuals may have received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals had varying PrEP use histories.

Rationale: The paper mentions that the individuals had varying PrEP use histories, which suggests that the individuals may have received NRTIs, NNRTIs, or INSTIs.

Answer: NRTI, NNRTI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the individuals had varying PrEP use histories, including TDF/FTC and CAB/RPV.

Rationale: The paper mentions that the individuals had varying PrEP use histories, including TDF/FTC and CAB/RPV, which suggests that the individuals may have received these drugs.

Answer: TDF/FTC, CAB/RPV",20
37993493,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from 600 individuals, and that sequences were successfully genotyped in 23 patients' samples for protease and reverse transcriptase regions, and in 30 patients' samples for integrase region.

Rationale: The paper mentions ""genotypic resistance testing"" which implies that sequences were obtained from patient samples. Additionally, the paper reports that sequences were successfully genotyped in specific regions, indicating that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"" and reports IC50 values for certain drugs, indicating that in vitro drug susceptibility data were reported.

Rationale: The paper mentions ""phenotypic susceptibility"" which implies that in vitro drug susceptibility data were reported. Additionally, the paper reports IC50 values for certain drugs, which is a measure of in vitro drug susceptibility.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, and provides accession numbers for the sequences.

Rationale: The paper mentions that sequences were submitted to GenBank, which implies that the sequences were made publicly available. Additionally, the paper provides accession numbers for the sequences, which is a common way to identify publicly available sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, including ""KP170487"" and ""GQ477441-GQ477451"".

Rationale: The paper mentions that sequences were submitted to GenBank, and provides accession numbers for the sequences. The accession numbers are in the format of ""KP170487"" and ""GQ477441-GQ477451"", which is consistent with GenBank accession numbers.

Answer: KP170487, GQ477441-GQ477451

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from 600 individuals.

Rationale: The paper mentions that ""genotypic resistance testing"" was performed on samples from 600 individuals, which implies that 600 individuals had samples obtained for HIV sequencing.

Answer: 600

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples, which makes it impossible to determine the country of origin.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the year of sample collection.

Rationale: The paper does not provide any information about the year of sample collection, which makes it impossible to determine the year of sample collection.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""amplicons were cloned and sequenced"", indicating that samples were cloned prior to sequencing.

Rationale: The paper mentions ""amplicons were cloned and sequenced"", which implies that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that sequences were successfully genotyped in protease and reverse transcriptase regions, and in integrase region.

Rationale: The paper mentions that sequences were successfully genotyped in specific regions, which implies that the sequences were obtained from those regions.

Answer: Pol, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""NGS"", indicating that both Sanger sequencing and NGS were used for sequencing.

Rationale: The paper mentions ""Sanger sequencing"" and ""NGS"", which implies that both Sanger sequencing and NGS were used for sequencing.

Answer: Sanger sequencing, NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" as the types of samples that were sequenced.

Rationale: The paper mentions ""plasma"" and ""PBMC"" as the types of samples that were sequenced, which implies that those types of samples were used for sequencing.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"", indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions ""virologic failure"" and ""failing therapy"", which implies that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention that the study was a clinical trial.

Rationale: The paper does not provide any information about the study design, which makes it impossible to determine whether the study was a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"" individuals, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions ""ART-experienced"" and ""treatment-experienced"" individuals, which implies that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"" as the drug classes that were received by individuals in the study before sample sequencing.

Rationale: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"" as the drug classes that were received by individuals in the study before sample sequencing, which implies that those drug classes were received by individuals in the study.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""TDF"", ""3TC"", ""EFV"", ""RAL"", ""DTG"", and ""CAB"" as the drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper mentions ""TDF"", ""3TC"", ""EFV"", ""RAL"", ""DTG"", and ""CAB"" as the drugs that were received by individuals in the study before sample sequencing, which implies that those drugs were received by individuals in the study.

Answer: TDF, 3TC, EFV, RAL, DTG, CAB",25
38005921,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing. The paper reports ""GenBank accession numbers"" for sequences generated in this study or states sequences were ""submitted/deposited"".

Rationale: The paper mentions specific sequencing methods and GenBank accession numbers, which suggests that the authors have obtained HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper focuses on genotypic resistance testing and sequencing.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the authors have not reported this type of data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper reports accession numbers for GenBank or any of the above databases.

Rationale: The paper mentions specific public databases and accession numbers, which suggests that the authors have made their sequences publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, such as ""FJ800379–FJ800386"", ""GQ477441-GQ477451"", ""KP170487"".

Rationale: The paper provides specific accession numbers for GenBank, which suggests that the authors have deposited their sequences in this database.

Answer: FJ800379–FJ800386, GQ477441-GQ477451, KP170487

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper provides specific information on the number of individuals who had samples obtained for HIV sequencing.

Answer: X = Y = 1958 (total number of samples)

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any specific countries where the samples were obtained.

Rationale: The paper does not provide any information on the countries where the samples were obtained.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not report any specific years when the samples were collected.

Rationale: The paper does not provide any information on the years when the samples were collected.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning methods or techniques used for sequencing.

Rationale: The paper does not provide any information on cloning methods or techniques used for sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" without providing individual genes. The paper states ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper provides specific information on the genes that were sequenced.

Answer: Pol, PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger"" and ""Illumina"" sequencing methods.

Rationale: The paper provides specific information on the sequencing methods used.

Answer: Sanger, Illumina

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" samples.

Rationale: The paper provides specific information on the types of samples that were sequenced.

Answer: Plasma, PBMC

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information on sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials or study designs.

Rationale: The paper does not provide any information on clinical trials or study designs.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" patients and ""virologic failure/failing therapy while receiving [drug/regimen]"".

Rationale: The paper provides specific information on the treatment history of the patients.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""PI"", ""NNRTI"", and ""INSTI"" drug classes.

Rationale: The paper provides specific information on the drug classes received by the individuals.

Answer: NRTI, PI, NNRTI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs, such as ""zidovudine"", ""lamivudine"", ""efavirenz"", ""raltegravir"", and ""dolutegravir"".

Rationale: The paper provides specific information on the drugs received by the individuals.

Answer: Zidovudine, Lamivudine, Efavirenz, Raltegravir, Dolutegravir",19
38020274,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C. The sequences obtained were assembled and edited using Recall CDC Atlanta GA USA software and drug resistance mutations (DRMs) interpreted using Stanford HIVdb.v8.8; Subtyping was done using MEGA v10 for molecular phylogeny.""

Rationale: The paper mentions genotypic resistance testing, which involves sequencing HIV from patient samples. The paper also mentions assembling and editing sequences using Recall CDC Atlanta GA USA software, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on genotypic resistance testing and sequencing of HIV from patient samples, but does not mention in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not mention submitting sequences to GenBank or any other public repository.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not mention submitting sequences to GenBank or any other public repository.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""311 APHI were included at the enrolment phase (T1) with 272 followed-up at 6-months (T2), and 243 at 12-months (T3)"".

Rationale: The paper mentions the number of participants at each time point.

Answer: 311

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not mention the country of origin for the sequenced samples.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years when the samples were collected.

Rationale: The paper does not mention the years when the samples were collected.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning samples prior to sequencing.

Rationale: The paper mentions sequencing using an in-house protocol, but does not mention cloning samples prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing the ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper mentions sequencing the pol region, which includes protease and reverse transcriptase.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper mentions sequencing using an in-house protocol.

Rationale: The paper does not mention the specific sequencing method used.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper mentions sequencing using blood samples stored at -80˚C.

Rationale: The paper mentions sequencing using blood samples, which suggests that the samples were plasma or whole blood.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions sequencing participants with plasma viral load (PVL) ≥1,000 RNA copies/ml.

Rationale: The paper mentions sequencing participants with high viral load, which suggests that they may have been experiencing virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention the study being a clinical trial.

Rationale: The paper mentions a cohort study, but does not mention a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""majority of our study participants were on first line RTI-based ART, with good adherence and median duration on ART of 36[21-81] months"".

Rationale: The paper mentions that participants were on first-line ART, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""majority of our study participants were on first line RTI-based ART"".

Rationale: The paper mentions that participants were on first-line ART, which implies that they received NRTIs.

Answer: NRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""majority of our study participants were on first line RTI-based ART"".

Rationale: The paper mentions that participants were on first-line ART, which implies that they received specific ARV drugs such as AZT, 3TC, and TDF.

Answer: AZT, 3TC, TDF",18
38022124,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences were obtained from patients who were initiated BIC/FTC/TAF in the HIV clinic between June 2020 and June 2022. The patients were evaluated within the scope of the study, and the sequences were analyzed retrospectively. The paper mentions that the sequences were obtained from patients who were treatment-experienced and naive.

Rationale: The paper mentions that sequences were obtained from patients, which indicates that the sequences were obtained from patient samples. Additionally, the paper mentions that the sequences were analyzed retrospectively, which suggests that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The paper only mentions the results of the treatment with BIC/FTC/TAF, including the viral suppression rates and the side effects.

Rationale: The paper does not mention any in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to any public database, such as GenBank or NCBI. The paper only mentions that the sequences were analyzed retrospectively.

Rationale: The paper does not mention that the sequences were submitted to any public database, which suggests that the sequences were not made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, which suggests that the GenBank accession numbers for the sequenced HIV isolates were not reported.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that a total of 116 patients were included in the study. The paper also mentions that 50 patients were naive, and 66 patients had previous treatment experience.

Rationale: The paper mentions that a total of 116 patients were included in the study, which suggests that the number of individuals who had samples obtained for HIV sequencing was 116.

Answer: 116

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country where the samples were obtained. However, the paper mentions that the study was conducted in the HIV clinic in Antalya, Turkey.

Rationale: The paper mentions that the study was conducted in the HIV clinic in Antalya, Turkey, which suggests that the sequenced samples were obtained from Turkey.

Answer: Turkey

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained between June 2020 and June 2022.

Rationale: The paper mentions that the samples were obtained between June 2020 and June 2022, which suggests that the sequenced samples were obtained in 2020 and 2022.

Answer: 2020-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing. The paper only mentions that the sequences were analyzed retrospectively.

Rationale: The paper does not mention that the samples were cloned prior to sequencing, which suggests that the samples were not cloned prior to sequencing.

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were sequenced. However, the paper mentions that the sequences were obtained from the pol region.

Rationale: The paper mentions that the sequences were obtained from the pol region, which suggests that the pol gene was sequenced.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper does not mention the method used for sequencing. However, the paper mentions that the sequences were analyzed retrospectively.

Rationale: The paper does not mention the method used for sequencing, which suggests that the method used for sequencing was not reported.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper mentions that the sequences were obtained from plasma.

Rationale: The paper mentions that the sequences were obtained from plasma, which suggests that the type of sample sequenced was plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention that any sequences were obtained from individuals with virological failure on a treatment regimen. However, the paper mentions that the patients were treatment-experienced and naive.

Rationale: The paper mentions that the patients were treatment-experienced and naive, which suggests that the sequences were obtained from patients who were not experiencing virological failure.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial. However, the paper mentions that the study was conducted in the HIV clinic in Antalya, Turkey.

Rationale: The paper does not mention that the study was a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patients were treatment-experienced and naive.

Rationale: The paper mentions that the patients were treatment-experienced and naive, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patients were treatment-experienced and naive.

Rationale: The paper mentions that the patients were treatment-experienced and naive, which suggests that the patients received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention which drugs were received by the individuals in the study before sample sequencing.

Rationale: The paper does not mention which drugs were received by the individuals in the study before sample sequencing, which suggests that the drugs received by the individuals in the study before sample sequencing were not reported.

Answer: Not reported",21
38031075,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"". The paper also mentions ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 2,253 patients.

Rationale: The paper mentions the extraction of viral RNA from plasma, which is a common method for obtaining HIV sequences from patient samples. Additionally, the paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from 2,253 patients, indicating that the study involved the analysis of HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and does not report any in vitro drug susceptibility data. The methods and results sections do not mention any susceptibility testing or biochemical enzyme or replication fitness studies.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that the data for this study is available at Fifth Medical Centre of PLA General Hospital, Beijing, China and Ministry of Health of Sierra Leone and will be made available upon request.

Rationale: The paper explicitly states that the data will be made available upon request, indicating that the sequences have been deposited in a public repository.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates, and the data availability statement only mentions that the data will be made available upon request.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 2,253 patients were recruited for the study.

Rationale: The paper explicitly states that 2,253 patients were recruited for the study, indicating that this is the number of individuals from whom samples were obtained for HIV sequencing.

Answer: 2253

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Sierra Leone.

Rationale: The paper explicitly states that the study was conducted in Sierra Leone, indicating that the sequenced samples were obtained from this country.

Answer: Sierra Leone

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the years in which the sequenced samples were obtained.

Rationale: The paper does not mention any specific years for the collection of the sequenced samples, and the study design and methods sections do not provide any information on the timing of the sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, and the methods and results sections do not provide any information on the sequencing workflow.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not provide any information on the specific HIV genes that were sequenced.

Rationale: The paper does not mention any specific HIV genes that were sequenced, and the methods and results sections do not provide any information on the sequencing targets.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that the HIV RNA was extracted using the TGuide S32 Magnetic Viral DNA/RNA Kit and the HIV viral load was determined by HIV-RNA Quantification Kit.

Rationale: The paper explicitly states that the HIV RNA was extracted using the TGuide S32 Magnetic Viral DNA/RNA Kit and the HIV viral load was determined by HIV-RNA Quantification Kit, indicating that the sequencing method was not explicitly stated.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the viral RNA was extracted from plasma.

Rationale: The paper explicitly states that the viral RNA was extracted from plasma, indicating that the sequenced samples were plasma specimens.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen, and the results section does not provide any information on the treatment outcomes of the study participants.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not mention any clinical trial, and the study design and methods sections do not provide any information on the trial status of the study.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study participants were receiving antiretroviral therapy (ART) for more than 24 months.

Rationale: The paper explicitly states that the study participants were receiving ART for more than 24 months, indicating that the study participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study participants were receiving a fixed dose combination of tenofovir, lamivudine, and dolutegravir.

Rationale: The paper explicitly states that the study participants were receiving a fixed dose combination of tenofovir, lamivudine, and dolutegravir, indicating that the study participants had received NRTIs and INSTIs.

Answer: NRTI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study participants were receiving a fixed dose combination of tenofovir, lamivudine, and dolutegravir.

Rationale: The paper explicitly states that the study participants were receiving a fixed dose combination of tenofovir, lamivudine, and dolutegravir, indicating that the study participants had received tenofovir, lamivudine, and dolutegravir.

Answer: Tenofovir, Lamivudine, Dolutegravir",22
38033131,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention any HIV sequences from patient samples. The study focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy in East Shewa hospitals, Oromia Region, Ethiopia.

Rationale: The paper does not mention any HIV sequences from patient samples, and the study focuses on clinical outcomes and predictors of virological failure.

Answer: No

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. The study focuses on clinical outcomes and predictors of virological failure.

Rationale: The paper does not mention any in vitro drug susceptibility data, and the study focuses on clinical outcomes and predictors of virological failure.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention any GenBank accession numbers or sequences being made publicly available.

Rationale: The paper does not mention any GenBank accession numbers or sequences being made publicly available.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention any HIV sequencing.

Rationale: The paper does not mention any HIV sequencing.

Answer: 0

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention any countries where the sequenced samples were obtained.

Rationale: The paper does not mention any countries where the sequenced samples were obtained.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention any years when the sequenced samples were obtained.

Rationale: The paper does not mention any years when the sequenced samples were obtained.

Answer: Not applicable

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not applicable

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any HIV genes being sequenced.

Rationale: The paper does not mention any HIV genes being sequenced.

Answer: Not applicable

**Question: What method was used for sequencing?**

Evidence: The paper does not mention any sequencing method.

Rationale: The paper does not mention any sequencing method.

Answer: Not applicable

**Question: What type of samples were sequenced?**

Evidence: The paper does not mention any samples being sequenced.

Rationale: The paper does not mention any samples being sequenced.

Answer: Not applicable

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences being obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences being obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not mention any clinical trial.

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs.

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes being received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any drug classes being received by individuals in the study before sample sequencing.

Answer: Not applicable

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drugs being received by individuals in the study before sample sequencing.

Rationale: The paper does not mention any drugs being received by individuals in the study before sample sequencing.

Answer: Not applicable",15
38058846,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"" were used. The paper also mentions that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". The paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper explicitly mentions the use of clinical samples such as plasma, serum, PBMC, buffy coat, and dried blood spots, which are commonly used for HIV sequencing. Additionally, the paper mentions the use of genotypic resistance testing, HIV sequencing, and various sequencing technologies, which are all relevant to HIV sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. The paper only reports on genotypic resistance testing and sequencing.

Rationale: The paper does not mention any in vitro drug susceptibility data, which is a key aspect of HIV drug resistance testing. The paper only reports on genotypic resistance testing and sequencing, which is a different aspect of HIV drug resistance testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank, but the accession numbers are not provided. The paper also mentions that the raw reads are in the SRA database.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which is a public database. However, the accession numbers are not provided, which makes it difficult to access the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which are necessary to access the sequences.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that three cases were included in the study, and each case had multiple samples obtained for HIV sequencing.

Rationale: The paper explicitly mentions that three cases were included in the study, and each case had multiple samples obtained for HIV sequencing.

Answer: 3

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information on the countries where the sequenced samples were obtained.

Rationale: The paper does not provide any information on the countries where the sequenced samples were obtained, which makes it difficult to determine the origin of the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the sequenced samples were obtained between 2020 and 2023.

Rationale: The paper explicitly mentions that the sequenced samples were obtained between 2020 and 2023.

Answer: 2020-2023

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information on whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information on whether the samples were cloned prior to sequencing, which makes it difficult to determine the sequencing method.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol gene was sequenced, including the protease and reverse transcriptase regions.

Rationale: The paper explicitly mentions that the pol gene was sequenced, including the protease and reverse transcriptase regions.

Answer: Pol, PR, RT

**Question 10: What method was used for sequencing?**

Evidence: The paper reports that Sanger sequencing was used to sequence the HIV isolates.

Rationale: The paper explicitly mentions that Sanger sequencing was used to sequence the HIV isolates.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the three cases included in the study had virological failure on a treatment regimen.

Rationale: The paper explicitly mentions that the three cases included in the study had virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information on whether the patients were in a clinical trial.

Rationale: The paper does not provide any information on whether the patients were in a clinical trial, which makes it difficult to determine the study design.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the three cases included in the study had previously received ARV drugs.

Rationale: The paper explicitly mentions that the three cases included in the study had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the three cases included in the study had received NRTI and NNRTI-based regimens.

Rationale: The paper explicitly mentions that the three cases included in the study had received NRTI and NNRTI-based regimens.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the three cases included in the study had received lamivudine, abacavir, lopinavir, and ritonavir.

Rationale: The paper explicitly mentions that the three cases included in the study had received lamivudine, abacavir, lopinavir, and ritonavir.

Answer: Lamivudine, Abacavir, Lopinavir, Ritonavir",21
38072961,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""CSF HIV RNA was 774 copies/mL, while plasma HIV RNA was undetectable."" The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"". Additionally, the paper reports ""GenBank accession numbers"" for sequences generated in this study.

Rationale: The paper mentions clinical samples (CSF and plasma) and sequencing methods (genotypic resistance testing, HIV sequencing, and Sanger sequencing). The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to GenBank.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data or assays.

Rationale: The paper focuses on clinical samples and sequencing methods, but does not report any in vitro susceptibility data or assays.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides GenBank accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which suggests that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper provides GenBank accession numbers, which can be used to retrieve the sequences from GenBank.

Answer: Not reported (the paper only provides a single accession number, but it is not clear if this is the only accession number or if there are others)

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that ""a 27-year-old man with HIV infection"" had samples obtained for HIV sequencing.

Rationale: The paper mentions a single individual who had samples obtained for HIV sequencing.

Answer: 1

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the country where the samples were obtained.

Rationale: The paper does not provide any information about the country where the samples were obtained.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the year when the samples were obtained.

Rationale: The paper does not mention the year when the samples were obtained.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions sequencing of the ""pol region"" and ""integrase coding region of pol"".

Rationale: The paper explicitly mentions sequencing of the pol region and integrase coding region of pol.

Answer: Pol, IN

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""Illumina MiSeq"".

Rationale: The paper explicitly mentions Sanger sequencing and Illumina MiSeq.

Answer: Sanger sequencing, NGS

**Question: What type of samples were sequenced?**

Evidence: The paper mentions sequencing of ""CSF"" and ""plasma"".

Rationale: The paper explicitly mentions sequencing of CSF and plasma.

Answer: CSF, Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy"".

Rationale: The paper explicitly mentions virologic failure and failing therapy.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""virologic failure"".

Rationale: The paper explicitly mentions ART-experienced and virologic failure.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""ART-experienced"" and ""virologic failure"".

Rationale: The paper explicitly mentions ART-experienced and virologic failure.

Answer: NRTI, NNRTI, PI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""tenofovir"", ""lamivudine"", and ""lopinavir/ritonavir"".

Rationale: The paper explicitly mentions specific drugs (tenofovir, lamivudine, and lopinavir/ritonavir).

Answer: Tenofovir, Lamivudine, Lopinavir/Ritonavir",16
38090027,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 1040 individuals. The paper also mentions that ""viral RNA was extracted from plasma"" and that ""sequences were amplified from patient plasma"". Additionally, the paper reports that sequences were submitted to GenBank with accession numbers.

Rationale: The paper mentions genotypic resistance testing, genotyping, and sequencing, which suggests that HIV sequences were obtained from patient samples. The mention of viral RNA extraction from plasma and sequence amplification from patient plasma further supports this. Finally, the paper reports that sequences were submitted to GenBank with accession numbers, indicating that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. However, the paper does mention genotypic resistance testing and sequencing, which suggests that the study focused on genotypic resistance rather than phenotypic susceptibility.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as IC50, EC50, EC90, or fold-change in susceptibility. The focus on genotypic resistance testing and sequencing suggests that the study did not investigate phenotypic susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank with accession numbers. The paper also mentions that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank with accession numbers, which indicates that the sequences were made publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank with accession numbers. The paper also mentions that the raw reads are in the SRA database or consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank with accession numbers, which indicates that the accession numbers are available.

Answer: Not reported (the paper does not provide the accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 1040 individuals.

Rationale: The paper explicitly states that genotypic resistance testing, genotyping, or sequencing was performed on samples from 1040 individuals, which indicates that 1040 individuals had samples obtained for HIV sequencing.

Answer: 1040

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples. However, the paper does mention that the study was conducted in Italy.

Rationale: The paper does not explicitly mention the country of origin for the sequenced samples. However, the paper does mention that the study was conducted in Italy, which suggests that the samples were obtained from Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the sequenced samples were obtained. However, the paper does mention that the study was conducted between June 2019 and June 2021.

Rationale: The paper does not explicitly mention the specific years when the sequenced samples were obtained. However, the paper does mention that the study was conducted between June 2019 and June 2021, which suggests that the samples were obtained during this time period.

Answer: 2019-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing. However, the paper does mention that ""sequences were amplified from patient plasma"".

Rationale: The paper does not explicitly mention cloning prior to sequencing. However, the paper does mention that sequences were amplified from patient plasma, which suggests that the sequences were amplified directly from the plasma without cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced. However, the paper does mention that ""genotypic resistance testing"" and ""sequencing"" were performed.

Rationale: The paper does not explicitly mention the specific HIV genes that were sequenced. However, the paper does mention that genotypic resistance testing and sequencing were performed, which suggests that the study focused on the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the specific sequencing method used. However, the paper does mention that ""sequences were amplified from patient plasma"" and that ""sequences were submitted to GenBank with accession numbers"".

Rationale: The paper does not explicitly mention the specific sequencing method used. However, the paper does mention that sequences were amplified from patient plasma and submitted to GenBank with accession numbers, which suggests that the study used a next-generation sequencing (NGS) method.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""viral RNA was extracted from plasma"" and that ""sequences were amplified from patient plasma"".

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma and that sequences were amplified from patient plasma, which suggests that the study used plasma samples for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""virologic failure"" occurred in 4.2% of the patients. The paper also mentions that ""sequences were amplified from patient plasma"" and that ""sequences were submitted to GenBank with accession numbers"".

Rationale: The paper explicitly mentions that virologic failure occurred in 4.2% of the patients, which suggests that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial. However, the paper does mention that the study was conducted in a real-world setting.

Rationale: The paper does not explicitly mention that the study was a clinical trial. However, the paper does mention that the study was conducted in a real-world setting, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""patients were on ART/cART/HAART"" and that ""sequences were amplified from patient plasma"".

Rationale: The paper explicitly mentions that patients were on ART/cART/HAART, which suggests that the study included individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""patients were on ART/cART/HAART"" and that ""sequences were amplified from patient plasma"".

Rationale: The paper explicitly mentions that patients were on ART/cART/HAART, which suggests that the study included individuals who had previously received NRTIs, NNRTIs, and/or PIs.

Answer: NRTIs, NNRTIs, and/or PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""patients were on ART/cART/HAART"" and that ""sequences were amplified from patient plasma"".

Rationale: The paper explicitly mentions that patients were on ART/cART/HAART, which suggests that the study included individuals who had previously received a variety of ARV drugs.

Answer: Not reported (the paper does not provide specific information about the ARV drugs received by the individuals in the study)",26
38140553,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""blood plasma collections (n = 2502), peripheral blood mononuclear cells (lymphocytes) collections (n = 613), and frozen whole blood collections (n = 63) obtained from HIV-infected patients at federal and regional centers for HIV/AIDS prevention (AIDS Centers) as part of molecular genetic monitoring of the HIV epidemic in Russia in the period from 2011 to 2020."" The paper also mentions that ""RNA and DNA extraction, amplification, and HIV-1 sequencing were performed using the ViroSeqTM HIV-1 Genotyping System kit (Celera Diagnostics, Alameda, CA, USA) for RNA extraction from blood plasma samples."" Additionally, the paper states that ""sequences were obtained from patients with HIV-1 infection in Russia.""

Rationale: The paper clearly states that the sequences were obtained from patient samples, specifically blood plasma, peripheral blood mononuclear cells, and frozen whole blood. The use of the ViroSeqTM HIV-1 Genotyping System kit for RNA extraction from blood plasma samples further supports this. Therefore, the answer to this question is ""Yes"".

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data. It only discusses the sequencing and genotyping of HIV-1 isolates from patient samples.

Rationale: The paper focuses on the sequencing and genotyping of HIV-1 isolates from patient samples, but it does not report any in vitro drug susceptibility data. Therefore, the answer to this question is ""No"".

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""all nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.""

Rationale: The paper explicitly states that the sequences were deposited in the Los Alamos laboratory, which is a public database. Therefore, the answer to this question is ""Yes"".

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""all nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.""

Rationale: The paper does not provide the specific GenBank accession numbers for the sequenced HIV isolates. However, it does mention that the sequences were deposited in the Los Alamos laboratory, which is a public database. Therefore, the answer to this question is ""Not reported"".

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""blood plasma collections (n = 2502), peripheral blood mononuclear cells (lymphocytes) collections (n = 613), and frozen whole blood collections (n = 63) obtained from HIV-infected patients at federal and regional centers for HIV/AIDS prevention (AIDS Centers) as part of molecular genetic monitoring of the HIV epidemic in Russia in the period from 2011 to 2020.""

Rationale: The paper provides the number of samples collected from each type of sample (blood plasma, peripheral blood mononuclear cells, and frozen whole blood). Therefore, the answer to this question is the sum of these numbers, which is 3178.

Answer: 3178

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from HIV-infected patients at federal and regional centers for HIV/AIDS prevention (AIDS Centers) in Russia.

Rationale: The paper explicitly states that the samples were obtained from patients in Russia. Therefore, the answer to this question is ""Russia"".

Answer: Russia

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from HIV-infected patients at federal and regional centers for HIV/AIDS prevention (AIDS Centers) as part of molecular genetic monitoring of the HIV epidemic in Russia in the period from 2011 to 2020.

Rationale: The paper provides the specific years during which the samples were obtained. Therefore, the answer to this question is the range of years, which is 2011-2020.

Answer: 2011-2020

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states that ""amplification of HIV-1 pol gene fragments was performed automatically by nested polymerase chain reaction (PCR) method according to the protocols presented in Table 1.""

Rationale: The paper mentions the use of PCR for amplification of HIV-1 pol gene fragments, but it does not mention cloning. Therefore, the answer to this question is ""No"".

Answer: No

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""Sanger-based sequencing of the HIV pol gene regions encoding the PR-RT (2253--3554 bp according to the HXB-2 strain, GenBank accession number K03455) was performed.""

Rationale: The paper explicitly states that the sequencing was performed on the pol gene region, which includes the protease and reverse transcriptase genes. Therefore, the answer to this question is ""Pol"".

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper states that ""Sanger-based sequencing of the HIV pol gene regions encoding the PR-RT (2253--3554 bp according to the HXB-2 strain, GenBank accession number K03455) was performed.""

Rationale: The paper explicitly states that the sequencing was performed using Sanger sequencing. Therefore, the answer to this question is ""Sanger sequencing"".

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""blood plasma collections (n = 2502), peripheral blood mononuclear cells (lymphocytes) collections (n = 613), and frozen whole blood collections (n = 63) obtained from HIV-infected patients at federal and regional centers for HIV/AIDS prevention (AIDS Centers) as part of molecular genetic monitoring of the HIV epidemic in Russia in the period from 2011 to 2020.""

Rationale: The paper provides the specific types of samples that were sequenced. Therefore, the answer to this question includes all the mentioned types of samples, which are blood plasma, peripheral blood mononuclear cells, and frozen whole blood.

Answer: Blood plasma, peripheral blood mononuclear cells, and frozen whole blood

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the sequencing and genotyping of HIV-1 isolates from patient samples, but it does not report any sequences obtained from individuals with virological failure on a treatment regimen. Therefore, the answer to this question is ""No"".

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trials.

Rationale: The paper does not mention any clinical trials, and it does not provide any information that would suggest that the patients were part of a clinical trial. Therefore, the answer to this question is ""No"".

Answer: No

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""all patients were HIV-1 infected and had not received antiretroviral therapy (ART) at the time of sampling.""

Rationale: The paper explicitly states that the patients had not received antiretroviral therapy (ART) at the time of sampling. Therefore, the answer to this question is ""No"".

Answer: No

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all patients were HIV-1 infected and had not received antiretroviral therapy (ART) at the time of sampling.""

Rationale: The paper explicitly states that the patients had not received antiretroviral therapy (ART) at the time of sampling. Therefore, the answer to this question is ""None"".

Answer: None

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""all patients were HIV-1 infected and had not received antiretroviral therapy (ART) at the time of sampling.""

Rationale: The paper explicitly states that the patients had not received antiretroviral therapy (ART) at the time of sampling. Therefore, the answer to this question is ""Not applicable"".

Answer: Not applicable",30
38140649,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as ""plasma"", ""serum"", ""PBMC"", ""buffy coat"", or ""dried blood spots (DBS)"". The paper also mentions that sequenced samples were obtained from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""cohorts"". Additionally, the paper refers to ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome"", or ""whole genome"" sequencing.

Rationale: The paper explicitly mentions the use of clinical samples and the sequencing of HIV from these samples, which indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assays. The paper only reports genotypic resistance testing and sequencing of HIV from patient samples.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, which suggests that the paper does not report in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers for the sequences. The paper also mentions that the raw reads are in the SRA database and consensus/amplicon sequences are in GenBank with accession numbers.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides accession numbers, which indicates that the sequences are publicly available.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for the sequences, which are OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly provides the accession numbers for the sequences, which can be used to access the sequences in GenBank.

Answer: OR605755-OR606279 and OR613869-OR613875

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that a total of 270 persons had samples obtained for HIV sequencing.

Rationale: The paper explicitly states that 270 persons had samples obtained for HIV sequencing, which indicates that the number of individuals is 270.

Answer: 270

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained. However, the paper mentions that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID in Croatia.

Rationale: The paper does not provide explicit information on the countries from which the sequenced samples were obtained, but it mentions that the study was conducted in Croatia.

Answer: Croatia

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the clinical samples were collected between 2019 and 2022.

Rationale: The paper explicitly states that the clinical samples were collected between 2019 and 2022, which indicates that the sequenced samples were obtained during this time period.

Answer: 2019-2022

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention the cloning of samples prior to sequencing. However, the paper mentions the use of Sanger sequencing and Illumina sequencing, which suggests that the samples may have been cloned prior to sequencing.

Rationale: The paper does not explicitly mention the cloning of samples prior to sequencing, but the use of Sanger sequencing and Illumina sequencing suggests that the samples may have been cloned prior to sequencing.

Answer: Not Reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the pol gene was sequenced, including the protease and reverse transcriptase regions.

Rationale: The paper explicitly mentions the sequencing of the pol gene, including the protease and reverse transcriptase regions.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper reports that Sanger sequencing and Illumina sequencing were used.

Rationale: The paper explicitly mentions the use of Sanger sequencing and Illumina sequencing, which indicates that these methods were used for sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper reports that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions the use of plasma samples for sequencing, which indicates that plasma samples were sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions the sequencing of individuals with virological failure on a treatment regimen, which indicates that sequences were obtained from these individuals.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention the patients being in a clinical trial.

Rationale: The paper does not provide explicit information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the study included individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions the inclusion of individuals who had previously received ARV drugs, which indicates that the paper reports HIV sequences from these individuals.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the individuals in the study had received NRTI and NNRTI-based regimens.

Rationale: The paper explicitly mentions the use of NRTI and NNRTI-based regimens, which indicates that these drug classes were received by the individuals in the study.

Answer: NRTI and NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the individuals in the study had received zidovudine (AZT), lamivudine (3TC), emtricitabine (FTC), tenofovir (TDF), and efavirenz (EFV).

Rationale: The paper explicitly mentions the use of these drugs, which indicates that they were received by the individuals in the study.

Answer: AZT, 3TC, FTC, TDF, and EFV",24
38140667,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as “plasma”, “serum”, “PBMC”, “buffy coat”, or “dried blood spots \(DBS\)”. The paper mentions sequencing and “ART-naïve” or “ART-experienced” patients, “baseline” or “virologic failure \(VF\)” samples, “transmitted drug resistance \(TDR\)”, “HIV drug resistance surveillance”. The paper reports “GenBank accession numbers” for sequences generated in this study or states sequences were “submitted/deposited”.

Rationale: The paper mentions specific types of clinical samples, which suggests that the sequences were obtained from patient samples. Additionally, the paper mentions ART-naïve and ART-experienced patients, baseline and virologic failure samples, transmitted drug resistance, and HIV drug resistance surveillance, which are all related to HIV sequencing. The paper also reports GenBank accession numbers, which indicates that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states “phenotypic susceptibility”, “phenotypic resistance testing”, or “drug susceptibility assay”. The methods or results report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper mentions cell-based susceptibility assays, such as TZM-bl, MAGIC-5, MT-2, PBMCs, SupT1, CEM-ss, HeLa-CD4, HEK293, with drug titrations and reporter readouts.

Rationale: The paper mentions phenotypic susceptibility, phenotypic resistance testing, and drug susceptibility assay, which are all related to in vitro drug susceptibility data. The paper also reports IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility, which are specific metrics used to measure drug susceptibility. Additionally, the paper mentions cell-based susceptibility assays, which are used to measure the susceptibility of HIV to different drugs.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to “GenBank”, “NCBI”, “EMBL”, “DDBJ”, “ENA”, or the “Short read archive \(SRA\)”. The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions specific public databases, such as GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the sequences were submitted to these databases. The paper also reports accession numbers, which are unique identifiers for the sequences in these databases.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank or any of the above databases. The paper reports that sequences have been deposited or made available in a sequence database.

Rationale: The paper mentions specific public databases, such as GenBank, NCBI, EMBL, DDBJ, ENA, and SRA, which suggests that the sequences were submitted to these databases. The paper also reports accession numbers, which are unique identifiers for the sequences in these databases.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that “genotypic resistance testing”, “genotyping”, or “sequencing” was performed on samples from X number of individuals. The paper reports that X sequences were reported from Y individuals.

Rationale: The paper mentions specific numbers of individuals who had samples obtained for HIV sequencing. The paper reports that genotypic resistance testing, genotyping, or sequencing was performed on samples from X number of individuals, which suggests that X individuals had samples obtained for HIV sequencing.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states patients or participants were recruited in, enrolled in, or followed at hospital or clinic in &lt;country\&gt;. The paper mentions nationwide “cohort” or “surveillance” or “registry” in &lt;country\&gt; or “national reference laboratory” of &lt;country\&gt;. The paper names a province or city uniquely tied to a country.

Rationale: The paper mentions specific countries where the sequenced samples were obtained. The paper states that patients or participants were recruited in, enrolled in, or followed at hospital or clinic in a specific country, which suggests that the samples were obtained from that country.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper reports that clinical samples were collected between &lt;Year1\&gt; to &lt;Year2\&gt; or &lt;Month/Year1\&gt; to &lt;Month/Year2\&gt;. The paper lists per-year counts “collected in 2008, 2009, 2010…”.

Rationale: The paper mentions specific years when the sequenced samples were obtained. The paper reports that clinical samples were collected between specific years, which suggests that the samples were obtained during that time period.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper states “amplicons were cloned and sequenced”, “all products were cloned before Sanger sequencing”, “TA cloning/Topo TA cloning was performed”, or cites a cloning kit. The paper describes “clonal analyses” or “clonal sequencing” of patient-derived amplicons or plasma.

Rationale: The paper mentions specific cloning techniques, such as TA cloning, Topo TA cloning, and Sanger sequencing, which suggests that the samples were cloned prior to sequencing.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states “pol genotyping/sequencing” without providing individual genes. The paper states “pol region encompassing protease and reverse transcriptase”, “PR/RT”, “ViroSeq”, or “TruGene \(PR/RT\)”. The paper states “integrase coding region of pol”, “IN”, “p31”, “GeneSeq/ViroSeq Integrase”, “INSTI resistance”, “integrase sequencing”, or “GeneSeq/PhenoSense Integrase”.

Rationale: The paper mentions specific HIV genes, such as pol, protease, reverse transcriptase, and integrase, which suggests that these genes were sequenced.

Answer: Pol, PR, RT, IN

**Question: What method was used for sequencing?**

Evidence: The paper mentions ABI instruments \(ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant\) or Beckman CEQ 2000 XL. The paper mentions BigDye/ABI PRISM Dye Terminator \(v1.0/v3.0/v3.1\), dye-terminator, dye–deoxy chain terminator, or dideoxy sequencing.

Rationale: The paper mentions specific sequencing technologies, such as ABI instruments and BigDye, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions “viral RNA was extracted from plasma”, “blood plasma”, “stored/archived/cryopreserved plasma”, or “plasma specimens/samples”. The paper mentions sequencing at “baseline”, “screening”, “virologic failure” or “rebound” uses plasma VL thresholds ≥400–1000 copies/mL or “sequences amplified from patient plasma”.

Rationale: The paper mentions specific types of samples, such as plasma, which suggests that these samples were sequenced.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states “virologic or virological failure \(VF\)” or “failing therapy or regimen” e.g., failing NNRTI/PI/INSTI or “salvage regimen”. The paper cites “confirmed or protocol-defined virologic failure \(CVF/PDVF\)” or “incomplete viral suppression”. The paper reports that sequencing or genotyping were done for participants with VL >50 copies/mL while on ART.

Rationale: The paper mentions specific terms related to virological failure, such as VF, CVF, and PDVF, which suggests that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper states “randomized”, “double-blind”, “placebo-controlled”, “open-label”, “controlled”, or “multicenter” with intervention arms. The paper mentions “phase I/II/III/IIIb/2/3 trial” or “analytical treatment interruption \(ATI\) within a trial”. The paper is registered at ClinicalTrials.gov or has an NCT number.

Rationale: The paper mentions specific terms related to clinical trials, such as randomized, double-blind, and placebo-controlled, which suggests that the study was a clinical trial.

Answer: Yes

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper uses phrases like “on ART/cART/HAART”, “ART-experienced”, “treatment-experienced”, “heavily pretreated”, “salvage regimen”, or “prior ARV exposure/regimens”. The paper states “virologic failure/failing therapy while receiving [drug/regimen]”, “second-line/third-line/switch”, “ritonavir-boosted PI as second-line”, or “salvage”.

Rationale: The paper mentions specific terms related to ARV drug use, such as ART-experienced and treatment-experienced, which suggests that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper says “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper states patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions specific drug classes and drugs, which suggests that the individuals in the study received these drugs before sample sequencing.

Answer: NRTI, PI, INSTI, CAI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper says “treatment-naïve”, “ART-naïve”, “drug-naïve”, “never exposed to antiretrovirals”, “before ART initiation”, “pre-ART”, “newly diagnosed”, “seroconverter”, “blood donor”, “primary/acute infection without ART”, or samples collected “at diagnosis/baseline prior to therapy”. The paper states patients received drugs belonging to a specific ARV class such as “NRTI”, “PI”, “NRTI”, “INSTI” and /or reports that patients received specific ARV drugs such as “3TC”, “FTC”, AZT”, “TDF”, “abacavir”, “efavirenz”, “rilpivirine”, “doravirine”, “atazanavir”, “lopinavir”, “darunavir”, “raltegravir”, “elvitegravir”, “dolutegravir”, “bictegravir”, “cabotegravir”, or “lenacapavir”.

Rationale: The paper mentions specific drugs, which suggests that the individuals in the study received these drugs before sample sequencing.

Answer: AZT, 3TC, FTC, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",45
38142692,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences were obtained from patients who were switched to second-line ART after virological failure while receiving first-line NNRTI-based ART. The study used routinely collected, de-identified data from 59 primary health-care facilities in eThekwini Municipality, KwaZulu-Natal, South Africa. The paper mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing.

Rationale: The paper mentions that sequences were obtained from patients, which indicates that the study involved patient samples. The paper also mentions genotypic resistance testing, HIV sequencing, and Sanger sequencing, which are all methods used to analyze HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention phenotypic susceptibility, phenotypic resistance testing, or drug susceptibility assay. The methods section does not report IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility. The paper does not mention any cell-based susceptibility assays or in vitro enzymatic inhibition assays.

Rationale: The paper does not mention any of the keywords associated with in vitro drug susceptibility data, which suggests that the study did not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short Read Archive (SRA). The paper does not report accession numbers for GenBank or any of the above databases.

Rationale: The paper does not mention that sequences were made publicly available, which suggests that the sequences were not deposited in a public database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not report any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any accession numbers, which suggests that the sequences were not deposited in GenBank.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that 1214 participants were included in the study, of whom 689 (57%) were switched to AZT/XTC/LPV/r, 217 (18%) to AZT/XTC/DTG, and 308 (25%) to TDF/XTC/DTG.

Rationale: The paper reports the number of participants included in the study, which suggests that the study involved a large number of individuals.

Answer: 1214

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted in South Africa, and the samples were obtained from 59 primary health-care facilities in eThekwini Municipality, KwaZulu-Natal, South Africa.

Rationale: The paper mentions the country where the study was conducted, which suggests that the samples were obtained from South Africa.

Answer: South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the study was conducted between December 1, 2019, and November 30, 2020.

Rationale: The paper reports the dates when the study was conducted, which suggests that the samples were obtained during this time period.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning methods or techniques, which suggests that the samples were not cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not mention any specific HIV genes, which suggests that the study did not report the sequencing of specific HIV genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger sequencing and Illumina sequencing.

Rationale: The paper mentions two different sequencing methods, which suggests that the study used both Sanger sequencing and Illumina sequencing.

Answer: Sanger sequencing and Illumina sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that the study used plasma samples.

Rationale: The paper mentions plasma samples, which suggests that the study involved the sequencing of plasma samples.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that the study included participants who were switched to second-line ART after virological failure while receiving first-line NNRTI-based ART.

Rationale: The paper mentions that the study included participants who were switched to second-line ART after virological failure, which suggests that the study involved sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the study was a clinical trial.

Rationale: The paper does not mention any clinical trial-related keywords, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that the study included participants who were switched to second-line ART after virological failure while receiving first-line NNRTI-based ART.

Rationale: The paper mentions that the study included participants who were switched to second-line ART after virological failure, which suggests that the study involved sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who were switched to second-line ART after virological failure while receiving first-line NNRTI-based ART.

Rationale: The paper mentions that the study included participants who were switched to second-line ART after virological failure, which suggests that the study involved sequences from individuals who had previously received NNRTI-based ART.

Answer: NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that the study included participants who were switched to second-line ART after virological failure while receiving first-line NNRTI-based ART.

Rationale: The paper mentions that the study included participants who were switched to second-line ART after virological failure, which suggests that the study involved sequences from individuals who had previously received specific ARV drugs.

Answer: AZT, 3TC, EFV, NVP, TDF, FTC",24
38152686,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that the patient was diagnosed with HIV and that the viral load was 437,927 cp/mL (Log = 5.64). The paper also mentions that the patient was treated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG). The paper further states that genotyping was requested, which revealed *H51Y* and *E157Q* mutations in the integrase.

Rationale: The paper mentions that the patient was diagnosed with HIV and that the viral load was high, indicating that the patient had a high viral load. The paper also mentions that the patient was treated with antiretroviral therapy (ART), which suggests that the patient had HIV. The paper further states that genotyping was requested, which suggests that the patient's HIV sequences were analyzed.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility data, such as phenotypic susceptibility or genotypic resistance testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not mention that the sequences were made publicly available, such as by submitting them to GenBank or another public database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers, which are used to identify and access sequences in public databases.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that the patient was diagnosed with HIV and that the viral load was 437,927 cp/mL (Log = 5.64). The paper also mentions that the patient was treated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG).

Rationale: The paper mentions that the patient was diagnosed with HIV, which suggests that the patient's HIV sequences were analyzed. The paper also mentions that the patient was treated with ART, which suggests that the patient had HIV.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country where the patient was diagnosed with HIV.

Rationale: The paper does not mention the country where the patient was diagnosed with HIV, which makes it difficult to determine the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year when the patient was diagnosed with HIV.

Rationale: The paper does not mention the year when the patient was diagnosed with HIV, which makes it difficult to determine the year of the sequenced samples.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not mention that the samples were cloned prior to sequencing, which suggests that the sequencing was done directly from the patient's samples.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the patient's HIV sequences were analyzed, but it does not specify which genes were sequenced.

Rationale: The paper mentions that the patient's HIV sequences were analyzed, but it does not specify which genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used, which makes it difficult to determine the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that the patient's HIV sequences were analyzed, but it does not specify the type of samples used.

Rationale: The paper mentions that the patient's HIV sequences were analyzed, but it does not specify the type of samples used.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient was treated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG) and that the patient's viral load was 12,182 cp/mL (Log = 4.08) after 7 months of treatment.

Rationale: The paper mentions that the patient was treated with ART and that the patient's viral load was high after 7 months of treatment, which suggests that the patient had virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper does not mention that the patient was part of a clinical trial, which suggests that the study was not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient was treated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG) before the sequencing.

Rationale: The paper mentions that the patient was treated with ART before the sequencing, which suggests that the patient had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was treated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG) before the sequencing.

Rationale: The paper mentions that the patient was treated with ART before the sequencing, which suggests that the patient received NRTIs and INSTIs.

Answer: NRTIs, INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient was treated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG) before the sequencing.

Rationale: The paper mentions that the patient was treated with ART before the sequencing, which suggests that the patient received Tenofovir, Lamivudine, and Dolutegravir.

Answer: Tenofovir, Lamivudine, Dolutegravir",21
38314093,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""serum samples collected from the HIV Confirmatory Laboratory of Meizhou People's Hospital Medical Laboratory Center (From May 2008 to December 2019) were analyzed."" The paper also mentions ""HIV-1 genetic mutation and drug resistance are major barriers to successful antiretroviral therapy."" Furthermore, the paper states that ""cDNA containing the protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.""

Rationale: The paper mentions the analysis of serum samples, which suggests that the samples were obtained from patients. The paper also mentions the amplification and sequencing of the PR-RT sequence of HIV-1, which indicates that the sequences were obtained from patient samples.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper only discusses the analysis of HIV-1 genetic mutation and drug resistance, but it does not provide any information on in vitro drug susceptibility data.

Answer: No

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to any public database.

Rationale: The paper does not provide any information on the submission of sequences to public databases, such as GenBank.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""195 positive cases were found"" and that ""most of the 195 positive cases were found to be male and, in the middle, and AIDS stages.""

Rationale: The paper mentions the number of positive cases, which suggests that the samples were obtained from 195 individuals.

Answer: 195

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected from Meizhou, China.

Rationale: The paper mentions the location where the samples were collected, which is Meizhou, China.

Answer: China

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were collected between May 2008 and December 2019.

Rationale: The paper provides the time period during which the samples were collected.

Answer: 2008-2019

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on the cloning of samples prior to sequencing.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the ""protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.""

Rationale: The paper mentions the amplification and sequencing of the PR-RT sequence of HIV-1, which suggests that the sequences were obtained from the PR and RT genes.

Answer: PR, RT

**Question: What method was used for sequencing?**

Evidence: The paper states that the ""cDNA containing the protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.""

Rationale: The paper mentions the use of high-throughput sequencing, which suggests that the sequencing method was NGS.

Answer: NGS

**Question: What type of samples were sequenced?**

Evidence: The paper states that ""serum samples collected from the HIV Confirmatory Laboratory of Meizhou People's Hospital Medical Laboratory Center (From May 2008 to December 2019) were analyzed.""

Rationale: The paper mentions the analysis of serum samples, which suggests that the samples were obtained from plasma.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper only discusses the analysis of HIV-1 genetic mutation and drug resistance, but it does not provide any information on sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not provide any information on the study being a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""most of the 195 positive cases were found to be male and, in the middle, and AIDS stages"" and that ""the initial antiviral treatment regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV)/nevirapine (NVP) in 31 cases (83.79%) or zidovudine (AZT)/lamivudine (3TC) plus EFV in 6 cases (16.21%).""

Rationale: The paper mentions the treatment regimen used by the patients, which suggests that the patients had previously received ARV drugs.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the initial antiviral treatment regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV)/nevirapine (NVP) in 31 cases (83.79%) or zidovudine (AZT)/lamivudine (3TC) plus EFV in 6 cases (16.21%).""

Rationale: The paper mentions the treatment regimen used by the patients, which suggests that the patients received NRTIs and NNRTIs.

Answer: NRTI, NNRTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""the initial antiviral treatment regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV)/nevirapine (NVP) in 31 cases (83.79%) or zidovudine (AZT)/lamivudine (3TC) plus EFV in 6 cases (16.21%).""

Rationale: The paper mentions the treatment regimen used by the patients, which suggests that the patients received AZT, 3TC, EFV, and NVP.

Answer: AZT, 3TC, EFV, NVP",23
38427738,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that HIV-1 was propagated in the presence of escalating concentrations of the INSTI dolutegravir, and HIV-1 became resistant to dolutegravir by sequentially acquiring mutations in the envelope glycoprotein (Env) and the nucleocapsid protein. The selected Env mutations enhance the ability of the virus to spread via cell-cell transfer, thereby increasing the multiplicity of infection (MOI). The paper also mentions that the sequences were obtained from patients.

Rationale: The paper reports that HIV-1 sequences were obtained from patient samples, which is a key criterion for answering this question. The paper also mentions that the sequences were obtained from patients who were undergoing treatment with dolutegravir, which further supports this answer.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper reports that the selected Env mutations confer broad resistance to multiple classes of antiretrovirals, including INSTIs, NRTIs, NNRTIs, and PIs. The paper also mentions that the Env mutations reduce the sensitivity of the virus to drugs such as dolutegravir, raltegravir, and cabotegravir.

Rationale: The paper reports that the selected Env mutations confer broad resistance to multiple classes of antiretrovirals, which is a key criterion for answering this question. The paper also mentions that the Env mutations reduce the sensitivity of the virus to specific drugs, which further supports this answer.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were submitted to a public database such as GenBank or NCBI. However, the paper does mention that the sequences were obtained from patients who were undergoing treatment with dolutegravir.

Rationale: The paper does not provide any information about the public availability of the sequences, which is a key criterion for answering this question. However, the paper does mention that the sequences were obtained from patients, which suggests that the sequences may be available upon request.

Answer: No

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any information about the GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers, which is a key criterion for answering this question.

Answer: Not reported

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals, which is a key criterion for answering this question.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries, which is a key criterion for answering this question.

Answer: Not applicable

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide any information about the years in which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years, which is a key criterion for answering this question.

Answer: Not applicable

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide any information about whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the cloning process, which is a key criterion for answering this question.

Answer: Not reported

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper reports that the sequences were obtained from the Env and nucleocapsid (NC) genes of HIV-1.

Rationale: The paper specifically mentions that the sequences were obtained from the Env and NC genes, which is a key criterion for answering this question.

Answer: Env, NC

**Question: What method was used for sequencing?**

Evidence: The paper does not provide any information about the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which is a key criterion for answering this question.

Answer: Not reported

**Question: What type of samples were sequenced?**

Evidence: The paper reports that the sequences were obtained from plasma samples.

Rationale: The paper specifically mentions that the sequences were obtained from plasma samples, which is a key criterion for answering this question.

Answer: Plasma

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that the sequences were obtained from individuals who were undergoing treatment with dolutegravir and had virological failure.

Rationale: The paper specifically mentions that the sequences were obtained from individuals who were undergoing treatment with dolutegravir and had virological failure, which is a key criterion for answering this question.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide any information about whether the patients were in a clinical trial.

Rationale: The paper does not provide any information about the study design, which is a key criterion for answering this question.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that the sequences were obtained from individuals who were undergoing treatment with dolutegravir.

Rationale: The paper specifically mentions that the sequences were obtained from individuals who were undergoing treatment with dolutegravir, which is a key criterion for answering this question.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the individuals were undergoing treatment with dolutegravir.

Rationale: The paper specifically mentions that the individuals were undergoing treatment with dolutegravir, which is a key criterion for answering this question.

Answer: INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that the individuals were undergoing treatment with dolutegravir.

Rationale: The paper specifically mentions that the individuals were undergoing treatment with dolutegravir, which is a key criterion for answering this question.

Answer: Dolutegravir",26
38864613,"**Question: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that sequences from clinical samples such as ""plasma"" and ""PBMC"" were used, and that the sequences were obtained from ""patients"" and ""participants"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", and ""Sanger sequencing"". Additionally, the paper reports that sequences were submitted to GenBank with accession numbers.

Rationale: The paper meets the criteria for reporting HIV sequences from patient samples, as it mentions clinical samples, patient-derived sequences, and sequencing methods. The paper also reports GenBank accession numbers, which suggests that the sequences were submitted to a public database.

Answer: Yes

**Question: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"" and ""drug susceptibility assay"", and reports IC50 values for ISL and LEN. The paper also describes cell-based susceptibility assays using MT4-GFP cells and drug titrations.

Rationale: The paper meets the criteria for reporting in vitro drug susceptibility data, as it mentions phenotypic susceptibility, IC50 values, and cell-based susceptibility assays.

Answer: Yes

**Question: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank with accession numbers, and provides the accession numbers in the text.

Rationale: The paper meets the criteria for making sequences publicly available, as it reports GenBank accession numbers and provides them in the text.

Answer: Yes

**Question: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports that sequences were submitted to GenBank with accession numbers, and provides the accession numbers in the text as ""PP827803 -- PP828572"".

Rationale: The paper provides the accession numbers for the sequenced HIV isolates, which can be used to retrieve the sequences from GenBank.

Answer: PP827803 -- PP828572

**Question: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that sequences were obtained from ""patients"" and ""participants"", and that a total of 9 LEN resistance-associated variants were evaluated.

Rationale: The paper does not provide a specific number of individuals, but mentions that sequences were obtained from patients and participants. However, it does report that 9 LEN resistance-associated variants were evaluated, which suggests that at least 9 individuals were involved in the study.

Answer: Not reported

**Question: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide information on the countries where the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries or locations where the samples were collected.

Answer: Not reported

**Question: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide information on the years when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years or time periods when the samples were collected.

Answer: Not reported

**Question: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""amplicons were cloned and sequenced"" and ""TA cloning/Topo TA cloning was performed"".

Rationale: The paper suggests that samples were cloned prior to sequencing, as it mentions cloning and sequencing of amplicons.

Answer: Yes

**Question: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""pol region encompassing protease and reverse transcriptase"".

Rationale: The paper suggests that the pol gene was sequenced, as it mentions pol genotyping and sequencing of the pol region.

Answer: Pol

**Question: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"".

Rationale: The paper suggests that Sanger sequencing was used, as it mentions ABI instruments and Sanger sequencing.

Answer: Sanger sequencing

**Question: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" as the types of samples sequenced.

Rationale: The paper suggests that plasma and PBMC samples were sequenced, as it mentions these types of samples.

Answer: Plasma, PBMC

**Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failing therapy or regimen"".

Rationale: The paper suggests that sequences were obtained from individuals with virological failure, as it mentions virologic failure and failing therapy.

Answer: Yes

**Question: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide information on whether the patients were in a clinical trial.

Rationale: The paper does not mention any clinical trials or study designs that would suggest the patients were in a clinical trial.

Answer: Not reported

**Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"" patients.

Rationale: The paper suggests that the patients had previously received ARV drugs, as it mentions ART-experienced and treatment-experienced patients.

Answer: Yes

**Question: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", and ""INSTI"" as the drug classes received by the individuals.

Rationale: The paper suggests that the individuals received NRTI, NNRTI, and INSTI drugs, as it mentions these drug classes.

Answer: NRTI, NNRTI, INSTI

**Question: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""AZT"", ""3TC"", ""TDF"", ""EFV"", ""RAL"", and ""DTG"" as the specific drugs received by the individuals.

Rationale: The paper suggests that the individuals received these specific drugs, as it mentions them.

Answer: AZT, 3TC, TDF, EFV, RAL, DTG",21
